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ILRAD International Laboratory for Research on Animal Diseases – Kenya
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LAPT Low affinity pentamidine transporter
LILIT Long incubation low inoculation test
MDR Multiple drug resistance
MEM Minimum essential medium
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mRNA Messenger RNA
MRT Mean residence time
MS Mass spectrometry
NPP New permeability pathway
P, log P Partition coefficient
PBS Phosphate buffered saline
PCR Polymerase chain reaction
P-gp P-glycoprotein
PSG Phosphate-buffered saline with glucose
RNA Ribonucleic acid
RT Reverse transcription
SCID Severe combined immune deficiency
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spp Species
t1/2 Half-life
TFA Trifluoroacetic acid
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UNC University of North Carolina
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SUMMARY
Resurgent human African trypanosomosis (HAT) displays a major burden for people living in
Sub-Saharan Africa, although it had been nearly eradicated in the 50`s, due to selective
ground spraying with DDT and an extensive vector control. Today, treatment of HAT relies
only on a few drugs at hand. The use of these drugs is restricted, since they show an
unacceptable toxicity, complicated administration, emerging and spreading of resistance,
shortness of availability and/or show only an impact on gambiense or rhodesiense
trypanosomes. Therefore, new drugs are urgently needed.
A consortium, the UNC lead consortium to discover new drugs for the treatment of parasitic
diseases, was founded with the aim to improve treatment of HAT. The ideal profile of a new
drug is an uncomplicated synthesis, easy administration, high efficacy, cost effectiveness and
no toxicity. Series of compounds were synthesised in analogy to pentamidine, the first line
drug in the treatment of first stage trypanosomosis. The so called DB compounds showed
promising results in vitro and in vivo, not only to trypanosomes but also to Leishmania spp,
Mycobacterium tuberculosis, Plasmodium spp and Pneumocystis carinii. Lead compound of
this project is the diamidine DB 75 and its oral applicable prodrug DB 289.
Although the prodrug had entered an open label phase IIa clinical trial already when this
thesis started, several questions referring to the interplay between DB 75, trypanosomes and
mice had been unanswered. To elucidate development of parasitaemia in first infection, first
and second relapse in mice, studies have been undertaken in immunocompetent and –deficient
mice, with two different trypanosome strains and various treatment schedules for DB 75.
At the same time, parasite clearance after drug application was studied. Since relapse
trypanosomes did not show any differences in sensitivity to selected drugs, observed relapses
were not due to resistant trypanosomes but rather due to re-invasion from extravascular sites.
Identification of these sites was a second goal of this project. A method based on the detection
of trypanosomal mRNA by nested PCR was established and tested. Results showed that more
time has to be invested to increase the sensitivity of this method. However, one organ was
found positive for trypanosomal mRNA, indicating the spleen to be one of the niches.
A system was established to check DB 75 for cross resistance in melarsoprol and pentamidine
resistant laboratory strains. With the aid of this system, further upcoming drugs may be tested
Vfor their cross resistance. For DB 75, only a low cross resistance was obtained in both
resistant strains.
Additionally, the pharmacokinetics for DB 75, DB 820 and the their corresponding prodrugs
DB 289, DB 844 in trypanosome infected and uninfected mice was studied. Differences in
plasma levels of uninfected compared to infected mice were obtained. Mainly, two effects
were shown to influence plasma levels considerably: accumulation of active drug in case of
DB 75 and DB 289, and inhibition of metabolism for DB 820 and DB 844.
The extent of DB 75 accumulation in trypanosomes was determined in vitro, to assess that the
differences between plasma levels of DB 75 after prodrug application obtained in infected
mice compared to uninfected mice were due to accumulation. In a further study, indications of
the presence of possible active metabolites were obtained when activity of plasma samples
was assessed by bioassay and compared to levels determined by HPLC/MS/MS.
In another pharmacokinetic study, it was shown that conversion of DB 289 to DB 75 in
P. berghei infected mice was poor, leading to subtherapeutic doses of active compound,
which explained that no activity in the in vivo model was obtained for the prodrug compared
to a moderate to good activity for the active compound.
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ZUSAMMENFASSUNG
Die wiederauftretende Afrikanische Schlafkrankheit stellt eine grosse Bürde für die
Menschen, die südlich der Sahara leben dar, obschon die Krankheit während der 50-iger
Jahren aufgrund des Gebrauchs von DDT und einer umfassenden Vektorkontrolle fast
ausgerottet worden war. Heute basiert die Behandlung der Afrikanischen Schlafkrankheit auf
wenigen zur Verfügung stehenden Medikamenten. Der Einsatz dieser Medikamente wird
durch eine inakzeptable Toxizität, eine komplizierte Verabreichung, das Auftreten und die
Ausbreitung von Resistenzen, die limitierte Verfügbarkeit und/oder die ausschliessliche
Wirkung gegenüber gambiense oder rhodesiense Trypanosomen eingeschränkt. Neue
Medikamente werden deshalb dringend benötigt.
Ein Konsortium, das von der UNC geführte Konsortium zur Entwicklung neuer Wirkstoffe
für die Behandlung parasitärer Erkrankungen, wurde gegründet um die Behandlung der
Afrikanischen Schlafkrankheit zu verbessern. Das Anforderungsprofil eines solchen
Wirkstoffes sieht folgendermassen aus: unkomplizierte Synthese, einfache Verabreichung,
hohe Wirksamkeit, Kosteneffizienz und keine Toxizität. Ganze Serien von Verbindungen
wurden in Analogie zu Pentamidine, dem Medikament der Wahl bei Afrikanischer
Schlafkrankheit im Erststadium, synthetisiert. Die so genannten DB Verbindungen zeigten
vielversprechende Wirkungen in vitro und in vivo, nicht nur gegen Trypanosomen, sondern
auch gegen Leishmanien, Mycobacterium tuberculosis, Plasmodien und Pneumocystis carinii.
Die beste Verbindung (lead compound) in diesem Projekt ist DB 75 und ihr oral
applizierbarer Prodrug DB 289.
Obwohl sich der Prodrug bereits in der Phase IIa einer offenen klinischen Studie befand als
diese Doktorarbeit begann, waren einige Fragen bezüglich der Wechselwirkungen zwischen
DB 75, Trypanosomen und Mäusen unbeantwortet. Studien wurden in immunokompetenten
und immundefizienten Mäusen, mit zwei verschiedenen Stämmen von Trypanosomen und
unterschiedlichen Behandlungsschemata mit DB 75 durchgeführt, um die Entwicklung einer
Parasitaemia bei einer Erstinfektion, beim ersten und zweiten Rückfalls zu klären.
Gleichzeitig wurde die Elimination der Parasiten nach Behandlung untersucht. Da die
Trypanosomen nach einem Rückfall keinen Unterschied bezüglich der Sensitivität gegenüber
ausgewählten Wirkstoffen zeigten, wurden die Rückfälle weniger den resistenten
Trypanosomen sondern eher der Wiedereinwanderung von Trypanosomen aus
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extravaskulären Orten zugeschrieben. Die Identifikation dieser Orte war ein zweites Ziel
dieser Arbeit. Eine Methode, die auf dem Nachweis der trypanosomalen mRNA durch nested
PCR basiert, wurde entwickelt und getestet. Die Ergebnisse zeigten, dass mehr Zeit zur
Erhöhung der Sensitivität dieser Methode investiert werden müsste. Trotzdem wurde in einem
Organ trypanosomale mRNA nachgewiesen, was darauf hinwies, dass die Milz eine dieser
Nischen ist.
Ein System wurde erstellt, mit dem die Kreuz-Resistenz von DB 75 gegenüber Melarsoprol
und Pentamidine resistenten Laborstämmen geprüft werden konnte. Mit Hilfe dieses Systems
können weitere Verbindungen auf ihre Kreuz-Resistenz hin überprüft werden. Im Falle von
DB 75 konnte nur eine geringe Kreuz-Resistenz gegenüber beiden resistenten Stämmen
nachgewiesen werden.
Zusätzlich wurde die Pharmakokinetik von DB 75, DB 820 und den dazugehörigen Prodrugs
DB 289, DB 844 in mit Trypanosomen infizierten und nicht infizierten Mäusen untersucht.
Unterschiede in den Plasmaspiegeln von nicht infizierten und infizierten Mäusen wurden
erhalten. Hauptsächlich beeinflussen zwei Effekte den Plasmaspiegel beträchtlich: die
Anreicherung der aktiven Verbindung im Falle DB 75, DB 289 und die Hemmung des
Metabolismus im Falle von DB 820, DB 844.
Das Ausmass der Anreicherung von DB 75 in Trypanosomen wurde in vitro bestimmt um zu
ermitteln, ob die DB 75 Plasmaspiegelunterschiede, die nach der Verabreichung des Prodrugs
in infizierten Mäusen im Vergleich zu nicht infizierten erhalten wurde, auf dieser
Anreicherung basierten. In einer weiteren Studie wurden Hinweise auf die Anwesenheit
möglicher aktiver Metabolite erhalten, als die Aktivität der Plasmaproben durch den Bioassay
bestimmt und mit den Spiegeln, die durch HPLC/MS/MS ermittelt wurden, verglichen wurde.
In einer anderen Pharmakokinetikstudie konnte gezeigt werden, dass die Umwandlung von
DB 289 zu DB 75 in P. berghei infizierten Mäusen gering war und zu subtherapeutischen
Dosen an aktivem Wirkstoff führte, was erklärte, dass man im in vivo Model keine Aktivität
für den Prodrug im Vergleich zu einer mässigen bis guten Aktivität für die aktive Verbindung
erhielt.
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General Introduction
Sleeping sickness – the disease
One of the most severe diseases in Sub-Saharan Africa is human African trypanosomosis
(HAT). It is estimated that 60 million people are at risk to be infected and that 300 000 new
cases occur every year [WHO Geneva (1998)]. The causative agents are trypanosomes,
protozoans belonging to the order Kinetoplastida, family Trypanosomatidae. Infection by two
subspecies of this family, Trypanosoma brucei rhodesiense (T. b. rhodesiense) and
Trypanosoma brucei gambiense (T. b. gambiense) result in HAT. T. b. rhodesiense mainly
occurs in Eastern Africa, whereas T. b. gambiense is present in Central and West Africa. Due
to the limited distribution of the vector, the tsetse fly, which transmits the pathogens while
biting, sleeping sickness occurs only in defined regions (foci). A distinction between an
infection caused by T. b. rhodesiense and T. b. gambiense is possible based on pathogenesis
and by immunological and molecular markers but not on morphological appearance.
Generally, T. b. rhodesiense causes acute symptoms, appearing within a short time after
infection, whereas the appearance of clinical symptoms in a T. b. gambiense infection can
emerge months or years after the infectious bite. Once infected, people suffer from unspecific
symptoms like fever, severe headache, joint pain, muscle aches, and others. These symptoms
represent the first stage, the haemolymphatic stage. When trypanosomes invade the central
nervous system (CNS) and cause neurological symptoms like sleep disturbances, alterations
of mental state or sensory disorders, the second stage or meningoencephalitic stage is reached
[WHO Geneva (1998)]. If untreated, patients always die.
Developmental cycle of T. brucei
Trypanosomes undergo different stages within their life cycle in both the mammalian host and
the vector. Changes in morphology, metabolism and gene expression are the basis of the
transformation into the different stages. The advantage of this multiple appearance is the
adaptation to survival and the better evasion of the host´s immune system. In mammals and in
the tsetse flies trypanosomes alter between proliferative phases, to establish themselves in the
new environment, and non-proliferative phases, which serve as transition stages. These
transition stages are important for the parasite, since within this stage of the life cycle the
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organism prepares itself for the new host. The most striking changes occur within the 
mitochondrial system and at the surface of the flagellate. In the tsetse fly, variable surface 
glycoproteins (VSG) of bloodstream forms are replaced by procyclins (GPEET, EP). Energy 
metabolism has to change from one based on glucose (bloodstream forms) to one depending 
mainly on proline (procyclic forms in the tsetse fly) and vice versa. 
In the mammalian blood the long slender (LS) form represents the proliferative stage, whereas 
the short stumpy (SS) form is non-proliferative and only able to survive when taken up by the 
vector where transformation into the procyclic stage is possible [Vickerman, K. (1985)]. 
Whether the short stumpy forms are susceptible to drugs is not yet known. 
 
Control of HAT 
Two approaches are carried out to improve the situation concerning HAT: 
 
a) Vector control 
A very important tool to reduce HAT is the elimination of the vector. Populations of 
tsetse flies can be reduced successfully with special traps and/or by using insecticides. In 
former days selective ground spraying with DDT was the method of choice, but has been 
discontinued due to environmental concerns. In October 2001, the Pan African Tsetse and 
Trypanosomiasis Eradication Campaign (PATTEC) was launched to eradicate the tsetse 
fly population by spreading sterile male tsetse flies. Such an approach was carried out 
successfully in a 4 year campaign (1994-98) on the Island of Zanzibar. Whether PATTEC 
will be successful remains uncertain, due to the extended study area and the vast diversity 
of tsetse fly species present. 
Applying repellents directly to the skin and clothes is another possibility to prevent 
infection [Barrett, J. (1997)]. 
 
b) Drug treatment 
Currently, five drugs are in use for the treatment of HAT. To cure patients in the first 
stage of infection, pentamidine or suramin are administered. Both drugs are highly 
protonated at physiological pH, so they are not able to cross the blood brain barrier 
(BBB). 
Suramin, synthesised as dye 1916, shows a naphthalene like structure. It strongly 
binds to plasma proteins like albumin and low-density lipoproteins from where it is  
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slowly released. The mode of action is not fully elucidated, but interaction with enzymes
due to its anionic structure is assumed to play a major role. [Denise, H. (2001)]. Suramin
is mainly restricted to the treatment of early stage trypanosomosis caused by
T. b. rhodesiense in Eastern Africa.
Pentamidine, an aromatic diamidine, was developed in analogy to synthalin, a
hypoglycaemic agent. Parasites were found up to 48 hours after treatment in the blood
which shows that this drug is slow acting [Pepin, J. (1994)]. Administration is performed
to treat first stage sleeping sickness in West and East Africa. In contrast to suramin,
pentamidine is reported to be actively accumulated in trypanosomes via specific
transporters [de Koning, H.P. (2001)]. The mode of action of pentamidine is not fully
understood. Interaction with the DNA at AT rich sites of the minor groove is discussed to
be important for its anti-parasitic effect [Sands, M. (1985)], [Denise, H. (2001)], [Nok,
A.J. (2003)].
Drugs like melarsoprol, eflornithine (both registered) and nifurtimox (not registered for
HAT, but clinically used as add-on therapy with melarsoprol) cross to some extent the
blood brain barrier and are used to treat 2nd stage infections.
Melarsoprol, a melaminophenyl arsenical, is the drug most frequently used in the
treatment of second stage sleeping sickness despite its high toxicity. A rapid clearance of
trypanosomes from blood within 30-120 min is reported for this drug [Pepin, J. (1994)].
Uptake into the trypanosome is performed by a nucleobase transporter: the P2 transporter
[Carter, N.S. (1993)]. The mode of action is not yet revealed completely, but melarsoprol
was shown to bind irreversibly to thiol groups. Therefore, all thiol-containing molecules
or enzymes like trypanothione or glycerol-3-phosphate dehydrogenase are possible
targets [Nok, A.J. (2003)], [Docampo, R. (2003)].
DMFO (D,L-α-difluoromethylornithine)/Eflornithine, is an ornithine analogue, which
acts as inhibitor of the ornithine decarboxylase, an enzyme in the polyamine synthesis. It
was developed as an anticancer agent and was found to be active also against
T. b. gambiense infections [Denise, H. (2001)]. The affordability and the large doses
required for treatment limits its use, apart from the specific action only against gambiense
trypanosomes [Barrett, M.P. (2003)].
Nifurtimox, a synthetic nitrofuran, was developed for the treatment of American
trypanosomosis (Chagas disease) caused by T. cruzi. Its use in HAT is mainly restricted
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to patients which were refractory to melarsoprol [Barrett, M.P. (2003)], [Denise, H.
(2001)].
Another drug, which has to be mentioned in this context is diminazene. Diminazene, also
an aromatic diamidine as pentamidine, is used to treat animals infected with
trypanosomes. This drug plays an important role in the control of trypanosomes in
domestic livestock [Peregrine, A.S. (1993)]. Clinical use in humans was reported from
several sites for first stage trypanosomosis, despite it has never been registered for human
use [Pepin, J. (1994)].
Since all mentioned drugs are old, show severe adverse reactions, lack efficacy and are
expensive, new drugs are urgently needed. However, development of new drugs to treat
sleeping sickness was stopped due to economic interests in the 80`s and 90`s. A few years
ago, several public-private-partnerships were founded and started to screen for drugs
against parasitic diseases occurring in the developing countries.
Within the same period, new regimens for DMSO and melarsoprol were suggested and
tested to improve the unsatisfactory situation in the treatment of HAT [Burri, C. (2000)],
[Pepin, J. (2000)].
Today, supply with drugs already on the market is guaranteed since the drug companies
Aventis and Bayer signed agreements in 2001 with the WHO to donate melarsoprol,
pentamidine, DMFO, Suramin and Nifurtimox for 5 years [Barrett, M.P. (2003)]. In total
U$25 million to support WHO`s activities in the field of African trypanosomosis for a
five-year period was offered by Aventis. This donation comprises the production of the
three key drugs pentamidine, melarsoprol and eflornithine, funds for the management and
control of the disease, as well as funds for research [www.who.int/tdr/publications/
tdrnews/news65/default.htm, TDR news, No.65 (June 2001)]. Even though production of
drugs is ensured, major efforts have to be made to improve the delivery of the drugs to
places where they were urgently needed.
Problem of resistance
Resistance to drugs used for the treatment of HAT was reported in various high transmission
areas and for most established drugs, but mainly for melarsoprol. Resistance is likely to occur
when only a few drugs are available to treat the disease over a long period of time and when a
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sufficient plasma level of drug cannot be reached (under-dosing) due to compliance problems 
or failure in treatment schedules. This favours selection of less susceptible trypanosomes. 
Reports on occurring relapses often do not distinguish whether these relapses were due to 
drug resistant trypanosomes or if they were due to patient related problems (e.g. metabolism, 
pharmacokinetics). 
 
Different mechanisms are involved in development of resistance by the trypanosome: 
1) Regulation of drug transport across the cell membrane by 
a) decrease of drug transport in the trypanosome caused by alteration of transporter 
proteins, 
b) increase of expression of an efflux pump like the P-glycoprotein (PGP), an ABC-
transporter. 
 
2) Alteration of target enzymes so that the drug is not able to bind and show its effect 
The DMFO resistance, for example, is believed to be caused by alteration of 
ornithine decarboxylase (ODC), a key enzyme in polyamine synthesis [Matovu, E. 
(2001)]. 
 
Dicationic compounds 
One of those mentioned new public private partnership is the “UNC lead consortium to 
discover new drugs for the treatment of parasitic diseases”, founded in 1999. The aim of this 
consortium is to improve treatment for certain parasitic diseases. Universities like Georgia 
State University, University of North Carolina at Chapel Hill, Ohio State University, London 
School of Hygiene and Tropical Medicine, Kenya Trypanosomiasis Research Institute and the 
Swiss Tropical Institute are involved in a project to improve the situation concerning HAT. 
Support is obtained by companies like Immtech International, MediChem, Applied Analytical 
International, Northwest Bioanalytical and Parexel. Funding is provided by the Bill and 
Melinda Gates foundation. The aim of this consortium is to develop a drug for first stage 
treatment, which may be produced very easily, cost efficient and preferably shows oral 
bioavailability. Thereto, series of new compounds were synthesised in analogy to the well 
efficient and well documented first line drug pentamidine. Since the active principle of 
pentamidine depends on two diamidine groups, which are separated by the so called spacer 
region, drugs were designed in structural similarity. Thereto, compounds showing variations  
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as well in the spacer regions as in the diamidine groups at either end were synthesised. 
Activity screening against parasites revealed that the distance between the diamidines is of 
major importance. The spacer region was shown to be necessary to keep the distance between 
the diamidine moieties. By chemical modelling of the spacer region, properties of the 
molecule like for example binding affinities to AT rich sequences within the DNA may be 
optimised. 
 
Generally, aromatic diamidines, like DB 75, showed an effect in vivo against Pneumocystis 
carinii [Trent, J.O. (1996)], [Tidwell, R.R. (1990)], Cryptosporidium parvum [Trent, J.O. 
(1996)], [Blagburn, B.L. (1991)], and trypanosomes [Steck, E.A. (1981)] and in vitro against 
Leishmania mexicana amazonensis [Bell, C.A. (1990)], Plasmodium falciparum [Bell, C.A. 
(1990)], Giardia lamblia [Bell, C.A. (1991)], Candida albicans [Del Poeta, M. (1998b)], 
Cryptococcus neoformans [Del Poeta, M. (1998a)], and Mycobacterium tuberculosis [Tidwell 
R. R., personal communication]. 
 
DB compounds, analogues of pentamidine, were synthesised by Dr. David Boykin at Georgia 
State University, USA [Das, B.P. (1977)]. DB 75 is a diphenylfuran derivative with diamidine 
moieties at either end. This dicationic molecule interferes with the DNA by a binding to the 
minor groove with AT specificity. As a result of this binding, selective inhibition of DNA-
dependent enzymes is achieved. 
A remarkable feature of this molecule is the intensive fluorescence, with a maximum 
excitation wavelength at 365 nm and maximum emission wavelength at 465 nm [Taylor, Y. 
(2001)], which can be exploited in various qualitative and quantitative analyses, such as 
determination of distribution patterns, uptake studies and many others. 
 
Another characteristic which DB 75 shares with its “ancestor” pentamidine is the 
accumulation in trypanosomes and plasmodia. Accumulation in mM concentration was 
obtained in trypanosomes [Bray, P.G. (2003)], and pentamidine concentration in plasmodia 
infected erythrocytes was 500x higher than in uninfected erythrocytes [Stead, A.M. (2001)]. 
Accumulation of DB 75 was found to occur preferably at sites where DNA is present as 
fluorescence microscopy reveals. 
Due to the limited oral bioavailability of DB 75, the bis-O-methylamidoxime prodrug was 
synthesised (DB 289). The proposed metabolic pathways of DB 289 metabolised by liver  
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enzymes leads via two sequential O-demethylation and two amidoxime reduction steps to the
active drug DB 75.
Other DB compounds like DB 820 and its prodrug DB 844 also showed promising results in
vitro and in vivo. In the case of DB 820/DB 844 one phenyl ring is replaced by a pyridyl ring
compared to the structure of DB 75/DB 289. This minor change in structure had a big effect
on the uptake of compound through membranes. The more lipophilic compounds
DB 820/DB 844 reached higher levels in plasma, and DB 844 was able to cross the blood
brain barrier to a higher extent compared to DB 289. This was shown in the chronic mouse
model where only 3 out of 5 mice were cured after application of DB 289, whereas total cure
was achieved after DB 844 application.
DB 75 and Malaria
As already mentioned above, DB 75 is accumulated in plasmodia infected erythrocytes. Data
obtained in the in vitro screening was very promising with an IC50 of 5.8 ng/ml for DB 75 in
the strain K1 (chloroquine/pyrimethamine resistant) and of 17 ng/ml in the strain NF54
[Wenzler T., Scheurer C., personal communication]. In vivo data revealed moderate to good
activity when DB 75 was applied to P. berghei infected mice, and almost no activity when
DB 289 was administered. The reason for this discrepancy should be revealed within this
Ph. D. project.
Another observation made, when in vivo testing is performed with DB compounds, is that
relapses were obtained 20-30 days after the treatment period when mice were infected with
trypanosomes of the T. b. rhodesiense strain STIB 900. Such relapses were not observed in
mice infected with the trypanosome strain STIB 795 (T. b. brucei). The reasons for the
re-appearance of trypanosomes in the blood is not known. Two possibilities are conceivable:
1. The applied drug is able to eliminate most of the trypanosomes. However, some
trypanosomes may be resistant to drug pressure. Within a certain time, trypanosomes
proliferated and it is possible to detect them in the blood, since the number of
trypanosomes exceeded the detection limit when tail blood is inspected microscopically.
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2. Re-appearance of trypanosomes in the blood is a due to a re-invasion process from 
extravascular sites which had served as niche. It is assumed that each organ creates a 
unique milieu, where drug levels different from the blood concentration may be found. 
Supposed, drug levels were lower in some organs, these organs may serve as niches, 
where proliferation independent of the amount of drug in the blood may take place and 
from where re-invasion after cessation of the drug is possible. 
 
To find out more about these relapses was another aim of this thesis. 
 
 
 
 
Goal of the thesis 
 
A first goal is to gain a better understanding of the kinetics of parasitaemia after drug 
treatment in mice, disappearance and recrudescence, and the origin of relapses. A second goal 
is the assessment of cross resistance of DB 75 to melarsoprol and pentamidine resistant 
trypanosome strains. A third aim is to gain knowledge on the pharmacokinetics of DB 75 and 
DB 289 in infected and uninfected mice. 
 
 
Objectives 
 
A. To determine the kinetics of parasitaemia in control animals and animals treated with 
DB compounds and to assess the influence of the immune system on pathogenesis and 
cure of trypanosomosis 
B. To elucidate the origin of relapses after subcurative treatment with DB compounds 
C. To determine if cross resistances between melarsoprol and pentamidine resistant 
trypanosome strains and DB 75 exists 
D. To determine the pharmacokinetics of the active compounds DB 75, DB 820 and their 
prodrugs DB 289, DB 844 in trypanosome infected and uninfected mice 
E. To determine the accumulation factor for DB 75 in trypanosomes in vitro 
 
 8
CHAPTER 1: General Introduction 
__________________________________________________________________________________________ 
 
F. To test for active metabolites in plasma samples of uninfected and trypanosome 
infected mice treated with DB 75, DB 820 and their corresponding prodrugs DB 289, 
DB 844 
G. To determine the pharmacokinetics of DB 75 and its prodrug DB 289 in P. berghei 
infected mice and uninfected mice 
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Studies of kinetics of parasitaemia and trypanosome disappearance
after drug treatment of first infection and relapses
UUUAbstract
Basic knowledge about a developing parasitaemia, clearance of trypanosomes after drug
treatment and reappearance of trypanosomes of first infection and relapse was gained in
immunocompetent and immunodeficient mice. Additionally, subpassaged trypanosomes were
monitored, paying attention to the development of the parasitaemia, clearance of parasites
after drug treatment and reappearance of trypanosomes in both immunocompetent and in
immunosuppressed mice. This procedure was performed with the trypanosome strain
STIB 900 (T. b. rhodesiense) and with trypanosomes of the strain STIB 795 (T. b. brucei).
The latter strain was monitored only in immunocompetent mice. Trypanosome populations,
isolated from first infection, first relapse and second relapse, were checked for changes in size
distribution, morphological appearance and sensitivity to four selected compounds (DB 75,
diminazene, melarsoprol and pentamidine) due to host factors and/or drug treatment.
It was shown that an intact immune system decreases the time for clearance of parasites from
blood after drug treatment and prolongs the kinetics of a reappearance of parasites.
Additionally, parasite free periods took longer when an intact immune system was present.
Infections with STIB 795 could be cured totally when treated with DB 75, whereas treatment
of mice infected with STIB 900 did not lead to complete cure. Relapse populations of
trypanosomes did not show any differences in size distribution, morphological appearance
and sensitivity to the selected drugs. These data indicated that relapses are not a problem of
resistant parasites but rather of invasion of extravascular sites from where re-invasion of the
blood is possible.
UUU1. Introduction
One of the most life-threatening diseases in Africa still is human African trypanosomosis
(HAT). The causative agents of HAT are the parasitic protozoans Trypanosoma brucei
gambiense (T. b. gambiense) and Trypanosoma brucei rhodesiense (T. b. rhodesiense) which
are transmitted by the bite of the tsetse fly. Two stages of infection can be distinguished
according to clinical progression of the disease: the first or haemolymphatic stage, when
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parasites are found in blood or lymphatic organs and the second or meningoencephalitic stage,
when parasites have crossed the blood brain barrier and can be detected in the cerebrospinal
fluid. Clinical symptoms of the haemolyphatic (first) stage are unspecific symptoms like
fever, headache and others due to propagation of the parasites in blood and lymphatic fluids.
Invasion of the central nervous system (CNS) leads to neurological symptoms (second stage)
and if not treated to death. Treatment depends on whether CNS invasion has occurred or not.
The drugs used to treat HAT are stage specific; however, they are old, expensive, lack
efficacy and show severe adverse effects.
An international consortium founded by the Gates Foundation was launched in 1999 with the
aim to improve the treatment of HAT. New drugs were designed modelling pentamidine, a
first stage drug, which was applied against sleeping sickness in 1939 for the first time. The
obtained analogues were tested in vitro and in vivo for their anti-trypanosomal activity. While
testing these compounds in the mouse model an important observation was made: mice
infected with STIB 795 (T. b. brucei) could be cured totally, whereas all mice infected with
STIB 900 (T. b. rhodesiense.) relapsed after an aparasitic period. Interestingly, both strains
showed a similar in vitro sensitivity to DB 75 when tested in the hypoxanthine incorporation
assay with an incubation period of 40 h, showing an IC BBB50 BBB value of 6.48 ng/ml for STIB 795
(also named S427.1) and 9.28 ng/ml for STIB 900. Why these relapses were obtained only in
the STIB 900 mouse model but not in the STIB 795 mouse model remains to be clarified. To
better understand this phenomenon, basic knowledge about a developing parasitaemia and
disappearance of trypanosomes after drug treatment in both mouse models (STIB 795 and
STIB 900) is a pre-requisite. Thereto, trypanosome populations were isolated from mice after
having undergone various treatment schedules and possible changes in morphology and in
drug sensitivity were monitored.
By comparing the course of parasitaemia of the trypanosome populations established in
immunocompetent vs. immunocompromised mice, the role of the immune system in a
developing parasitaemia and its role in the clearance of parasites after drug treatment is
assessable.
Additionally, knowledge about relapses may be gained. After having performed this study it
will be possible to assess if these relapses are due to acquired resistance of the trypanosomes
to the applied drug. Otherwise, it would be possible that trypanosomes invade extravascular
sites which are less accessible to the drug and re-invade the blood from there after drug
pressure decreased.
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UUU2. Materials and methods
In the following, the word line always refers to the different mouse strains, whereas the word
strain refers to the different trypanosome sub-species.
UUU2.1. Trypanosomes
UUU2.1.1. Trypanosoma brucei rhodesiense (STIB 900)
UUUSTIB 900 is a derivative of STIB 704. Pathogens were isolated from a male patient at
St. Francis Hospital in Ifakara/Tanzania in 1982. After several passages in rodents and a
cyclic passage in Glossina morsitans morsitans, a cloned population was adapted to axenic
growth in vitro.
UUU2.1.2. Trypanosoma brucei brucei (STIB 795)
UUUTrypanosomes were isolated by ILRAD -International Laboratory for Research on Animal
Diseases, Kenya- (strain S427.1) from Glossina pallidipes in Uganda in 1960. After a passage
in a sheep, a tsetse fly and several passages in mice, a clone was adapted to axenic cultivation
in vitro.
UUU2.2. Immunocompetent and immunodeficient mice
As immunocompetent mice, female NMRI mice, aged 4-6 weeks with a weight of 24-34 g
were used. They were obtained from RCC, Ittingen, Switzerland.
Female SCID (Cb17/lcr-PrkdcP PPscid PPP/Crl) mice, representing the immunodeficient mice, aged 4
weeks, with a weight of 17-20 g were purchased from Charles River, Sulzfeld, Germany.
Animal use adhered to the guidelines issued by the Swiss Federal Veterinary Department
(BVET) for laboratory animals.
UUU2.3. Drugs (Fig. 1)
The diamidine compound DB 75 was synthesised at Georgia State University, Atlanta, USA
by the group of D. W. Boykin. Diminazene aceturate was purchased from Sigma-Aldrich
Chemie GmbH, Steinheim, Germany. Melarsoprol was obtained from Specia France, Rhone-
Mérieux, Toulouse, France, and Pentamidine isethionate (Pentacarinat) from Rhone-Poulenc,
Thalwil, Switzerland.
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UUU2.4. Cultivation and in vitro screening
UUU2.4.1. Culture medium
Bloodstream forms of trypanosomes were cultivated in Minimum Essential Medium (MEM)
with Earle`s salts (powder, GIBCO, Invitrogen, Basel, Switzerland), supplemented with
25 mM HEPES (GIBCO, Invitrogen, Basel, Switzerland), 1 g/l additional glucose,
2.2 g/l NaHCOB BB3 B BB and 10 ml/l MEM nonessential amino acids (100x, GIBCO, Invitrogen,
Basel, Switzerland). The medium was further supplemented with 0.2 mM 2-mercaptoethanol,
2 mM sodium pyruvate, 0.1 mM hypoxanthine, 0.016 mM thymidine and 15% heat
inactivated horse serum [Baltz, T. (1985)].
UUU2.4.2. Screening medium (without hypoxanthine and thymidine)
For drug sensitivity assays the same medium as mentioned above was used but without the
addition of hypoxanthine and thymidine.
UUU2.4.3. Hypoxanthine solution
A solution containing 50 µCi/ml of P PP3 PP P[H]-Hypoxanthine (Amersham Biosciences,
Buckinghampshire HP7 9NA, UK) in screening medium was prepared.
UUU2.5. Infection and treatment of mice
Mice were divided into 5 groups (A-E), each consisting of 5 mice. Groups A-C were infected
at day 0 with trypanosomes. Group A served as untreated control group, whereas groups B
and C each underwent a treatment period with DB 75 for 3 days starting at day 3 post
infection (p.i.). After an aparasitic period, mice of group C were treated again with DB 75 for
3 days, at day 3 after the first trypanosome could be detected in the tail blood or immediately,
when parasitaemia was classified as + (categories: see below: 2.6.1. Tail blood examination).
Trypanosomes of a randomly chosen mouse of group B were subpassaged into mice of groups
D and E. Mice of group D were left untreated, whereas mice of group E were treated with
DB 75 for 3 days starting 3 days after the first trypanosome was detected in the blood or the
day the mouse showed a + parasitaemia.
To characterise the trypanosome populations, cardiac puncture was performed with 3 out of
5 mice, the day parasitaemia was classified as +++ (or as ++ when mice showed severe
symptoms of an acute trypanosome infection). For further investigations as morphological
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examinations and drug sensitivity, trypanosomes were separated from blood by DEAE
column [Lanham, S.M. (1970)].
The whole infection and treatment procedure (2.5.) was performed with 2 different strains of
trypanosomes (STIB 795 and STIB 900) and within 2 different lines of mice (immuno-
competent NMRI and immunodeficient SCID mice).
UUU2.5.1. Infection of mice
Cryopreserved stabilates containing bloodstream forms of trypanosomes (STIB 795,
STIB 900) were thawed and diluted with phosphate-buffered saline with glucose (PSG) buffer
to a final concentration of 1*10PPP5 PP P trypanosomes/0.25 ml. Administration of parasites was
performed intraperitoneally at day 0 into mice of groups A, B and C.
UUU2.5.2. Subpassage of trypanosomes
Blood of mice, obtained from cardiac puncture of a parasitaemic mouse, was diluted with
PSG to a final concentration of 2.5*10PPP4 PPP trypanosomes/0.25 ml and inoculated
intraperitoneally into mice of groups D and E.
UUU2.5.3. Treatment of mice
A drug solution containing 1 mg/ml DB 75 in 10% DMSO was prepared. 10 mg/kg body
weight was administered intraperitoneally for 3 days once a day.
UUU2.6. Monitoring the course of parasitaemia
UUU2.6.1. Tail blood examination
Tail blood was checked daily in parasitic periods and twice a week in aparasitic periods.
Thereto, one drop of blood obtained by tail snip was diluted with one drop of
sodium citrate 3.2% in sterile water and observed under the microscope at a magnification of
200x. To classify the grade of parasitaemia, trypanosomes per field were counted and
categorised using the table below:
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Trypanosomes per field Category
no trypanosome within 20 fields ((-))
1-20 trypanosomes within 20 fields,
(x) representing the number of parasites
((X))
1-10 trypanosomes in 1 field +
10-20 trypanosomes in 1 field ++
More than 20 trypanosomes in 1 field +++
UUU2.6.2. Count in Neubauer haemocytometer
Tail blood was diluted 1:10 with PSG buffer and stored at –80° C. After thawing, the number
of trypanosomes were determined by a count in the Neubauer haemocytometer.
UUU2.7. Harvesting trypanosomes
UUU2.7.1. Cardiac puncture
Mice showing a medium or high grade parasitaemia (++ - +++), were anaesthetised with CO BBB2 BBB.
Cardiac puncture was performed using a 1 ml syringe containing 0.05 ml PSG to which
heparin (100 I.U., diluted 1: 50, Fresenius, Fresenius Medical Care Schweiz AG, Stans) had
been added.
UUU2.7.2. DEAE column
Trypanosomes were separated from blood components by anion exchange chromatography
using DEAE cellulose [Lanham, S.M. (1970)].
UUU2.7.3. Cryopreservation
Stabilates containing 10% glycerol in PSG were prepared from extracted trypanosomes and
stored at –80° C.
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2.8. Characterisation of trypanosomes
2.8.1. Morphological examination
2.8.1.1. Morphological appearance
Blood smears were made, fixed in methanol and stained with Giemsa solution (9% for
10 min). Trypanosome morphology was compared microscopically at a magnification of 500x
and 1000x.
2.8.1.2. Size distribution
The size distribution of the trypanosomes was determined using the CASY (Cell Counter and
Analysing System, Schärfe System GmbH, Reutlingen, Germany ). A 1000-fold dilution of
the trypanosome suspension (pre-diluted 1:5, 1:10 or 1:100, depending on the trypanosome
density) was measured three times using a 60 µm capillary. Obtained data was analysed
visually and an analysis of variance was performed using the statistic program SAS System.
To determine any differences in the size, average volumes were analysed. The GLM
Procedure (three-way ANOVA- Analysis of variance-) using the least squares analysis was
chosen to test for differences.
2.8.2. Drug sensitivity
A drug sensitivity profile of each population was generated based on the ICBBB50 BBB values for
DB 75, diminazene, melarsoprol and pentamidine obtained in the P PP3 PPP[H]-hypoxanthine
incorporation assay [Brun, R. (1989)].
To determine the ICB BB50B BB of the trypanosome populations of each group, 3 mice per group were
selected and their trypanosomes were separated from blood by DEAE column. The extracted
parasites were used directly, or from cryopreserved stabilates. When using the cryopreserved
stabilates, trypanosomes underwent several passages in BMEM medium until they showed a
stable growth rate, before the assay was performed.
Hypoxanthine assay
Drug sensitivity was determined by assessing the viability of trypanosomes incubated with
drug for 40 hours at 37° C and 5% COBBB2 BBB. A serial drug dilution in screening medium was
prepared in a 96-well plate and trypanosomes of a given concentration
(5*10 PPP5P PP trypanosomes/ml) were added to each well. Some wells served as control containing
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trypanosomes and screening medium without drug, others as background consisting of
screening medium without drug and without trypanosomes (see plate layout Fig. 2). After an
incubation period of 24 hours, radioactively labelled hypoxanthine was added to each well for
another 16 hours. Incorporation of radioactive hypoxanthine was determined for each well.
Thereto, the contents of the wells were transferred onto a glass fibre filter (Filtermat A,
Wallac, Perkin Elmer, Schwerzenbach, Switzerland) using a cell harvester (Wallac, Berthold
Technologies GmbH, Regensdorf, Switzerland). Filtermats were dried and sealed into a
plastic foil containing scintillation fluid (Betaplate Scint, Wallac, Perkin Elmer,
Schwerzenbach, Switzerland) which amplifies the radioactive signal of the radiolabelled
hypoxanthine when read by a liquid scintillation counter (1205_021 Betaplate, Wallac, Perkin
Elmer, Schwerzenbach, Switzerland). To assess the ICBBB50 BBB value, the ratios of the obtained
signal of incorporated radioactivity of each well to the signals of incorporated radioactivity of
the control wells were calculated using EXCEL software. The ratios were plotted in a graph
from which the ICBBB50B BB could be assessed. The obtained ICB BB50 BBB values represent the drug
concentrations at which 50% of the incorporated hypoxanthine was obtained compared to the
control, and therefore the concentration which kills 50% of the parasites. This determination
was performed with each trypanosome population extracted from mice 3 times, each time in
duplicate.
Data based analysis
To assess influences of any parameter (various trypanosome strains, lines of mice and
treatment schedules) on the ICBBB50 B BBof DB 75, diminazene, melarsoprol and pentamidine a three
way analysis of variance was performed using the mixed procedure (PROC MIXED) of the
statistic program SAS System. As estimation method REML (Restricted Maximum
Likelihood) was used.
3. Results
3.1. Kinetics of different populations
In the following, the courses of parasitaemia will be described for each group separately. To
facilitate the understanding, mice which show a different behaviour compared to the group
were mentioned showing their coding in brackets.
CHAPTER 2: Studies of kinetics of parasitaemia and trypanosome disappearance after drug treatment of
 first infection and relapses
__________________________________________________________________________________________
20
3.1.1. Kinetics of first infection parasitaemia in untreated mice (control)
A NMRI 900: (Fig. 3, 4, 5)
4 days after inoculation with 1*10P PP5 PPP trypanosomes 4 out of 5 mice showed a high parasitaemia.
24 hours later all mice were infected heavily. Based on the counts in the Neubauer
haemocytometer, the 5P PPth PPP mouse (St) developed the parasitaemia less rapidly than the other
four.
A SCID 900: (Fig. 6, 7, 8)
In SCID mice development of a full parasitaemia took slightly less time than in NMRI mice,
on average 3.8 days vs. 4 days in NMRI. Analysing the data obtained from the counts in the
Neubauer haemocytometer, the infection was established with a similar velocity in all five
SCID mice.
A NMRI 795: (Fig. 9, 10, 11)
In an infection with STIB 795, the time to reach the same high level of parasitaemia (+++) is
prolonged compared to the STIB 900 infections (4.5 days vs. 4 days in STIB 900 infected
NMRI mice). One mouse (K) showed a completely different parasitaemia pattern, decreasing
the parasite density of + at day 3 and 4 to ((-)) within 1 day. Parasitaemia rose and decreased
once more, before a high density was reached at day 12. As the counts in the Neubauer
haemocytometer showed, the course of infection varied within this group.
3.1.2. Kinetics of first infection parasitaemia, trypanosome disappearance of first infection
after DB 75 treatment and parasitaemia of the relapse population
B NMRI 900: (Fig. 12, 13, 14)
3 days after inoculation a heavy parasite load could be detected in only one mouse (St), the
others showed a low grade parasitaemia. Under treatment all mice could reduce their number
of trypanosomes immediately and no parasites were detectable within 2 days, except the
mouse showing the high grade parasitaemia. This mouse responded with delay to drug
treatment and clearance took 5 days after beginning of the drug treatment. Average time to
clear blood from parasites was 2 days.
The time period between total clearance and re-appearance of trypanosomes took 9 to 20
days, with an average of 16.2 days. Interestingly the mouse, that reacted with delay to drug
treatment got the relapse first.
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Clearly, it took more time to develop a high level parasitaemia after having undergone a first
treatment period compared to first infection.
B SCID 900: (Fig. 15, 16, 17)
Clearance of trypanosomes after drug treatment took more time compared to clearance in
NMRI mice (3.2 days vs. 2 days). The first trypanosomes re-appeared already 2 to 7 days
(average: 4.4 days) after their elimination under drug treatment. It could be monitored that in
SCID mice the development of the relapse-parasitaemia was slowed down also. Counts in the
Neubauer haemocytometer showed a small increase of parasites over time for 4 mice. One
mouse (KSt) behaved differently, reaching a high grade parasitaemia quickly (see growth rate:
B SCID 900 Neubauer count). Although no daily observation of the tailblood was performed,
it seemed that the development of the relapse parasitaemia occurred the faster, the longer the
elimination of parasites after the treatment period took.
B NMRI 795: (Fig. 18, 19, 20)
Within 1 day after DB 75 treatment no parasites could be detected in the blood anymore.
Screening for parasites was performed up to the end of the study period at day 185, without
detecting any trypanosomes.
3.1.3. Kinetics of first infection parasitaemia, disappearance of trypanosomes of first infection
after drug treatment, relapse parasitaemia, disappearance of relapse parasitaemia after second
drug treatment and second relapse parasitaemia
C NMRI 900: (Fig. 21, 22, 23)
On average it took 1.8 days to clear the first infection and 11 days (between 8 and 18 days) till
the trypanosomes re-emerged. The average time between the second treatment period and the
second relapse was with 17.6 days (11 - 27 days) longer compared to the time between first
treatment and first relapse.
Three mice out of five were able to reduce their parasite load of the second relapse without
further drug treatment for a certain time (R, KR, KSt). One of those mentioned mice (KR)
was able to reduce the parasites of the second relapse without any further treatment for 14
days. Then trypanosomes re-appeared for 24 days, before another parasite-free period lasting
4 days was monitored. Even in an additionally performed haematocrit no trypanosome could
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be detected. After 4 days the parasitaemia rose rapidly (from 0 to +++ in 4 days), leading to
death after 15 days.
C SCID 900: (Fig. 24, 25, 26)
The data of one mouse was rejected, because this mouse was suspected not to be a SCID
mouse (R) due to her resistance to relapse (1P PPst PPP relapse on day 66, death on day 111).
First parasite clearance averaged 2 days, whereas 3.2 days were obtained for B SCID 900
mice. After treatment trypanosomes re-appeared in SCID mice in almost half of the time
compared to trypanosomes in NMRI mice (5.25 days vs. 11.6 days). The time between
clearance of first relapse and second relapse was surprisingly short: 1.5 days (compared to
17.6 days in NMRI mice) and also shorter than between first treatment and first relapse.
C NMRI 795: (Fig. 27, 28, 29)
Total cure was achieved in 3 out of 5 mice already after the first treatment day (based on the
Neubauer counts), one day later the other 2 mice were trypanosome-negative, too. Up to the
end of the study period (day 185) no trypanosome was detected anymore.
3.1.4. Kinetics of a first infection parasitaemia of a subpassaged relapse trypanosome
population
D NMRI 900: (Fig. 30, 31, 32)
The development of a trypanosome infection obtained from parasites of mouse B NMRI R
inoculated into mice of group D took more time, due to the lower number of parasites applied
with the inoculum (2.5*10PPP4 PPP vs. 1*10P PP5 PPP trypanosomes). A parasitaemia pattern typical for a first
infection could be monitored.
D SCID 900: (Fig. 33, 34, 35)
Development of parasitaemia did not differ from the one of group D NMRI 900. The
inoculated trypanosomes derived from mouse B SCID KR.
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3.1.5. Kinetics of first infection, disappearance of trypanosomes after treatment and relapse
parasitaemia of a subpassaged relapse trypanosome population
E NMRI 900: (Fig. 36, 37, 38)
The average time till trypanosomes were eliminated after treatment lasted 3.4 days. 7 to 11
days (mean: 8.2 days) after clearance trypanosomes could be found in the blood again.
In this group, one mouse (K) responded with delay to drug treatment, too. As already
observed for other groups, this mouse relapsed first. Another mouse (KSt) showed the
phenomenon of self-cure and died within the parasite-free period.
E SCID 900: (Fig. 39, 40, 41)
Clearance as well as re-appearance took little time, on average 2.4 days ( 2 - 3 days) for the
elimination of the parasites and 5.6 days (5 - 8 days) till the relapse trypanosomes could be
detected.
3.2. Comparing groups
3.2.1. Time to develop a +++ parasitaemia after first infection
Infections with STIB 900 were established faster (A NMRI: 4, A SCID 3.8 days) than
infections with the strain STIB 795 (4.5 days). It was not possible to determine this period in
group B, C and E since treatment was performed at day 3 after the first trypanosome was
detected independent of the grade of parasitaemia, which led to a reduction of parasites before
a +++ parasitaemia was developed.
3.2.2. Time period from high grade parasitaemia to death of mice
3.2.2.1. Mice without any treatment period (groups A and D)
NMRI mice endured a high parasitaemia longer than SCID mice (on average 4.5 days vs. 2
days). The day the mice died, a +++ parasitaemia was detectable in all animals.
3.2.2.2. Mice which underwent at least one treatment period (groups B, C, and E)
A comparison was not possible, because some mice died with a low level parasitaemia.
Possibly, these mice were weakened by the antecedent first infection.
CHAPTER 2: Studies of kinetics of parasitaemia and trypanosome disappearance after drug treatment of
 first infection and relapses
__________________________________________________________________________________________
24
3.2.3. Time for clearance of parasites after treatment
The time to eliminate the parasites varied between the different trypanosome strains in the
same line of mice. Generally, elimination of trypanosomes of strain STIB 795 was performed
faster than elimination of STIB 900 trypanosomes in NMRI mice.
group B: STIB 900: 2 days STIB 795: 1 day
group C: STIB 900: 1.8 days STIB 795: 1.2 days
Differences between clearance of STIB 900 in NMRI compared to clearance in SCID mice
were also observed.
period average number of trypanosomes
before treatment
group B: NMRI mice: 2 days 2.20*10PPP6 PPP per ml (w/o St)P PP⊗PPP
SCID mice: 3.2 days 2.49*10PPP6 PPP per ml
group C: NMRI mice: 1.8 days 6.04*10PPP6 PPP per ml
SCID mice: 1.8 days 2.19* 10PPP6 PPP per ml
group E: NMRI mice: 3.4 days 1.92* 10PPP7 PPP per ml
SCID mice: 2.4 days 1.24* 10PPP6 PPP per ml
[P PP⊗ PPPdata of St mouse was neglected, since mouse reacted with delay to treatment]
Taking the counts in the Neubauer haemocytometer into consideration, the same number of
parasites was eliminated faster in NMRI than in SCID mice (see group B). In group C,
elimination of parasites took as long in NMRI mice as in SCID mice, but the number of
trypanosomes in the blood differed, being approximately 3 times higher in NMRI mice than
in SCID mice. In group E, the time to clear parasites from the blood was prolonged in NMRI
mice compared to SCID mice. Here also, the number of trypanosomes varied considerably:
around 10 times more parasites were detectable in blood of NMRI mice than in the one of
SCID mice.
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3.2.4. Time period between clearance and relapse
Independent of the treatment schedules, aparasitic periods were longer in NMRI mice
compared to SCID mice.
NMRI    SCID
group B: 16.2 vs. 4.4 days
group C: 11 vs. 5.25 days (first clearance – first relapse)
group C: 17.6 vs. 1.5 days (second clearance - second relapse)
group E: 8.2 vs. 5.6 days
3.3. Morphological examination
3.3.1. Morphological appearance
Visually no differences in morphological appearance were observed between trypanosomes
separated from the different groups of mice when examined at a magnification of 500x and
1000x (Fig. 42).
3.3.2. Size distribution
3.3.2.1. Visual analysis
All graphs of the size distribution obtained from CASY showed consistently the same
distribution pattern with a steep rise on the left hand side of the curve and a less steeper fall
on the right hand side (Fig. 43).
3.3.2.2. Data based analysis
The mean volumes of trypanosomes of all groups were compared, ranging from
32.6 – 40.7 fl. Performing an analysis of variance with this data no significant differences
within the size distribution could be detected, neither between trypanosomes proliferating in
immunocompetent or in immunodeficient mice (FBBB1,28 BBB < 0.01, p = 0.97), nor between the
different trypanosome strains (FB BB1,28 BBB = 1.1, p = 0.3), nor between trypanosome populations
which underwent different treatment schedules (FB BB2,28 BBB = 0.07, p= 0.9).
3.4. Drug sensitivity (Fig. 44), (Chapter 10 Appendix A Table 1-5)
3.4.1. Sensitivity to DB 75
The ICBBB50B BB values for all STIB 900 populations were consistently similar, ranging on average
from 11.84 ng/ml to 16.44 ng/ml independent of the strain of mouse, or treatment schedule.
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Interestingly, the ICB BB50B BB value for STIB 795 was decreased being 7 ng/ml on average (3 ng/ml
to 10 ng/ml).
3.4.2. Sensitivity to diminazene
Comparing the ICB BB50 BBB of the various populations to diminazene, a trend to lower values was
obtained in SCID mice, and for STIB 795.
3.4.3. Sensitivity to melarsoprol
No difference was detectable in melarsoprol ICB BB50 BBB values of trypanosomes of different strains,
nor when isolated from different lines of mice, nor when the trypanosome populations
underwent different treatment schedules.
3.4.4. Sensitivity to pentamidine
ICBBB50B BB values were similar, independent of the strain of trypanosome, the line of mice from
which they got extracted, or the treatment schedule which was performed.
Data based analysis
A three-way analysis of variance was used to test the effects of treatment schedules, mouse
line and strain of parasite on the ICBBB50 BB B of each of the four drugs: DB 75, diminazene,
melarsoprol and pentamidine.
DB 75
The ICBBB50B BB of DB 75 was not significantly affected by different treatment schedules (FB BB4,66 BBB = 0.5,
p = 0.72) nor by different lines of mice (FBBB1,66 BBB = 0.1, p = 0.75), but was lower in strain
STIB 795 (mean: 7 ng/ml, stand. dev. 2.6), than strain STIB 900 (mean: 14.6 ng/ml, stand.
dev. 4.8) (FB BB1,66B BB = 13.1, p = 0.0006).
Diminazene
All parameters affected the ICB BB50 BB B value of diminazene significantly: the treatment schedule
(FBBB4,66B BB = 4.57, p = 0.0025), the line of mice (FB BB1,66B BB = 14.17, p = 0.0004), and the used
trypanosome strain (FB BB1,66 BBB = 15.56, p = 0.0002).
Melarsoprol
Different treatment schedules (FB BB4,66 BBB = 1.54, p = 0.2), or different line of mice (FBBB1,66 BBB = 0.33, p =
0.57), or different trypanosome strains (F BBB1,66B BB = 2.59, p = 0.11) had no significant effect on the
ICBBB50 BBBvalue of melarsoprol.
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Pentamidine
The same result as for melarsoprol was observed for the ICBBB50 BBB value of pentamidine: neither a
statistically significant influence of the treatment schedule (FBBB4,66 BBB = 0.77, p = 0.55), nor of the
different line of mice (FBBB1,66 BBB = 1.43, p = 0.24), nor of the different trypanosome strain
(FBBB1,66B BB = 0.44, p = 0.51) could be assessed.
ICBBB50 BBBof reference trypanosomes (STIB 795 and STIB 900) vs. ICB BB50 BBBof trypanosomes extracted
from mice
Trypanosomes of the strain STIB 795 extracted from mice did not show any differences in the
ICBBB50B BB compared to reference trypanosomes of the strain STIB 795 (ICB BB50 BBB (reference):
6.48 ng/ml, ICB BB50B BB (extracted from mice): 7 ng/ml). Whereas slightly higher ICBBB50 BBB values were
obtained for STIB 900 trypanosomes extracted from mice (ICBBB50 BBB 14.6 ng/ml) compared to an
ICBBB50B BB of 9.28 ng/ml for reference trypanosomes of the strain STIB 900.
4. Discussion
4.1. General aspects
As the study design implied, 3 mice were sacrificed to further investigate their trypanosomes
and therefore population of mice of each group was reduced from 5 to 2 individuals when
mice showed a +++ parasitaemia. Therefore, statements concerning the time after having
reached this parasitaemia just show the behaviour of two animals and should be interpreted
with caution.
Tail blood examination is a rapidly performed examination method to determine the grade of
parasitaemia. The accurate number of parasites is not assessable by this method, but a rough
estimation of the density of the trypanosome population is possible. When the course of
parasitaemia determined by tail blood examination is compared to the course of parasitaemia
determined by counts in the Neubauer haemocytometer, a good correlation of these curves is
clearly visible. The advantage of the determination of the trypanosome density in the
Neubauer haemocytometer is, that the velocity can be assessed with which the population
grows. A comparison between different individuals is therefore possible, even if a constant
parasite level is determined by tail blood examination.
Freezing and thawing facilitated the determination of the numbers of trypanosomes in the
blood samples, since erythrocytes but not trypanosomes get lysed by this technique.
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The number of trypanosomes was diminished to one fourth when trypanosomes from one
mouse were subpassaged to other mice compared to the number of trypanosomes inoculated
straight from a stabilate. This was done to take the loss of trypanosomes obtained by the
freezing process into consideration. This reduction in the number of inoculated trypanosomes
was too high, as the course of parasitaemia showed. Mice of groups D and E, which were
inoculated with subpassaged trypanosomes, had less parasites per ml blood at any given time
before the first treatment period started compared to mice which were inoculated with
trypanosomes from the stabilate.
Apparently, infections with trypanosomes of the strain STIB 795 proceeded milder than
infections with trypanosomes of the strain STIB 900. Although the same number of
trypanosomes had been injected, the course of parasitaemia differed already within the first
days. A high level parasitaemia was reached more rapidly in mice infected with STIB 900
compared to mice infected with STIB 795. After drug treatment, mice infected with the more
virulent strain STIB 900 needed more time to clear the blood from trypanosomes compared to
mice infected with STIB 795, although in vitro sensitivity to DB 75 was about the same, with
an IC50 of 6.48 ng/ml for STIB 795 and 9.28 ng/ml for STIB 900.
In this study the immunocompetent mice were represented by Hanlbm: NMRI mice. These
albino white mice were raised in a so called outbreeding system. The aim of this breeding
system is to obtain the highest possible degree of heterozygousity of alleles. This leads to
genetically undefined animals. Therefore it was not surprising, that some animals behaved
differently from the average when subjected to parasites and also to treatment (A NMRI STIB
795 K, B NMRI STIB 900 St, C NMRI STIB 900 KR, E NMRI STIB 900 KSt).
SCID mice show a severe combined immune deficiency (SCID) caused by a spontaneous
occurring autosomal recessive mutation. Primary immune defects of these mutations are
B and T cell deficiency, which are expressed in a developmental rest at a preliminary stage of
B and T cells. Additionally, there are deficits in the CD3+ cells and in T cell receptor ab+
cells [Bosma, G.C. (1983)], [Bosma, M.J. (1991)]. Macrophages, antigen presenting cells
(APC), natural killer cells and the activity of the complement are not affected by this mutation
[Czitrom, A.A. (1985)]. SCID mice show an increased susceptibility to certain murine
pathogens as trypanosomes, which is the reason for the proliferation of Trypanosoma brucei
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gambiense in SCID mice. Even if immunosuppressed with cyclophosphamide, it is almost
impossible to establish a T. b. gambiense infection in the NMRI mice.
This genetic defect is not stable, since “leakiness” was reported for these mice. This means
that depending on the original line of the immunodeficient mouse, its environment and its age,
SCID mice may produce some functional B and T cells. There are several mice lines on the
market showing severe combined immune deficiency. In this study mice of the strain Cb17
were used. Leakiness is not expected, because very young mice were used in this experiment.
4.2. Expectations
When comparing immunocompetent vs. immunodeficient mice in this study, differences are
expected.
The first infection parasitaemia, which represents the first challenge of the animal by the
parasite, will develop with the same velocity in the immunocompetent as in the
immunodeficient mice. At this time the immune system is naive, and therefore reasons for any
differences occurring must lie within the elements of the unspecific immune response. Since
the unspecific immune response is not affected by the genetic defect of the SCID mice, no
differences are expected to show up.
As it is known from literature, the aid of the immune system is required to clear the blood
stream from parasites after drug treatment (see below: immune-dependency of
chemotherapy). Therefore, the clearance of parasites from the blood stream is expected to be
prolonged in immunodeficient mice.
The development of the relapse parasitaemia will take longer in NMRI mice than in SCID
mice, since memory cells were produced after the first contact which may control the parasite
growth for a certain time when challenged the next time.
Additionally, it is expected that SCID mice will not survive an infection as long as NMRI
mice since the immune system is weakened by the genetic defect.
4.3. Influence of the immune system on the development of an infection, on clearance after
drug treatment and on relapses
Differences in the development of a STIB 900 parasitaemia
As expected, no big differences were detectable within the first 4 days after infection referring
to the velocity with which the numbers of trypanosomes increased in SCID mice compared to
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NMRI mice. Also, the survival time of mice showing a high parasitaemia behaved as
expected. No SCID mouse survived longer than five days (p.i.), whereas one of the NMRI
mice survived up to day 9 (p.i.). From day 5 to 9 this mouse was infected heavily (more than
1*10 PPP7 PPP trypanosomes per ml). Within this period the numbers of parasites increased very little.
Differences after drug treatment
Clearance of parasites from the blood stream was prolonged in SCID mice compared to
NMRI mice. The exact mechanisms of this elimination process are not known to date, but
many components of the immune system were shown to play an important role in the past.
Depending on the drug used to treat the trypanosome infection, different factors of the
immune system were discussed to be responsible for the clearance of the parasite. In all
studies the so called immune-dependence of chemotherapy was observed to be elementary:
showing that a close relationship between the drug therapy and the immune system is
necessary for clearance.
1934, Von Jancso N. et al. showed that the reticulo-endothelial (monocyte/macrophage)
system is involved in removal of the parasites after suramin treatment. Rodents which were
splenectomised and/or treated with colloidal copper to suppress phagocytosis by reticulo-
endothelial cells, cleared trypanosomes slower than immunocompetent mice. Changes in the
morphology of trypanosomes could be detected only in these immunosuppressed rodents,
which led to the hypothesis, that suramin damages trypanosomes in a way, that they were
recognised and opsonised by the reticulo-endothelial cells, which are only present in
immunocompetent animals.
Anti-trypanosomal antibodies play an important role after treatment with DMFO. Removal of
trypanosomes after DMFO treatment in immunocompromised rodents (cyclophosphamide,
dexamethasone) was inefficient or prolonged compared to immunocompetent counterparts.
These chemically suppressed rodents were shown to have very low levels of anti-
trypanosomal antibodies [de Gee, A.L. (1983)], [Bitonti, A.J (1986)].
Athymic mice, which lack T cells, cleared parasites as immunocompetent mice, which
indicated that the anti-trypanosomal antibody response is T cell independent [Campbell, G.H.
(1977)].
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Curative doses of melarsoprol were ineffective in cyclophosphamide or gamma irradiation
suppressed mice [de Gee, A.L. (1983)]. The same applied for cortisone suppressed mice after
treatment with arsenicals. Corticosteroids are known to affect antibody and cell mediated
immune responses, affecting inhibition of antigen presentation as well as inhibition of T cell
independent antibody responses.
Immunodeficient mice in this study lack B and T cells. Therefore no T cell dependant
antigens, nor a proliferation from B cells to antigen producing B cells, nor T cells which may
present antigens are present. The only mechanism of immune defence in these mice is the
unspecific immune response, based on the reticulo-endothelial system, the natural killer cells,
complement and T cell independent antibodies. As the graphs show, these components are
able to clear the blood from trypanosomes, even though the time is prolonged compared to
mice with an intact immune system.
Differences in the duration of the aparasitic period between clearance and relapses
The aparasitic period after drug treatment and before the occurrence of the relapse was longer
in NMRI mice than in SCID mice. SCID mice were probably more susceptible to the relapse
because of their weakened general condition. An additional immunosuppression occurs
naturally in trypanosome infected hosts [Sacks, D.L. (1980)]. In NMRI mice, the production
of specific antibodies may control the growth of the parasites on a low level for a certain time.
This ability is lacking in SCID mice. The production of specific antibodies may be the reason
for the prolongation of the establishment of the parasitaemia of a relapse population compared
to the one of a first infection. A certain role in the prolonged establishment of an infection
must play also the unspecific antibodies since a similar prolongation was detected when SCID
mice relapse.
An indirect correlation of the density of trypanosomes to the duration of the aparasitic period
between infection and relapse could be detected. In all mice, independent of the status of their
immune system, relapses occurred the faster the higher the parasite load was at the day
treatment started. The reason for this could be that the slower the drug acts the higher the
chance that trypanosomes invade tissues to which the drug has less access to and from where
they could re-invade the blood. Additionally, the more trypanosomes are present in the blood
the less drug per trypanosome is at disposal. Trypanosomes are also known to accumulate
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diamidines as DB 75 and therefore subcurative plasma levels of the drug may be possible (see
chapter 6: Accumulation of DB 75 in trypanosomes in vitro).
This experiment showed clearly that there is a difference between SCID and NMRI mice
concerning the survival time with a high parasitaemia. Generally, NMRI mice can endure a
high parasite load significantly longer than SCID mice.
first infection relapse second relapse
group A group B /group C group C /group E
NMRI: 2-5 days 13-15 /5-6 days 13+12 PPP⊗PPP /13 days
SCID: 1 day n.d.* /2-3 days 9 /10-11 days
(n.d.* = not determinable: all mice were sacrificed, P PP⊗PPP one mouse could reduce parasitaemia
for some days (12) within recurrent +++ periods (13 days), the other mouse died with a low
grade parasitaemia)
4.3. Morphological characterisation
Morphological appearance between smears obtained from the different trypanosome
populations was compared. No significant differences between the populations could be
detected, neither at magnification of 500x nor at 1000x. Smears of the trypanosomes looked
identical to smears obtained of reference populations of STIB 795 and STIB 900
trypanosomes. No differences referring to increased number of abnormal looking cells could
be detected.
Size distribution was determined by using the CASY. The obtained profiles did not differ
significantly in their appearance within the different groups of mice nor to reference
trypanosomes of the corresponding trypanosome strain, neither did the average volume.
4.4. Drug sensitivity
To find out whether the various treatment schedules in different mouse strains had an effect
on the sensitivity of the parasites to different drugs, the ICBBB50 BBBs of each trypanosome population
from the different study groups of mice to 4 different drugs (DB 75, diminazene, melarsoprol
and pentamidine) were determined. This was done to find out if the impairment of the host
immune system leads to a rapid development of drug resistance, as was reported
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for Trypanosoma evansi to mel Cy, diminazene aceturate and isometamidium chloride in
immunosuppressed mice [Osman, A.S. (1992)].
The hypoxanthine incorporation assay was used, because this assay delivers reliable and
reproducible results, even for a low number of trypanosomes or if the proliferation time is
prolonged, which is expected for these trypanosome populations since their environment
changes drastically when transferred from mice to the in vitro system. The separation from
the blood by the DEAE column will stress the trypanosomes additionally, which is expected
to result in a slower growth rate.
By using a scintillation cocktail, the signal of the incorporated radioactive hypoxanthine will
be converted to a photo emission. Detection of this converted signal is more sensitive than the
radioactive signal itself. Samples containing low-energy beta emitters, like Tritium ( PPP3 PPP[H]), are
placed in a scintillation cocktail, which consists of an organic solvent and a fluor molecule
(scintillant). Solvent molecules become excited when an emitted beta particle passes through
the scintillation fluid and strikes the solvent molecules. Energy is transferred from the solvent
molecules to the fluor molecules, which emit photons when decay from the excited to the
ground state takes place. Direct excitation of the fluor molecule by the emitted beta radiation
is also possible. The emission is detected by a photomultiplier and is registered as a count.
The number of counts correlates to the incorporated radioactivity and represents therefore the
viability of the trypanosomes.
Results of the data analysis showed no differences within the ICB BB50 BBB of the different groups after
various treatment schedules in different mice for DB 75, melarsoprol and pentamidine.
Interestingly, the ICB BB50B BB of diminazene was found to be influenced by all parameters: strain of
trypanosomes, line of mouse and various treatment schedules. Standard deviations of the
performed diminazene assays showed a great variability. The reason for this lies probably in
the stability of the drug itself. Diminazene is reported to be stable in aqueous solution only for
2-3 days at room temperature [Peregrine, A.S. (1993)]. Since trypanosomes were incubated at
37° C for 40 hours in BMEM when the hypoxanthine assay is performed, the activity of the
drug will decline, since the drug could be degraded partly to that time or may have interacted
with ingredients of the medium. This would be a minor problem if diminazene would be a
fast-acting drug, which kills parasites within the first hours, but from other studies,
diminazene is known to exhibit a moderately fast activity.
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Diminazene for veterinary use is marketed in combination with the stabiliser phenyldimethyl
pyrazolone, what prolongs the duration of stability to up to 10-15 days when stored at room
temperature.
Problems with instability in aqueous solutions are not reported in literature for melarsoprol
and pentamidine. Melarsoprol is only slightly water soluble, but this is not expected to be a
problem since the concentrations which were needed when performing the assay are very low
and therefore below the limit of solubility.
ICBBB50 BBBof DB 75 from reference trypanosomes vs. IC50 of trypanosomes extracted from mice
Differences in the ICBBB50B BB did not occur when reference trypanosomes of the strain STIB 795
were compared to trypanosomes of the same strain extracted from mice.
In contrast, trypanosomes of the strain STIB 900 showed a trend to a slight increase of the
ICBBB50 BBBwhen extracted from mice compared to STIB 900 reference trypanosomes, independent
of the treatment schedule performed and from which line of mouse trypanosomes were
extracted. Since this effect is very small and only detectable for the STIB 900 trypanosomes,
one could speculate about an interaction between this strain and the host.
5. Conclusion
Immune system and trypanosome infections
This study showed that an intact immune system is important for the control of a developing
parasitaemia and for the clearance of parasites after drug treatment. However, an intact
immune system is not able to eliminate the parasites without the support of anti-trypanosomal
drugs.
Effect of hosts, trypanosome strains and treatment schedules on morphology and sensitivity to
anti-trypanosomals
Trypanosomes did not alter their size distribution, morphological appearance or sensitivity to
drugs significantly, when various treatment schedules were performed or when trypanosomes
were raised in various lines of mice. Probably, no effect could be shown, since the influence
of the drug on trypanosomes was too short to induce resistance to the drug applied and also to
develop cross resistance to other drugs. Alike, the time was too short for the trypanosomes for
major alterations in any of the inspected criteria when proliferated in various mouse lines.
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Another reason that no changes in any of the chosen criteria could be found, could be that the
sensitivity of the determination methods is too insensitive to detect small changes which
could have been possible in that short time.
This experiment clearly showed the reproducibility and predictability of the relapses in STIB
900 infected animals after DB 75 treatment. Knowledge gained from this studies was
important for the work described in Chapter 3 “An attempt to identify organs in mice which
may serve as niches for trypanosomes for relapse development”.
However, the most important conclusion that can be drawn from this experiment is, that
relapse populations in this mouse model are not less sensitive to drugs than the first infection
trypanosomes. Therefore, relapses are not phenomena of resistance to applied drugs, but
rather of invasion of sites which were less accessible to the drug and from where re-invasion
of the blood is possible.
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Fig. 1: Chemical structures of compounds to treat trypanosomosis
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Fig. 2: Plate layout hypoxanthine assay
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Fig. 4: Course of parasitaemia:
untreated STIB 900 infected NMRI mice
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Fig. 5: Counts on Neubauer:
untreated STIB 900 infected NMRI mice
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Fig. 7: Course of parasitaemia:
untreated STIB 900 infected SCID mice
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Fig. 8: Counts on Neubauer:
untreated STIB 900 infected SCID mice
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Fig. 10: Course of parasitaemia:
untreated STIB 795 infected NMRI mice
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Fig. 11: Counts on Neubauer:
untreated STIB 795 infected NMRI mice
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Fig. 14: Counts on Neubauer:
STIB 900 infected NMRI mice with one treatment period
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Fig. 13: Course of parasitaemia:
STIB 900 infected NMRI mice with one treatment period
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Fig. 17: Counts on Neubauer:
STIB 900 infected SCID mice with one treatment period
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Fig. 16: Course of parasitaemia:
STIB 900 infected SCID mice with one treatment period
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Fig. 19: Course of parasitaemia:
STIB 795 infected NMRI mice with one treatment period
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Fig. 20: Counts on Neubauer:
STIB 795 infected NMRI mice with one treatment period
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Fig. 23: Counts on Neubauer:
STIB 900 infected NMRI mice with two treatment periods
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Fig. 22: Course of parasitaemia:
STIB 900 infected NMRI mice with two treatment periods
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Fig. 26: Counts on Neubauer:
STIB 900 infected SCID mice with two treatment periods
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Fig. 25: Course of parasitaemia:
STIB 900 infected SCID mice with two treatment periods
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Fig. 28: Course of parasitaemia:
STIB 795 infected NMRI mice with one treatment period
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Fig. 29: Counts on Neubauer:
STIB 795 infected NMRI mice with one treatment period
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Fig. 31: Course of parasitaemia:
untreated subpassaged STIB 900 infected NMRI mice
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Fig. 32: Counts on Neubauer:
untreated subpassaged STIB 900 infected NMRI mice
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Fig. 34: Course of parasitaemia:
untreated subpassaged STIB 900 infected SCID mice
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Fig. 35: Counts on Neubauer:
untreated subpassaged STIB 900 infected SCID mice
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Fig. 38: Counts on Neubauer:
subpassaged STIB 900 infected NMRI mice with one treatment periods
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Fig. 37: Course of parasitaemia:
subpassaged STIB 900 infected NMRI mice with one treatment period
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Fig. 41: Counts on Neubauer:
subpassaged STIB 900 infected SCID mice with one treatment period
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Fig. 40: Course of parasitaemia:
subpassaged STIB 900 infected SCID mice with one treatment period
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Fig. 42: Morphological appearance at magnification 1000x
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Fig. 43: Example of CASY data
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Fig. 44: Sensitivity of isolated trypanosomes to selected compounds 
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An attempt to identify organs in mice which may serve as niches for
trypanosomes for relapse development
Abstract
In vivo screening of new diamidine analogues (DB compounds) in mice infected with the
trypanosome strain STIB 900 revealed that treatment with some of these new compounds did
not lead to total cure of the mice, whereas when infected with the trypanosome strain
STIB 795 total cure was achieved. Blood was cleared from parasites in both cases, but
STIB 900 trypanosomes reappeared after an aparasitic period again, proliferated and lead to
death when no further treatment was performed. Taking the results from “Studies of kinetics
of parasitaemia and trypanosome disappearance after drug treatment of first infection and
relapses” into account, reappearance of parasites due to resistant trypanosomes was excluded.
Therefore, the hypothesis was set up, that trypanosomes invade extravascular sites (niches)
where they are not fully exposed to the drug and cause relapses by re-invading the blood
again when no drug was present. In this study, a method to evaluate which organs may serve
as niches was developed by tracing mRNA of trypanosomes using nested PCR. Organs of
mice were homogenised and tested for trypanosomal presence. The method was shown to
work, but unfortunately, the extraction of mRNA was not always successful. Additionally, it
could be shown that improvements have to be made to increase the sensitivity of the detection
when mouse mRNA is predominantly present. However, one organ, the spleen was detected
to contain trypanosomal mRNA. This indicates that this organ may be the or one of the
niches.
1. Introduction
The UNC lead consortium to discover new drugs for the treatment of parasitic diseases was
founded in 1999. One of their projects is to improve treatment of human African
trypanosomosis. Thereto, compounds were synthesised in analogy to pentamidine, the first
line drug in treatment of first stage trypanosomosis. Promising results were obtained for some
of the synthesised compounds, the so called DB compounds, when tested in vitro. While
screening these compounds in vivo routinely, the observation was made, that no total cure
could be achieved after treatment with DB 75 in the acute mouse model [Brun, R. (1999)],
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when mice were infected with the trypanosome strain STIB 900 (Trypanosoma brucei
rhodesiense). The compounds which were tested and did not achieve total cure belong
chemically to the group of diamidines. They were synthesised as analogues to pentamidine
with the aim to improve beside its efficacy its pharmacokinetic and pharmacodynamic
properties. Although a rapid parasite clearance is achieved after treatment with DB
compounds, relapses occur after a certain time with doses which are not curative. These
relapses were thought to result from trypanosomes sequestering in extravascular sites
inaccessible for the drug (niches) and from where re-invasion of the blood may take place
once drug levels drop below therapeutic levels. The duration of the aparasitic periods between
clearance of the parasites after drug treatment and re-appearance of trypanosomes in the blood
depend on the drug, the dose, the dosage scheme and the line of the infected mouse. The
protocol of the acute mouse model looks as follows: mice are infected intraperitoneally with
1*103 trypanosomes. Three days post infection, when parasites can be detected
microscopically in the tail blood, the 4 day treatment period starts with a high but tolerated
dose using the intraperitoneal route.
To identify possible niches, some adaptations to this protocol were made: mice were infected
with 105 trypanosomes. Additionally, the duration of the treatment period was reduced to
shorten the aparasitic period between clearance and re-appearance of trypanosomes in the
blood. In summary: NMRI mice infected with the trypanosome strain STIB 900 were treated
3 days post infection with 10 mg/kg DB 75 once per day for 3 days. Already after the first
treatment, trypanosomes were cleared from blood in almost all mice, a day later 100% of the
animals were parasite free. In the case of DB 75, the duration of the aparasitic period between
clearance and re-appearance of trypanosomes in the blood is different in each mouse, lasting
from 9 to 20 days (see “ Studies of kinetics of parasitaemia and trypanosome disappearance
after drug treatment of first infection and relapses”). After this period, trypanosomes can be
found again when tail blood is inspected microscopically. The number of trypanosomes
increases and the mice die if untreated. Taking all the above mentioned facts into account, the
hypothesis was set up, that trypanosomes sequestered in organs could circumvent the
influence of the drug and initiate a parasitaemia when drug levels drop below therapeutic
doses. From literature such relapses were already known. Jennings observed relapses
occurring dependent on the beginning of the treatment period in mice infected with the
trypanosome strain GVR 35 (T. b. brucei), when treated with diminazene. Mice which were
treated within 7 days after trypanosome infection could be cured totally, whereas mice
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undergoing treatment after day 21 post infection relapsed after a certain period. The source of
the relapses was identified to be the CNS [Jennings, F.W. (1979)].
The blood-brain-barrier (BBB) is thought to be the reason for relapses. This barrier allows
only small and lipophilic molecules to cross unless there is a specific transporter for a
molecule. The existence of the BBB creates an unique milieu where trypanosomes may be
protected from certain drugs circulating in the blood stream. Polar molecules like diamidines
would be too charged to cross, and to date no specific transporter for diamidines is known to
be located in the cells forming the BBB. For this reason, the CNS is thought to be the ideal
niche for trypanosomes. One could speculate if invasion of the brain by trypanosomes may be
facilitated when an infectious disease is present, because factors accompanying an infection
were known to break down the integrity of the BBB. Then, passage of the BBB would be
easier not only for the parasites but also for other molecules [Chaudhuri, J.D. (2000)]. One of
these factors is nitric oxide (NO), which is synthesised by a NO oxidase which may be
stimulated by stress, inflammation and infection [Thiel, V.E. (2001)].Whether a trypanosome
infection is able to break down the integrity of the BBB within 3 days after infection is not
known, nor is the mechanism of the trypanosomes to cross this barrier.
Furthermore, to date only late stage trypanosomosis is associated with CNS infection.
Reflecting this, one could draw the following conclusions:
1. All organs, not only the CNS, in which lower drug levels than in the blood are found
could serve as niches.
And/ Or
2. CNS infection could take place at an earlier stage of the disease (at least in this model).
Various methods to identify these niches were discussed in advance. An approach to detect
trypanosome presence with the aid of antibodies was rejected, since antibody-based assays
cannot always distinguish between past and current infections [Nutman, T.B. (1994)].
Additionally, differentiation between trypanosomes which are alive or dead is not possible by
this method, what is a pre-requisite for this experiment since only trypanosomes which are
alive may cause relapses. Using polymerase chain reaction (PCR) was thought to be the most
appropriate tool to detect these niches by amplifying a trypanosome-specific gene.
Evidence should have been supplied on the genomic DNA level, selecting primers amplifying
a sequence occurring only in the genome of the trypanosome. Since the trypanosomal genome
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is known to possess 200 copies of a 1390 bp long sequence, which is found mostly clustered
as direct tandem repeats, and contains the 35 nucleotides known as spliced leader (SL or mini
exon), primers within this sequence were chosen [de Lange, T. (1983)], [Dorfman, D.M.
(1984)]. Nested PCR was performed to increase the sensitivity of this method. Thereto,
primers were chosen which amplify a fragment within the sequence selected for the primary
PCR (Fig.1).
The method of detection had to be changed from amplification and detection of a DNA
sequence to a mRNA sequence (see results and discussion). Additionally, inoculation of brain
pellets obtained from infected and melarsoprol, DB 75 respectively, treated mice into
recipient mice was performed to determine whether brains may serve as niches. Thereto,
blood of the recipient mice was checked for the presence of trypanosomes.
2. Material and Methods
2.1. Trypanosomes:
Trypanosoma brucei rhodesiense (STIB 900):
STIB 900 is a derivative of STIB 704. Pathogens were isolated from a male patient at St.
Francis Hospital in Ifakara/Tanzania in 1982. After several passages in rodents and a cyclic
passage in Glossina morsitans morsitans, a cloned population was adapted to axenical growth
in vitro.
Trypanosoma brucei brucei (GVR 35):
Trypanosomes were isolated from a wilde-beast in the Serengeti in 1966 and were passaged in
a group of irradicated mice before stabilates were made [Jennings, F.W. (1982)].
2.2. Mice
Female NMRI mice with a body weight of 20-25 g, obtained from RCC, Ittingen,
Switzerland, were used.
2.3. Drugs and Primers
2.3.1. DB 75
DB 75 was synthesised by Dr. D. W. Boykin, Georgia State University, Atlanta, USA. An
aqueous solution of 1 mg/ml DB 75 in 10% DMSO was prepared the day of treatment.
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2.3.2. Melarsoprol 
Melarsoprol was obtained from WHO (Geneva, Switzerland, donated by Sanofi-Aventis). A 
suspension 0.8 mg/ml melarsoprol in water was prepared the day of treatment. 
 
2.3.3. Endoxan®, Cyclophosphamide 
Cyclophosphamide was purchased from Baxter (Volketswil, Switzerland). 
 
2.3.4. Diminazene 
Diminazene was purchased from Sigma-Aldrich Chemie GmbH (Steinheim, Germany). 
 
2.3.5. Primers 
All primers designed were tested for self complementarity using “Oligonucleotide properties 
Calculator” software (www.basic.northwestern.edu/biotools/oligocalc.html). They were 
purchased from Qiagen (Qiagen, Hilden, Germany). A stock solution containing 100 µM 
primers in TE (Tris HCl 10 mM, EDTA 1 mM) was prepared. For PCR, primers were diluted 
further to 10 µM. The sequences of the primers were mentioned below. 
 
2.4. Infection and treatment of mice 
2.4.1. Infection of mice 
Cryopreserved stabilates containing bloodstream forms of trypanosome strain STIB 900 were 
diluted with phosphate-buffered saline with glucose (PSG) buffer to a final concentration of 
1*105 trypanosomes/0.25 ml. Inoculation of parasites was performed intraperitoneally. 
 
2.4.2. Monitoring the parasitaemia 
The days treatment was performed, blood was checked by tail blood examination. Thereto, 
one drop of blood, obtained by tail snip, was diluted with one drop of sodium citrate (Merck, 
Darmstadt, Germany) 3.2% and inspected under the microscope at a magnification of 200x.  
 
2.4.3. Treatment of mice 
Treatment was performed 3 days after inoculation, once a day for 3 days with 10 mg/kg 
bodyweight DB 75 or 8 mg/kg bodyweight melarsoprol, respectively. 
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2.5. Preliminary experiment: check for absence of trypansomal DNA in blood after clearance
of parasites
In a preliminary study, blood obtained from five mice which were infected with trypanosomes
and treated three days post infection for 3 days with 10 mg/kg DB 75 was tested for the
presence of trypanosomes. Thereto, blood obtained by cardiac puncture was DNA extracted
using QIAamp® DNA Mini Kit (Qiagen, Hilden, Germany) performing the spin protocol.
Concentration of DNA was performed by extraction with 3 M sodium acetate (Merck,
Darmstadt, Germany). Precipitate was washed with ethanol 70% (Merck, Darmstadt,
Germany) and reconstituted in 20 µl TE/0.1% Tween 20 (Fluka Chemie GmbH, Buchs,
Switzerland). PCR was performed as mentioned for DNA extracted from tissues.
2.6. Microscopical blood monitoring
One week after the last treatment was performed, blood was harvested by performing a
cardiac puncture. As anticoagulant 0.1 ml of a solution containing 3.2 % sodium citrate was
used. Trypanosomes were separated from blood cells using a DEAE column [Lanham, S.M.
(1970)]. The column eluent was centrifuged at 2700 rpm (Jouan, Johnson Control, Basel,
Switzerland). Supernatant was discarded except for 0.5 ml. Pellet was resuspended and
transferred into a pasteur pipette with a tip which had been melted to seal. A second
centrifugation step was performed (2700 rpm). The tip of the pasteur pipette was inspected for
the presence of trypanosomes under the microscope at a magnification of 200x. If no
trypanosomes could be detected, preparation of the isolated organs was performed, if
trypanosomes were detected the whole infection and treatment procedure was performed with
a new mouse. A similar centrifugation method was described by Lumsden and co-workers
[Lumsden, W.H. (1977)].
2.7. Preparation of organs
Mice were sacrificed and dissected. Each organ was stored separately in PSG on ice until it
was further proceeded. The following organs were isolated:
• pancreas • liver • brain • genitalia • lung
• heart • spleen • kidney • fat tissue • muscle tissue
• thymus • spine • eyes • skin
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The identification of the isolated organs was confirmed by an experienced technician and a 
mouse anatomy book [Iwaki, T. (2001)]. 
 
Homogenisation of the isolated organs was performed using a homogeniser (Ultra-Turax T 
25, IKA Labortechnik, Janke & Kunkel GmbH & Co KG, Staufen, Germany) with disperser 
(S 25 N 10 G). After homogenisation of each organ, the Ultra-Turax was disassembled, 
cleaned with soap and rinsed with plenty of water to prevent contamination from one organ to 
another. After being homogenised, tissues underwent a slow centrifugation step (700 rpm). 
Supernatant was transferred and underwent a further centrifugation step (2700 rpm). With 
these two centrifugation steps, the amount of material could be reduced drastically without 
losing any trypanosomes. If trypanosomes would have been in any of these organs, they 
should be found in the pellet after these two centrifugation steps. 
 
Positive control: trypanosomes from culture 
For positive control, DNA/mRNA were extracted from a well growing trypanosome culture. 
Thereto, a solution containing 1*106 trypanosomes was centrifuged at 2750 rpm. The 
supernatant was discarded and the pellet was extracted for DNA/mRNA as mentioned for the 
tissue samples. 
 
Negative control: uninfected and untreated mouse 
DNA/mRNA of a mouse, which had never been infected nor treated was isolated from organs 
(liver, brain, spleen) with the aid of the Qiagen® Kit/mRNA extraction method respectively, 
as mentioned below. These samples were used additionally to determine the limit of detection 
of the performed PCR. 
 
2.8. Screening for trypanosomal DNA 
2.8.1. Extraction of DNA with Qiagen® Kit 
DNA of the pellet was extracted using the Qiagen DNeasy® Tissue Kit for DNA purification 
from animal tissues according to the DNeasy® protocol for animal tissues (DNeasy Tissue 
Kit Handbook 05/2002). After the extraction, the obtained volume was further reduced to 
concentrate the DNA by precipitation with 3 M sodium acetate (Merck, Darmstadt, Germany) 
and absolute EtOH (Merck, Darmstadt, Germany). After an additional washing step with 
EtOH 70% and subsequently drying, the pellet was reconstituted in 20 µl TE/0.1% Tween 20. 
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2.8.2. PCR
All PCR reactions were performed in an Eppendorf Mastercycle gradient (Dr. Vaudaux AG,
Schönenbuch/Basel, Switzerland). Amplification by PCR was done with the following
reaction mixtures (50 µl):
DNA cDNA
buffer (10x) 5.0 µl buffer for advantage taq (10x)
dNTPs (2 mM) 5.0 µl
primer fwd (10 µM) 2.5 µl
primer rv (10 µM) 2.5 µl
taq (5 units/µl) 0.2 µl taq (advantage: 50 units/µl) 0.3 µl
water 31.8 µl 31.7 µl
template 3.0 µl
Unless not stated otherwise the following protocol was used: initial denaturation was
performed at 94° C for 3 min. Thereafter, a program performing 25 cycles for DNA samples,
30 cycles for cDNA samples respectively, of 30 s at 94° C, 40 s annealing at 60° C and 1 min
extension at 72° C was run. The obtained products were separated by electrophoresis on a
0.5% agarose (QA-Agarose TM, Qbiogene, Basel, Switzerland) gel and stained with ethidium
bromide.
Primary PCR of DNA extracts
Primary PCR was performed with additional MgCl2 in the reaction mixture. Thereto, 3 µl of
water were replaced by 3 µl a of solution containing 25 mM MgCl2, leading to a total MgCl2
concentration of 3 mM in the reaction mixture. As forward primer SLfa: 5`- GAG AAG CTC
CCA GTA GCA GC and as reverse primer SLr3: 5`- TCG CCT GCT CAG TAG ACA TG was used.
The expected length of the amplified fragment was 554 bp.
Secondary PCR of DNA extracts
In the nested PCR the following primers were used: forward: SLfb: 5`- GCC AAC ACA CGC
ATT GTG C and reverse: SLr2: 5`- CAT GAA AGC GCC CAT CGA GG. The product is expected to
be 342 bp.
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Limit of detection
To find out the limit of detection of this method, mouse DNA was mixed with DNA obtained
from cultured trypanosomes. Dilutions containing 100, 20, 4, 0.8, 0.16 and 0.0032
trypanosomes per µl were tested with nested PCR.
2.9. Screening for trypanosomal mRNA
All reagents used for mRNA extraction and transcription to cDNA were supposed to be
RNase free.
2.9.1. mRNA Isolation
The pellet obtained after the centrifugation steps was transferred to an Eppendorf tube and
five times the volume of this pellet Trizol (Invitrogen AG, Basel, Switzerland) was added.
After vortexing, the tube was incubated at 37° C for 5 minutes and then stored at –80° C.
After thawing, chloroform (Sigma Aldrich GmbH, Steinheim, Germany) was added (1/5 of
the Trizol volume). The content of the tube was mixed well and incubated at room
temperature for 3 min, then spun for 30 minutes at 4° C. The aqueous phase (supernatant) was
transferred into a new Eppendorf tube and 0.8 volume of isopropanol was added. The mixture
was vortexed and precipitated over night at –20° C.
The tube was spun 30 min at 4° C. Supernatant was discarded and the pellet was washed with
Ethanol 75% (Merck, Darmstadt, Germany) and dried. Trizol was added and the whole
procedure was performed again. The obtained pellet was processed as mentioned under 2.9.2..
2.9.2. DNA digestion of RNA
The pellet was dissolved in 38 µl 5 mM Tris/0.1 mM EDTA (Fluka Chemie GmbH, Buchs,
Switzerland) and incubated for 5 min at 50° C with open lid. 2.5 µl 0.1 M DTT, 1 µl RNase
inhibitor (10 units/µl), 5 µl RQ1 10x buffer and 3.5 µl (1 unit/µl) DNase RQ1 (all Promega,
Catalys AG, Wallisellen, Switzerland) was added and the mixture was incubated at 37° C for
30 min. 180 µl Trizol was added, followed by another incubation period of 5 min at 37° C.
Chloroform (40 µl) was added, the tube was vortexed and incubated at room temperature for
3 min. After having spun the tube for 30 min at 4° C, the aqueous phase was transferred to a
new Eppendorf tube and isopropanol (0.8 volume) was added. The mixture was vortexed and
incubated at –20° C overnight to precipitate the RNA. The pellet was washed with
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ethanol 75% and dried. This procedure was repeated once, the obtained pellet was processed
as mentioned in 2.9.3..
2.9.3. Reverse transcription
The pellet was dissolved in 50.2 µl 5 mM Tris/0.5 mM EDTA. 0.3 µl hexamers (random
primer: 3 µg/µl, Invitrogen AG, Basel, Switzerland) was added. After incubation at 65° C for
5 min, the tube was placed on ice. 3.5 µl 0.1 mM DTT, 2 µl RNase inhibitor (10 units/µl),
7 µl reaction buffer 10x, 7 µl 5 mM dNTPs (Qiagen, Hilden, Germany) was added. 40 µl of
this mixture were place into a new tube and served as positive control. The remaining 30 µl
represented the negative control. To the positive control 1 µl of reverse transcriptase
(Sensiscript, Qiagen, Hilden, Germany) was added. All tubes were incubated at 37° C for
1 h 15 min. Afterwards, the tubes were incubated for 3 min at 93° C and 1 µl RNase A
(500 µg/ml) was added. An incubation period of 20 min at 37° C took place, before tubes
were put on ice. A solution of 10% Tween 20 was added to the cDNA to achieve a final
concentration of 0.01% Tween 20. Then cDNA was stored at –20° C.
2.9.4. Test for presence of cDNA
A fragment of 785 bp is expected to be amplified from genomic DNA when using the mouse
primers poly_fwd_2: 5´- CTT CCT TGA CTG TTC TAG C and poly_rv_2: 5´- AAT GGC CAG GAC
GGA AC as reverse primer. Fragments amplified from cDNA will show a length of 395 bp
using the same primers. 55° C annealing temperature was evaluated to give the best results.
To be more sensitive, advantage taq and corresponding advantage buffer (Becton Dickinson
AG, Basel, Switzerland) was used.
2.9.5. Primary cDNA PCR for trypanosome presence
In the primary PCR spliced_l_for:5`- ATT ATT AGA ACA GTT TCT GTA CTA TAT TG and
tub_b_rv: 5`- ACA CAT CGA GCA CAG AGT CG were used as primers. The amplified cDNA
sequence is expected to have 436 bp. PCR was performed using advantage taq.
2.9.6. Nested cDNA PCR
Spliced_l_for: 5`- ATT ATT AGA ACA GTT TCT GTA CTA TAT TG and tub_b_nested_rv: 5`- CAC
CCT CCG TGT AGT GGC C were used as primers for secondary PCR, resulting in a fragment of
406 bp on the cDNA level using advantage taq.
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2.10. Inoculation of brain homogenates
2.10.1 Brain of a GVR 35 infected mouse
A mouse, infected with trypanosomes of the strain GVR 35, was treated at day 21 with
diminazene 40 mg/kg intraperitoneally and sacrificed nine days later. Blood obtained by
cardiac puncture was analysed for trypanosomal presence microscopically. Since no parasites
were found in the blood, the brain was homogenised, centrifuged and injected i.p. into an
immunosuppressed recipient mouse. Immunosuppression was performed with
cyclophosphamide (200 mg/kg) applied 5 hours in advance of injection of the brain pellet.
Tail blood was checked for trypanosomes a week after injection of the homogenate.
2.10.2. Brain of a STIB 900 infected mouse
Half of the organ homogenates of brains from melarsoprol and DB treated mice, were injected
into immunosuppressed mice. Thereto, mice were treated with cyclophoshamide 200 mg/kg
5 hours prior to application of the homogenate intraperitoneally. Weekly, parasitaemia was
checked in tail blood and immunosuppression was performed once a week for 4 weeks.
3. Results
3.1. Detection of trypanosomal DNA
3.1.1. Preliminary experiment (Fig. 2)
Blood of infected and subsequently treated mice, was collected in the aparasitic period and
checked for presence of trypanosomal DNA by nested PCR. Only when blood samples were
PCR negative, testing for trypanosomes hidden in tissue would be sensible. Otherwise, it
could not be excluded that positive signals obtained for tissues may be caused by
trypanosomal DNA from dead trypanosomes which was found in the circulating blood. Since
no trypanosomal DNA could be detected in DNA extractions obtained from the blood of
5 mice one week after the last treatment when checked by PCR, the experimental procedure
was modified. Instead of extracting DNA from the blood and testing for the presence of
trypanosomal DNA, blood was checked visually for trypanosomes. Thereto, blood underwent
a centrifugation procedure and was inspected microscopically. The advantage of this method
was that re-appearance of trypanosomes could be detected in a very early stage already.
Therefore, time and material was saved when organs were prepared, since the presence of any
trypanosomes would lead to an abort of the experiment before organs were proceeded further
after isolation from the mouse. With the help of this centrifugation procedure it is possible to
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detect single trypanosomes, which is of importance when evaluating if these mice already
relapsed or were still in the aparasitic period.
3.1.2. Limit of detection (Fig. 3)
It was possible to detect less than 1 trypanosome by PCR. Reaction containing
0.32 trypanosomes tested by PCR showed a clear band at the same position that was obtained
for the positive control. For the solution containing 0.064 trypanosome no band could be
detected.
3.1.3. Melarsoprol and DB treated mice
Mice having been infected and subsequently treated with melarsoprol or DB 75 were
sacrificed. Blood was checked microscopically after double centrifugation to confirm that
mice had been still in the aparasitic period. Organs were isolated, homogenised and amount of
material was reduced further by centrifugation. The obtained pellets underwent DNA
extraction and were tested for the presence of trypanosomal DNA.
The melarsoprol treated mouse was thought to serve as negative control, since in vivo
observations showed that these mice were cured totally, developing no relapse anymore
within 185 days after treatment (see “Studies of kinetics of parasitaemia and trypanosome
disappearance after drug treatment of first infection and relapses”). Clearance of parasites
from blood after drug treatment was even a bit faster than the one seen after DB 75 treatment,
since all mice were trypanosome negative within 24 hours. However, when DNA extracted
from organs isolated one week after the last treatment was checked for the presence of
trypanosomal DNA, all organs gave a positive signal after nested PCR (Fig. 4).
Inspecting organs obtained from four DB treated mice, no clear pattern was obtained when
organs were checked by PCR for the presence of trypanosomal DNA (Fig. 5).
This lead to the assumption that the DNA from dead trypanosomes had not been degraded yet,
and was therefore still detectable.
The consequence of this finding was, that it is not possible to identify these niches using the
genomic level. Therefore, the evidence for the existence of the invasion of niches should be
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supplied by amplifying a mRNA sequence. mRNA is known to be very unstable in non-living 
cells and is therefore only traceable when the parasite is alive. 
 
3.2. Detection of trypanosomal cDNA 
To prove the existence of trypanosomes in any tissue, organs were isolated, homogenised and 
centrifuged as mentioned for DNA. The obtained pellet underwent a RNA extraction, 
processed by a subsequent transcription of the RNA into cDNA. The advantage of this reverse 
transcription (RT) was that introns were spliced out and that only the sequence of the 
trypanosomal mRNA, and not the one of DNA, could be amplified by choosing specific 
primers. For amplification, the forward primer was designed complementary to a sequence 
within the spliced leader gene (Fig. 1) and the reverse primer was designed reverse 
complementary to a sequence within the tubulin beta gene (Fig. 6). Approximately 15 α- 
tubulin and β- tubulin genes are arranged alternating in a tandem array within the genome of a 
trypanosome. In the intergenic region of those tubulins no spliced leader sequence was found, 
indicating that the SL sequence originates from small RNA transcript encoded at other sides 
and is trans-spliced subsequently (Fig. 7) [Sather, S. (1985)], [Ullu E. (1996)]. 
To increase the sensitivity of this procedure, nested PCR was performed. Thereto, additional 
primers had to be designed. Since the part of spliced leader sequence which is trans-spliced in 
front of the tubulin beta gene is very short (35 bp), the same forward primer was used also in 
the nested PCR. The nested reverse primer was designed a few base pairs upstream of the 
primer of the first PCR. Fragments which were amplified by these PCRs showed the size of 
436 bp after primary and 406 bp after the nested PCR (Fig. 6). 
 
Before performing a PCR to detect trypanosomal cDNA, it was checked whether mRNA 
extraction and transcription to cDNA was successful. Thereto, a sequence of the mouse 
genome was amplified, since mouse cDNA would be present in excess after the mRNA 
extraction and transcription procedure. Primers were chosen, which bind to the polymerase II 
sequence in the mouse genome only. Intron spanning primers were designed, so that two 
products may be obtained when performing PCR: one product from genomic (DNA) level and 
the other from mRNA level (Fig. 8). The advantage of this selection was that within one PCR 
both fragments may be obtained and therefore contaminating DNA which got co-extracted in 
the mRNA procedure may be monitored. 
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3.2.1. Detection of mouse cDNA 
PCR detecting mouse cDNA showed that all organs of melarsoprol treated mice were 
extracted successfully (Fig. 9). Variations in the amount of cDNA were clearly visible, 
reflected by the intensity of the obtained bands. 
 
In the first run, only pancreas, liver, brain, spleen and spine gave a positive signal when 
organs of DB 75 treated mice were tested by PCR (Fig. 10). In the second run, when organs of 
3 DB 75 treated mice were isolated and mRNA extracted, 3 pancreas, 1 liver, 2 brains, 1 lung, 
1 heart, 3 spleens, 2 thymus, 3 spines and 3 eyes showed presence of mouse cDNA (Fig. 11). 
 
Brain homogenates (Fig. 12) 
6 out of 8 brain pellet from melarsoprol and all brain pellets from DB 75 treated mice were 
extracted successfully as could be shown by the presence of mouse cDNA. 
 
3.2.2. Detection of trypanosomal cDNA 
Limit of detection (Fig. 13, Fig. 14) 
When a dilution series of trypanosomal cDNA in TE buffer was tested by PCR, 0.0857 
trypanosomes per reaction were still detectable. A dilution series of trypanosomal cDNA in 
mouse cDNA showed a remarkable reduction in sensitivity, since at least 40 trypanosomes 
had to be present in the PCR reaction mixture, otherwise no positive signal was obtained. 
 
Melarsoprol and DB 75 treated mice (Fig. 15, Fig. 16) 
The homogenate obtained from the brain of the melarsoprol treated mouse gave a positive 
signal for trypanosomal cDNA (Fig. 15). No cDNA of trypanosomes could be detected by 
PCR in organs obtained after treatment with DB 75 from the first run (Fig. 15). When 
analysing cDNA obtained from mice treated with DB 75 obtained from the second run, the 
spleen of one mouse gave a positive signal (Fig. 16). 
 
Brain homogenates (Fig. 17) 
The presence of trypanosomal cDNA could be detected in none of the brain homogenates, 
neither in the ones of mice treated with melarsoprol nor the ones treated with DB 75. 
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3.3. Injection of brain homogenates
In a parallel experiment it was checked whether trypanosomes get damaged, lose their
infectivity or get lost when organs undergo the homogenisation and centrifugation procedure.
Basis of this experiment was the protocol for the in vivo testing of compounds against late
stage trypanosomosis [Gichuki, G. (1999)]. Within this model a relapse based on re-invasion
of trypanosomes out of the brain is simulated. Thereto, a mouse infected with the
trypanosome strain GVR 35 (T. b. brucei) was treated on day 21 after infection with
diminazene. Since diminazene is not able to cross the BBB, only the blood is cleared from
parasites. Some days after diminazene treatment, the pellet of the brain of the GVR infected
mouse (obtained as described for tissue samples), was injected into an immunosuppressed
recipient mouse, since no trypanosome could be detected in the blood of the donor mouse
after double centrifugation microscopically. Establishment of an infection due to
trypanosomes present in the brain pellet, was checked by tail blood inspection one week after
injection.
Additionally, half of the pellet volume obtained after centrifugation of homogenised brains
obtained from melarsoprol and DB 75 treated mice, was injected into immunosuppressed
mice. This was performed with 8 mice, treated with either melarsoprol or DB 75. Tail blood
was checked for trypanosomes within a 4 week period to detect if a parasitaemia results from
those pellets. Immunosuppression was performed once a week.
One week after injection of the brain homogenate obtained from the GVR 35 infected mouse
parasites were found in the blood of the recipient mouse when tail blood was inspected.
Whereas, brain pellets obtained from STIB 900 infected mice treated with melarsoprol or DB
75 did not lead to a parasitaemia in immunosuppressed recipient mice.
4. Discussion
General aspects
When blood was collected, sodium citrate was used as anticoagulant, since heparin the
anticoagulant usually used, would inhibit the polymerase within the PCR. Heparin, a
negatively charged polysaccharide (glucosaminoglycan), is known to bind positive ions like
Mg2+, Ca2+ and others. Especially the presence of Mg2+ is important for PCR, since it forms
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complexes with dNTPs, primers and DNA templates which were needed by the polymerase to 
anneal and to synthesise the anti-strand. 
 
Blood check microscopically vs. PCR 
Testing mouse blood by PCR revealed that trypanosomal DNA was cleared within 7 days 
after the last DB 75 treatment. DNA extracted from blood of 5 mice clearly showed no 
presence of trypanosomal DNA. Therefore, it was possible to change the protocol and to 
introduce the microscopical control after double centrifugation of blood obtained by cardiac 
puncture in the aparasitic period. With the shift to the microscopical control instead of the 
check by PCR, the detection of any parasites could be performed within a shorter time and 
with less effort. Additionally, a lot of material and labour could be saved, since parasites were 
detected in an early stage of the experiment, before organs were DNA extracted. 
 
To reduce the amount of material which was obtained by homogenising the isolated organs, 
centrifugation steps played an important role. With the aid of a first slow centrifugation step 
at 700 rpm, dense particles could be eliminated. Carrying out a fast centrifugation at 2700 rpm 
with the supernatant obtained after the first centrifugation step, trypanosomes were found in 
the pellet. This centrifugation procedure leads to a reduced pellet size of a volume from 
approximately 100 to 250 µl. 
The homogenisation and centrifugation procedure performed did not lead to damage, 
reduction in infectivity nor total loss of trypanosomes, since pellets of brains of GVR 35 
infected mice were shown to trigger a parasitaemia in immunosuppressed recipient mice.  
 
Genomic level 
After having optimised parameters like annealing temperature and the Mg2+ concentration for 
the PCR to detect trypanosomal DNA, a dilution series was generated to test the sensitivity of 
this method. It could be shown, that it is possible to detect less than 1 trypanosome with this 
method despite the predominant presence of mouse DNA. Since DNA of one organ was 
extracted in 20 µl, it is possible to detected 3-4 trypanosomes per organ. 
 
Organs of melarsoprol treated mice were tested for the presence of trypanosomal DNA. These 
mice should have served as negative control, showing that total clearance of trypanosomal 
DNA had taken place within one week after treatment. Microscopical blood check after  
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double centrifugation technique revealed no trypanosomes, indicating that the mouse was in 
the aparasitic period when sacrificed. Since melarsoprol treated mice were known to be cured 
after treatment and not to relapse within the observation period of 185 days after the last 
treatment, presence of trypanosomal DNA was not expected. Surprisingly, DNA extracts of 
all organs showed a positive band identical with the band obtained for the positive control. 
This result lead to the assumption, that DNA persisted in organs longer than 7 days after the 
last treatment without being degraded. 
The problem of persistent free circulating DNA which may be detected during a certain time 
is already known from the treatment of visceral leishmaniasis, were kinetoplast DNA could be 
detected within 37 days after initiation of the drug treatment. One of the patients did not even 
turn PCR negative within 145 days after treatment [Disch, J. (2004)]. 
Another example is the free circulating DNA that is exploited in the diagnosis of occult 
infection with microfilariae (loa loa) by PCR [Toure, F.S. (1998)]. In occult loiasis, no 
microfilariae can be found in the peripheral blood and patients do not show any clinical 
symptoms. 
 
DNA of organs from DB 75 treated animals did not show a clear pattern in invading organs 
when checked by PCR. The reason could be that no specific niche is preferred and therefore 
depending on the individual mouse different organs may be invaded and serve as niche. More 
likely, it could be that these organs were positive because DNA of trypanosomes had not been 
degraded totally and could therefore be detected. DNA in tissues may be degraded slower 
than DNA circulating in the blood, as PCR of blood samples indicated. 
 
Taking the PCR results for melarsoprol and DB treated mice into account, it is not sure 
whether these positive signals obtained were due to free circulating DNA or if the DNA 
detected belonged to trypanosomes hidden in these organs. Results of melarsoprol treated 
mice indicate that the detected trypanosomal DNA is more likely to be DNA of dead 
trypanosomes, whose DNA was not degraded completely within the week after the last 
treatment. Since relapses after DB 75 treatment occur between day 9 and day 20, it was not 
possible to postpone the day of sacrifice any longer, since then relapses would have to be 
encountered. A mouse being in the early stage of the relapse would also deliver positive 
signals from any organ as soon as trypanosomal DNA within the blood could be detected by  
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PCR. In this case, trypanosomes would be found also when inspected microscopically after 
double centrifugation. 
 
mRNA level 
The presence of mouse cDNA increased the limit of detection over 400-fold from 0.0857 
trypanosomes per reaction in TE to 40 trypanosomes per reaction in mouse cDNA. Therefore, 
an organ has to be populated by at least 270 trypanosomes, in order to be identified as 
positive. 
 
Melarsoprol treated mice 
Extraction and transcription of mRNA from organs of melarsoprol treated mice seemed to be 
successful, since mouse cDNA could be detected for all samples. When these cDNAs were 
tested for the presence of trypanosomal DNA, one positive signal was obtained. The sample 
represented a homogenate of the brain. A possible explanation for this may be that 
trypanosomes managed to cross the BBB before drug treatment was performed. Treatment 
with melarsoprol, which is able to cross the BBB to a certain extent, did clear the blood from 
parasites and had also a certain toxic effect on parasites in the brain. The parasites in the brain 
may not be killed immediately and could have survived for some time. Since control mice did 
not relapse anymore, it is assumed that this population of parasites in the brain died without 
triggering a relapse. 
After having shown a trypanosome positive brain homogenate, 8 additional brains of 
melarsoprol treated mice were tested for the presence of trypanosomes. This time, half of the 
pellet obtained after the centrifugation steps was injected i.p. into immunosuppressed mice. 
Results will be discussed below. The remaining half of the pellet underwent mRNA extraction 
and transcription to cDNA. None of these samples could confirm the colonisation of the brain, 
when brain pellets were analysed by PCR.  
 
DB treated mice 
Unfortunately, extraction and transcription of organs from DB treated mice was unsuccessful 
for most of the samples in the first run. Why only 5 organs were extracted successfully and 
the others not, is not known. Since this extraction was performed parallel to the extraction of 
the organs obtained from the melarsoprol treated mouse, it could be excluded that one of the  
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substrates used for extraction and transcription did not work properly or was contaminated
with RNases. Therefore, the whole experiment was performed again with 3 mice. Here again,
the extraction of mRNA and transcription to cDNA was only partly successful. Organs which
delivered cDNA were tested for presence of trypanosomes. Interestingly, one positive organ
could be detected, showing a band at the same position as the positive control (Fig. 16). This
organ was identified to be the spleen. The spleen serves not only as efficient blood-filtering
system, but also as important element of the immune system. Based on its structure, a
distinction between red and white pulp is possible. The red pulp consists of large numbers of
sinuses and sinusoids. Removal of old and damaged erythrocytes and platelets is performed
within this zone. In addition, the present macrophages are discussed to be involved in iron
recycling and removal of bacteria from the blood. The white pulp represents the lymphoid
region of the spleen. There, T and B cell compartments can be distinguished. In the T cell
zone, T cells interact with dendritic cells and passing B cells, whereas in the B cell follicles
(B cell zones) clonal expansion of activated B cells takes place. Both zones are of importance
when an immunological response to antigens in the blood has to be generated [Mebius, R.E.
(2005)]. An intact immune system is of importance not only in the control of a developing
parasitaemia, but also in clearance of parasites after treatment (immune-dependence of
chemotherapy) [Berger, B.J. (1992)]. Therefore, this organ was suspected to serve as niche
already before the experiment was performed.
Since the detection of trypanosomal cDNA in mouse cDNA is not very sensitive, other organs
also may serve as niche, but detection may just not be possible since less than 270
trypanosomes could be present.
As already mentioned for melarsoprol, brains of DB treated mice were checked both by PCR
and by inoculation into naive, immunosuppressed mice. The inoculation of half of the pellet
obtained after centrifugation was performed to improve the detection limit. As seen, detection
limit for trypanosomal cDNA in mouse cDNA was not very sensitive. Inoculation of parasites
is very sensitive, since one trypanosome may be sufficient to initiate a parasitaemia. No mice,
neither injected with brain pellets of melarsoprol nor DB 75 treated mice turned parasitic
within 4 weeks although immunosuppression took place once per week.
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Since the centrifugation method was shown to work without having a negative effect on the 
trypanosomes, the result of this inoculation experiments indicated that the CNS had not been 
invaded within 3 days after injection of the parasites. 
 
The performed experiment clearly showed the mRNA extraction process and transcription to 
cDNA to be the bottleneck. Maybe, yield of the extraction may be increased and degradation 
of mRNA may be reduced within the preparation when a commercial RNA kit like the 
RNeasy® Kit from Qiagen would be used. 
This experiment was stopped at this stage due to limitations in time. To get better results, 
RNA extraction has to be improved, as well as the sensitivity of the PCR in presence of 
predominant mouse cDNA. 
 
5. Conclusion 
This experiment indicated that the brain is unlikely to be the source of relapse when treatment 
is performed already three days after infection as it is the case for the in vivo screening of 
compounds tested for activity in the acute mouse model. Based on the outline of this 
experiment and the results obtained from this study, other organs, like the spleen for example, 
have to be considered to serve as niche. It also showed, that the approach to detect the 
presence of trypanosomes by PCR would be possible on the level of mRNA. Thereto, 
sensitivity of the PCR performed with transcribed cDNA has to be increased. Using Southern 
blot technique would be one possibility to enhance sensitivity: after having transferred the 
amplified sequences to a membrane, denaturation to single strand cDNA is performed. 
Hybridising with a specific, radioactive labelled probe complementary to the sequence to 
detect, would lead to a signal indicating the presence of the amplified sequence. Another 
possibility to increase the sensitivity would be the use of different primers and/or a different 
gene, where inhibition of mouse cDNA may not be so strong. Additionally, improvements in 
the extraction of mRNA and its transcription to cDNA are of major importance. 
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Fig. 1: Nucleotide sequence of the 1390 bp fragment  
containing the spliced leader sequence: 
NCBI Sequence Viewer v. 2.0 
www. ncbi.nlm.nih.gov 
1390 BP 
 
 
aacgctatta ttagaacagt ttctgtacta tattggtatg agaagctccc agtagcagct        60 SLfa 
gggccaacac acgcattgtg ctgttggttc ctgccgcata ctgcggaatc tggaaggtgg       120 SLfb 
ggtcggatga cctttatctc tttttatttt ttttattttt ttttatttat tttttttttg       180 
atctttattt gctacgctga cacacacacg caaacacgca cacgcacact cacactcaca       240 
ctcactcata tatatatata tatattttct ttatttattt atttatttat ttatttattt       300 
gtttgtttat ttatttattt atatgcaaat ataattatac tatagcttat ggttttcttg       360 
catatctgta taagcgcgtt ggggtcctcg atgggcgctt tcatggctta tacgtgctcg       420 SLr2 
tttctcccgt tcatttttac gcagtcggac aatttcatgt cgctcttacc attgcaatta       480 
ctcattttca ctttacacat cactttctta cacatatagg cgctttaaag tctgctgccc       540 
gccgttttca atggcggtcg gcatgcccct ctacatgtct actgagcagg cgaacggccc       600 SLr3 
cggcatggca acaccaaata tcccctttca gggttttgcc tcattttgcc gatgttctta       660 
acctggttat acccgcaata tgccagctgc accctcagtt cgtgatgtta tatactttcc       720 
caattttggg gccggccccc gcccaacacc acccgccgct aataaacggc ggagaataac       780 
agcgagcata ccgccggcca gccacagagc cgaaagaagc cggcctgcgc gccctattca       840 
tgttattagc cgccattaag cattatatta cactcagttc aaccgtcctt cttctttgcg       900 
ttgttgttgt tgccgttgtg ttctatataa agtttatcgg cagaggcgcc ctggctcctc       960 
cccatcaccc cctgcccacc ctccaaaatc tggcgccgcc ggctggtcct gcacgcccca      1020 
gaaacgcgtt tcttttattg ttggttgatt gccttaatgt tctgttgcag atggcgattc      1080 
accattaagc atttaatatt ttagaaataa gagagcgctg gtaaaagacg gcgggtcgcg      1140 
ccacacggtg gttgccgtta tgcacgatac cccatgtagt atatatgcgg tcccgcttat      1200 
tccgccaccc tcccccataa cggcttaagc acaagacccc tttgtttccc ataggtctac      1260 
cgacacattt ctggcacgac agtaaaatat ggcaagtgtc tcaaaactgc ctgtacagct      1320 
tatttttggg acacacccat gctttcaact aacgctatta ttagaacagt ttctgtacta      1380 spliced_ 
tattggtatg                                                             1390 l_for 
 
 
PCR products DNA level: 
Primary PCR: SLfa – SLr3 :  554 bp 
Nested PCR: SLfb – SLr2 : 342 bp 
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 Fig. 6: Nucleotide sequence of Beta Tubulin 
NCBI Sequence Viewer v. 2.0 
www. ncbi.nlm.nih.gov 
1329 bp 
 
    1  atgcgcgaaa tcgtctgcgt tcaggctggc caatgcggta accagatcgg ctcaaagttc 
   61  tgggaggtga tcagtgacga gcacggtgtg gaccccacag gtacctacca gggtgactct 
  121  gacctgcagc tggagcgcat caatgtgtac tttgatgagg caacgggagg tcgctatgtg 
  181  ccccgctccg tgctgattga tctggagcca ggtacaatgg actccgtacg tgctggcccc 
  241  tatggtcaga tcttccgccc cgacaacttc atctttggac agtctggcgc cggcaacaac 
  301  tgggcaaagg gccactacac ggagggtgcg gaactgatcg actctgtgct cgatgtgtgc tub_b_nested_ 
361  tgcaaggagg cggagagctg tgactgcctc caaggcttcc agatctgcca ctcccttggt rv/tub_b_rv 
  421  ggtggtactg gctccggcat gggtacgctg ctcatctcga agcttcgcga gcagtaccct 
  481  gaccgtatca tgatgacttt ctccatcatc ccatccccca aggtgtccga cactgtcgtc 
  541  gagccgtaca atacgactct ctccgtgcac caacttgtgg aaaactccga tgagtcgatg 
  601  tgcattgaca acgaggcact gtacgatatt tgcttccgca ccctgaaact gacaacacca 
  661  acgttcggtg acctgaacca cttggtgtct gctgttgtgt ccggcgtcac ctgctgcctg 
  721  cgcttccctg gtcagttgaa ctctgacctc cgtaagttgg ctgtgaacct tgtcccattc 
  781  ccgcgtctgc acttcttcat gatgggcttc gccccgctga ccagccgcgg ctcgcagcag 
  841  taccgcggtc tctccgtgcc cgagctaacg cagcagatgt tcgatgcgaa aaacatgatg 
  901  caagctgcag atcctcgtca cggccgctac ctgacagcgt ctgcactctt ccgcggccgc 
  961  atgtcgacga aggaggttga tgagcagatg ctgaacgtgc agaacaagaa ctcgtcctac 
 1021  ttcattgagt ggatcccgaa caacatcaag tcctctgttt gcgatatccc acccaaggga 
 1081  ctcaagatgg ctgtcacctt cattggcaac aacacctgca tccaggagat gttccgccgt 
 1141  gtgggagagc agttcaccct catgttccgt cgcaaggcgt tcttgcactg gtacactggc 
 1201  gagggtatgg acgagatgga attcacggag gcagagtcca acatgaacga tctcgtgtct 
 1261  gagtaccagc agtaccagga tgccacgatt gaggaggagg gcgagttcga cgaggaggag 
 1321  caatactag 
 
PCR product: 
Spliced leader sequence 5`UTR β-tubulin 3`UTR  Poly A 
 35 bp 49 bp 1329 bp 
in PCR: 29 bp 49 bp 358 bp (1°), 328 bp (2°)  
primary PCR/secondary PCR:  436 bp / 406 bp 
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Fig. 8: CLUSTAL W (1.82) multiple sequence alignment:  
Mouse polymerase II and its mRNA sequence 
 
 
polyII          GCGTCCGGCGCAGGCTCCGTGCTGGCAGCTCCACGAGCGCGCGTGCACAGTTGTTTGGGA 60 
transcript      ------------------------------------------------------------ 
                                                                             
 
polyII          AGCGCGACAGCATGGACGACGAGGAGGAGACCTACCGGCTGTGGAAGATCCGCAAGACGA 120 
transcript      ------------------------------------------------------------ 
                                                                             
 
polyII          TCATGCAGGTGATCAAGCGTGAGGAGCTTTATGCGAGCGAGCGTTCAGTTGCGGACTAAC 180 
transcript      ------------------------------------------------------------ 
                                                                             
 
polyII          TGCGGGTTGTCCGCCGAGGCCCGCCTCCCGCAGGGGCCAATCCTCCTGGATTGGAATGCA 240 
transcript      ------------------------------------------------------------ 
                                                                             
 
polyII          TCCCCGTTTAAAGTGTGGAGCCCACCCACGCTGGCTTCAACTCTTAGAAATCCTACTGCT 300 
transcript      ------------------------------------------------------------ 
                                                                             
 
polyII          TCCACCTCCTAACTCTGCCTCAGGGGAAAAGGCCTGGGTGGGCTCCGTTTCGGGAGAGGG 360 
transcript      ------------------------------------------------------------ 
                                                                             
 
polyII          GGCTGCTGCGTGGTCACACTTGGTTTTATGCGAGCTAGGTAGCCGCCCACACGAAAGCTA 420 
transcript      ------------------------------------------------------------ 
                                                                             
 
polyII          TCAACCATCTGTAACCCCAGTTCCAGGGGATCTGACGCCCTGTCCTGATCTCTGGGGACT 480 
transcript      ------------------------------------------------------------ 
                                                                             
 
polyII          CCAGACACACATAGGATGAAAAAACAGTATTTTTAAAAACAGAACAAGCCGGTATGATGG 540 
transcript      ------------------------------------------------------------ 
                                                                             
 
polyII          TACACGCCTTTAATCCCAGCACTCTGGAGGCAGAAGCAAGCGAATCTCTTTAAATTAGAA 600 
transcript      ------------------------------------------------------------ 
                                                                             
 
polyII          GTCAGCCTCATCTACATAGTGATTTCCAGAATAGACAAAGTCACGCAGAGAAACCCTGTC 660 
transcript      ------------------------------------------------------------ 
                                                                             
 
polyII          TTGAAAAAGAAAAAGGGAATAAAAGAAAAAATTCTTGGTTGTTTTGAGTTGAACACATGA 720 
transcript      ------------------------------------------------------------ 
                                                                             
 
polyII          GACACCATTATTAGATAAAGAGGTATGCATAGTTTTGACTTATGCTGTGTTGGTGGAGCC 780 
transcript      ------------------------------------------------------------ 
                                                                             
 
polyII          CAGGGCCACCTCATGCCTGTTCCTCAGCCCTGATCCTGGATGATGCTCTAGTCTCCCTCA 840 
transcript      ------------------------------------------------------------ 
 
polyII          TCAGGAACACTCAAGACTGGGGACAGGAAGGTGCCTGTATTCAGAAGGTTGCCTACAGTT 900 
transcript      ------------------------------------------------------------ 
                                                                             
 
polyII          GCCAGGGGATTAATCCCAGCCTGCTCCACTGAGGTTGGGGGGAGGAGAGGCTTGGCCGGG 960 
transcript      -------------------------------------------CCACGCGTCCGGCGCAG 17 
                                                             *   *   ***   * 
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polyII          CCGCTGTGGTCTGAGCCTATACAGAGTTTGGGTACTGCTGGATCAGTTCAGTGTTAGTCC 1020 
transcript      GCTCCGTGCTGGCAGCTCCACGAGCGCGCGTGCACAGTTG--TTTGGGAAGCGCGA---- 71 
                 * * *** *   ***      ** *   * * ** * **  *  *   ** *  *     
 
polyII          CCAGCCTCGGCCATTCAGGGTCAGGTCTGCGAGCTAAGTGCTCAGGCTGACTGCCTCTTT 1080 
transcript      -CAGCATGGACGACG-AGGAGGAGACCTACCGGCTGTGGA---AGA-----------TCC 115 
                 **** * * * *   ***   **  ** *  ***  *     **            *   
 
polyII          GCCTCTTGTCTCTGCAGCTGTGTCATGACCGTGGCTACCTGGTGACCCAGGATGAACTGG 1140 
transcript      GCAAGACGATCATGCAGCTGTGTCATGACCGTGGCTACCTGGTGACCCAGGATGAACTGG 175 
                **     *    ************************************************ 
 
polyII          ACCAGACACTTGAGGAATTCAAGGCGCAGTTTGGGGACAAGCCCAGCGAAGGACGGCCAA 1200 
transcript      ACCAGACACTTGAGGAATTCAAGGCGCAGTTTGGGGACAAGCCCAGCGAAGGACGGCCAA 235 
                ************************************************************ 
 
polyII          GGCGCACAGACCTCACGGTGCTGGTGGCCCACAACGATGACCCCACAGACCAGATGTTTG 1260 
transcript      GGCGCACAGACCTCACGGTGCTGGTGGCCCACAACGATGACCCCACAGACCAGATGTTTG 295 
                                                                             
 
polyII          TGTTCTTCCCAGGTGAGGCCCTTGGGCTGGCAGGAGTGGTCTCCTCCAGGCCCTGGCTCA 1320 
transcript      TGTTCTTCCCAGGTGAGGCCCTTGGGCTGGCAGGAGTGGTCTCCTCCAGGCCCTGGCTCA 355 
                ************************************************************ 
 
polyII          GGTGCCAGTGAATGCATGTCCCACTCTGGCCTAACGCTGCCTGTAAGATTGTGGCAGCTG 1380 
transcript      GGTGCCAGTGAATGCATGTCCCACTCTGGCCTAACGCTGCCTGTAAGATTGTGGCAGCTG 415 
                ************************************************************ 
 
polyII          CCTGCTTTTGTCCCTGTCTCCCCTGGGAAGCCTCCCTTTTGCTGGTGTCGTTTTCATCCC 1440 
transcript      CCTGCTTTTGTCCCTGTCTCCCCTGGGAAGCCTCCCTTTTGCTGGTGTCGTTTTCATCCC 475 
                ************************************************************ 
 
polyII          ATAAGCCCCAGAACCAGCTCTCAGCCCTCCACCCCCTGGCTCCTATATGCTGTATTCTAT 1500 
transcript      ATAAGCCCCAGAACCAGCTCTCAGCCCTCCACCCCCTGGCTCCTATATGCTGTATTCTAT 535 
                ************************************************************ 
 
polyII          AGCTTCTGCCTGGGAGTCCCAGGGCCAGCTATGCCACCCCCACACCCCCTGTGTGCTGTA 1560 
transcript      AGCTTCTGCCTGGGAGTCCCAGGGCCAGCTATGCCACCCCCACACCCCCTGTGTGCTGTA 595 
                ************************************************************  
 
polyII          TTCTACAGCTTCTGCCAGCAGCGCAGGTGTCTTGTGGGAGTGAAGGCTATTGGGGAGCCC 1620 
transcript      TTCTACAGCTTCTGCCAGCAGCGCAGGTGTCTTGTGGGAGTGAAGGCTATTGGGGAGCCC 655 
                ************************************************************ 
 
polyII          AGGACCTCCCTGTGCAGCTACATTCAGTCTCCCCAGACAGCTTGCCTCTTTTAATACCTA 1680 
transcript      AGGACCTCCCTGTGCAGCTACATTCAGTCTCCCCAGACAGCTTGCCTCTTTTAATACCTA 715 
                ************************************************************ 
 
polyII          ATGCTTTGTGGCCCCGGGACCTGGTTTTTAGTGTGAGAATTGGGGGGTGCGGGGATGGGC 1740 
transcript      ATGCTTTGTGGCCCCGGGACCTGGTTTTTAGTGTGAGAATTGGGGGGTGCGGGGATGGGC 775 
                ************************************************************  
 
polyII          ATGGTAGCATATGCCTGTAAGCCCAGTGTTTGAGAGGCAGAGGCAGGCAGTCGAGGCCAG 1800 
transcript      ATGGTAGCATATGCCTGTAAGCCCAGTGTTTGAGAGGCAGAGGCAGGCAGTCGAGGCCAG 835 
                ************************************************************ 
 
polyII          CCTGGTCTATACAATGACTTCCGGGACAACTATGGAGGGCATTGGTTCTCAGCCTTCCTG 1860 
transcript      CCTGGTCTATACAATGACTTCCGGGACAACTATGGAGGGCATTGGTTCTCAGCCTTCCTG 895 
                ************************************************************ 
 
polyII          ATGCTGGGACCCCTTAGTACACTTCACATTGTGACCTCCAACCATAAAATCTTCATTGCT 1920 
transcript      ATGCTGGGACCCCTTAGTACACTTCACATTGTGACCTCCAACCATAAAATCTTCATTGCT 955 
                                                                             
 
polyII          AATTCATAACTAATTTTGCTACTATTATGAGTCATAATGTAAATATACCTGTGTTTATCC 1980 
transcript      AATTCATAACTAATTTTGCTACTATTATGAGTCATAATGTAAATATACCTGTGTTTATCC 1015 
                ************************************************************ 
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polyII          AGCAATTTGCAAACTAGGTGGCCTGGGTCTGCTCCTGCGCTCTGCCTGAGGAGACAAGGC 2040 
transcript      AGCAATTTGCAAACTAGGTGGCCTGGGTCTGCTCCTGCGCTCTGCCTGAGGAGACAAGGC 1075 
                ************************************************************ 
 
polyII          TAGCCTCATGTAGACACAGGGTCCATCTCTTGGTCAGTCAGTTTCTCCTTGAGGCTGTCT 2100 
transcript      TAGCCTCATGTAGACACAGGGTCCATCTCTTGGTCAGTCAGTTTCTCCTTGAGGCTGTCT 1135 
                ************************************************************ 
 
polyII          AAGCTGACAGTACCATATCCCCCAAACCCCAGAGCTGCTGAGAGCCCCCACCCCCGTTCC 2160 
transcript      AAGCTGACAGTACCATATCCCCCAAACCCCAGAGCTGCTGAGAGCCCCCACCCCCGTTCC 1195 
                ************************************************************ 
 
polyII          AGGGGGGCCGCAGTTCCTGCATACCCTGCAGCTTCTGCAGTGATAGCTGAGCCCCCTGGC 2220 
transcript      AGGGGGGCCGCAGTTCCTGCATACCCTGCAGCTTCTGCAGTGATAGCTGAGCCCCCTGGC 1255 
                ************************************************************ 
 
polyII          AGCCCCATCATGGCTGCCTTGATGTTCTAGTCTTCCCTTGCAAGCAGAGAAACTAAGACC 2280 
transcript      AGCCCCATCATGGCTGCCTTGATGTTCTAGTCTTCCCTTGCAAGCAGAGAAACTAAGACC 1315 
                ************************************************************ 
 
polyII          ACAGGCTCCAGTAGTGAGTGTGAGGGTGGTGCTTGTGTGCCCGCAGAGGAGCCCAAGGTG 2340 
transcript      ACAGGCTCCAGTAGTGAGTGTGAGGGTGGTGCTTGTGTGCCCGCAGAGGAGCCCAAGGTG 1375 
                ************************************************************ 
 
polyII          GGCATCAAGACCATCAAGGTATACTGCCAGCGCATGCAGGAGGAAAACATCACACGGGCG 2400 
transcript      GGCATCAAGACCATCAAGGTATACTGCCAGCGCATGCAGGAGGAAAACATCACACGGGCG 1435 
                ************************************************************ 
 
polyII          CTGATTGTGGTGCAGCAGGGCATGACGCCCTCCGCCAAGCAGTCCCTGGTGGACATGGCC 2460 
transcript      CTGATTGTGGTGCAGCAGGGCATGACGCCCTCCGCCAAGCAGTCCCTGGTGGACATGGCC 1495 
                ************************************************************ 
 
polyII          CCGAAGTATGTGCTGGAACAGTTTCTACAGCAGGAGCTGCTCATCAATATCACAGAGCAC 2520 
transcript      CCGAAGTATGTGCTGGAACAGTTTCTACAGCAGGAGCTGCTCATCAATATCACAGAGCAC 1555 
                ************************************************************ 
 
polyII          GAGGTGTGTGTGGTGGGGTGGGGCGTAGTGCTGCCTGCATCCAGGACACGGGCCGGGGCG 2580 
transcript      GAGGTGTGTGTGGTGGGGTGGGGCGTAGTGCTGCCTGCATCCAGGACACGGGCCGGGGCG 1615 
                                                                             
 
polyII          GGGTGCTTCCCCGGTTTTGGCCCTGAGCATCCAACTTGGTGATATTAATAGCCTGGTTTT 2640 
transcript      GGGTGCTTCCCCGGTTTTGGCCCTGAGCATCCAACTTGGTGATATTAATAGCCTGGTTTT 1675 
                ************************************************************ 
 
polyII          GTCCTCTGTCCCAGCCCCATGACAATACCCATTAGTCTGTTGGTCTGTTGAAGTTCCTGA 2700 
transcript      GTCCTCTGTCCCAGCCCCATGACAATACCCATTAGTCTGTTGGTCTGTTGAAGTTCCTGA 1735 
                ************************************************************ 
 
polyII          TGGCCGCGTGCCTGTGGGTGGGTCTCTGTCTCCACAGCTAGTCCCTGAGCACGTGGTCAT 2760 
transcript      TGGCCGCGTGCCTGTGGGTGGGTCTCTGTCTCCACAGCTAGTCCCTGAGCACGTGGTCAT 1795 
                ************************************************************ 
 
polyII          GACAAAGGAGGAGGTGACTGAACTGCTGGCTCGATAGTATCCTTTACTCTGTCCCCACAC 2820 
transcript      GACAAAGGAGGAGGTGACTGAACTGCTGGCTCGATAGTATCCTTTACTCTGTCCCCACAC 1855 
                ************************************************************ 
 
                                                 poly_fwd_2 
 
polyII          CCCCCTCACCCCAGCGCTGCCCGCCAGCTGCTTCCTTGACTGTTCTAGCAAGCTTCGTGA 2880 
transcript      CCCCCTCACCCCAGCGCTGCCCGCCAGCTGCTTCCTTGACTGTTCTAGCAAGCTTCGTGA 1915 
                ************************************************************ 
 
polyII          GAGCCAGCTACCCAGAATCCAGGCCGGGGACCCAGTGGCACGGTACTTTGGGATCAAGCG 2940 
transcript      GAGCCAGCTACCCAGAATCCAGGCCGGGGACCCAGTGGCACGGTACTTTGGGATCAAGCG 1975 
                ************************************************************ 
 
polyII          AGGGCAGGTGAGAAGCCACAGTGGTTGTTCCCCTCCTAGGCCCTTTGGGAATTATTGGAT 3000 
transcript      AGGGCAGGT--------------------------------------------------- 1984 
                *********                                                    
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polyII          CTCCCTGGTTCCTCCATCTCCTCCCTGTCTCTGAGGCCAAGACCACCATTGCCATAGGCC 3060 
transcript      ------------------------------------------------------------ 
                                                                             
 
polyII          AGTGGTCCCAAGGCCCTGCCACCACCACTCCCTCGCCTGCCTGCTCCCACAGGTCGTGAA 3120 
transcript      ------------------------------------------------------CGTGAA 1990 
                                                                      ****** 
 
polyII          GATCATCCGCCCCAGTGAGACGGCTGGCCGCTACATCACCTACCGCCTGGTGCAGTAGCC 3180 
transcript      GATCATCCGCCCCAGTGAGACGGCTGGCCGCTACATCACCTACCGCCTGGTGCAGTAGCC 2050 
                ************************************************************ 
 
polyII          GCAGGTGAGCCCAGCACTGCCCAGATGAGCCTGCTACTTGTCCTTGACCCGGTAGAGGGT 3240 
transcript      GCAGG------------------------------------------------------- 2055 
                *****                                                        
 
polyII          CAGAGCTGCACCCACAAAAATAAAATGTAACGGGAGGGTAGGCTTGAATCCTAATGCCCA 3300 
transcript      ------------------------------------------------------------ 
                                                                             
 
polyII          GGGGCAAAGGCAGGCAGATGTCTGTGAGTTCCAGACCAGCCAGGGCTACATAGTAAGCCT 3360 
transcript      ------------------------------------------------------------ 
                                                                             
 
polyII          CAGAAAGCAAGCAAACAAACAAACCCAAAACAACCCATACTCTTGCCAGGGGAAACCTAG 3420 
transcript      --------------------------------------------------GGAAACCTAG 2065 
                                                                  ********** 
 
polyII          TGCTCAGAGACTGAAGCAGGAGGATTGCTGCACATCTGTGGACTCCTTCTCGGTGTGAGT 3480 
transcript      TGCTCAGAGACTGAAGCAGGAGGATTGCTGCACATCTGTGGACTCCTTCTCGGTGTGAGT 2125 
                ************************************************************ 
 
polyII          GTCTCCAGGAAAACAATGAAGAGGAACCCACAGCTGCACCGCATGCAGGGAAACCCAGAG 3540 
transcript      GTCTCCAGGAAAACAATGAAGAGGAACCCACAGCTGCACCGCATGCAGGGAAACCCAGAG 2185 
                ************************************************************ 
 
polyII          CCCACTGCTCTGCACAGCACCCTGACAGCTGTGGGCCACAGCCTGTGGGTCATAACTGGA 3600 
transcript      CCCACTGCTCTGCACAGCACCCTGACAGCTGTGGGCCACAGCCTGTGGGTCATAACTGGA 2245 
                ************************************************************ 
 
                               poly_rv_2 
 
polyII          TTGCCTTTTGACTGACGGGTTCCGTCCTGGCCATTGTCGCAGGATGAGTGACTCCAGAGC 3660 
transcript      TTGCCTTTTGACTGACGGGTTCCGTCCTGGCCATTGTCGCAGGATGAGTGACTCCAGAGC 2305 
                ************************************************************ 
 
polyII          TGCAGCCACACCCCCACTCCTTACTCCAGGGTCACTGTTCTGTTCAGAGTTCTCCATTCT 3720 
transcript      TGCAGCCACACCCCCACTCCTTACTCCAGGGTCACTGTTCTGTTCAGAGTTCTCCATTCT 2365 
                ************************************************************ 
 
polyII          CGAAGGACTCTCCTGAGAATTAAAGGATACTTTGATAAGTT------------------- 3761 
transcript      CGAAGGACTCTCCTGAGAATTAAAGGATACTTTGATAAGTTAAAAAAAAAAAAAAAAAAA 2425 
                *****************************************                    
 
polyII          ---- 
transcript      AAAA 2429 
 
 
 
PCR products: 
poly_fwd_2 – poly_rv_2: 
DNA level: 785 bp 
mRNA level 395 bp 
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Melarsoprol and pentamidine resistant strains  
and their cross resistance 
 
Abstract 
Resistance to melarsoprol and pentamidine, respectively, was induced in trypanosomes of the 
strain STIB 900 in vitro. The obtained resistant trypanosome populations were tested for their 
sensitivity to DB 75, melarsoprol and pentamidine.  
Additionally, resistant populations were inoculated in immunosuppressed mice to check 
whether they were still infective and to monitor if a selection takes place. After having been 
proliferated in the mouse, trypanosomes were isolated and their IC50 to the above mentioned 
drugs were determined. To assess the stability of this drug induced resistance, drug pressure 
was ceased for 2 months. Then again, sensitivity to the drugs mentioned above was tested. 
Resistance was shown to be stable. IC50 of the drugs showed that cross resistance occurred 
between all drugs, but to a different extent. Melarsoprol resistant trypanosomes showed the 
same resistance to pentamidine as the pentamidine resistant strain did. This relationship was 
not the same vice versa, since melarsoprol resistance was lower in pentamidine resistant 
trypanosomes compared to the one in melarsoprol resistant trypanosomes. Interestingly, the 
same sensitivity to DB 75 was determined for both resistant strains. Proliferation of resistant 
trypanosomes in mice did not have any effect on the sensitivity to the tested drugs. 
 
1. Introduction 
Resistance to drugs is a major problem in treatment of diseases. Basically, a distinction 
between an innate and an acquired resistance can be made. Innate resistance is found, when an 
organism per se is not sensitive to treatment without having had a previous contact to the 
drug, whereas an acquired resistance may be the result of drug exposure, drug pressure, cross 
resistance or mutagenesis. Today, mechanisms of resistance of bacteria against most 
antibiotics are well investigated and documented. 
Trypanosomal resistance to treatment had been reported very early: Ehrlich postulated 
resistance of trypanosomes to fuchsin already in 1907 [Ehrlich, P. (1907)]. However, little is 
known about the mechanism of resistance in trypanosomes. The identification of the P2 
transporter and its recognition motif was a big breakthrough in the investigation of a 
developing resistance of trypanosomes to melarsoprol. 
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Problems of anti-parasitic drugs are, that they are acting specifically against a target within 
the parasites, and therefore resistance may occur very easily when minor changes within this 
target happen. These minor changes of the target are mostly based on spontaneous mutation in 
the genome and emerge particularly in organisms which show a short generation time and a 
high frequency of combinatorial events. High intergenetic exchange is occurring mainly in 
bacteria and viruses. In trypanosomes, combinatorial events were known to exist only in the 
procyclic forms in the tsetse fly and not in bloodstream forms [Jenni, L. (1986)]. Generally, 
mutations of the genome leading to drug resistance have to deliver a selective advantage of 
the mutant over the wild type. Additionally, this mutation has to be passed on to the 
descendants and should not get lost when parasites enter the next stage of their life-cycle. 
Acquiring resistance always imposes a certain cost for the parasites, possibly a reduction in 
infectivity or in the transmission rate. The cost for melarsoprol resistance is not exactly 
known, but mutations in the P2 transporter could lead to reduced uptake of nucleobases like 
adenosine, which are essential for the parasites. 
 
Resistance to a drug is defined by the ability to tolerate certain concentrations without having 
any negative effects on the parasite. Many mechanism of resistance are known to date: 
 One strategy is to produce more targets (overexpression), so that some of the targets are 
still free available. Binding of morphine at the opioid receptor is known to stimulate the 
synthesis of this receptor. Therefore, an increase of drug is necessary to reach the same effect: 
so called pharmacodynamic tolerance in pain therapy. 
 Another mechanism is that the target itself undergoes mutations. Differences at the drug 
binding site may lead to a decrease in affinity. An example for this type of resistance is the 
reduced affinity of streptomycin which can not bind anymore to the modified 30 s subunit of 
the bacterial ribosome. The modification of the RNA-polymerase beta subunit is responsible 
for resistance to rifampicin. 
 Mutations of drug transporters are also a strategy in development of resistance. 
Transporters responsible for drug uptake show mutations as the example of the chloroquine 
transporter in plasmodia does. Resistance to chloroquine is linked to multiple mutations in a 
protein (PfCRT: P. falciparum chloroquine resistance transporter) that is assumed to function 
as transporter in the parasite´s digestive vacuole. Chloroquine is assumed to interact in the 
detoxification of hematin by binding to it and forming toxic complexes. [Wellems, T.E. 
(2001)], [Wellems, T.E. (2004)]. 
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Induction of export pumps like P-Glycoprotein (P-gp), a protein encoded by the multiple
drug resistance gene (MDR), is also one strategy to decrease drug concentration within a cell.
Protease inhibitors used in therapy of HIV were shown to be exported massively by P-gp.
Combination with P-gp inhibitors, like other protease inhibitors (ritonavir, saquinavir,
nelfinavir) or a calcium channel blocker like verapamil, is used to reach higher levels of
protease inhibitors [Fardel, O. (1996)].
Resistance may be transient, as the example of chloroquine resistance in Malawi showed
[Kublin, J.G. (2003)]. After having had high treatment failures due to resistance of malaria
parasites to chloroquine, first line treatment was changed to the combination
sulfadoxine/pyrimethamine. Several years later, re-introduction of chloroquine was possible
since resistance got lost. A possible explanation for the increase of the sensitivity to
chloroquine may be caused by re-emergence of chloroquine sensitive plasmodia due to
withdrawal of drug pressure. It seemed that resistance burdens in vivo fitness and therefore
wild type plasmodia spread again after drug pressure had gone.
Today, one strategy to delay or prevent development of resistances is to combine drugs acting
on different targets and therefore exhibiting different modes of action. Combination
chemotherapy decreases the probability of resistance, since it is less likely that one parasite is
resistant both to drug A and drug B. Another advantage, which is of importance especially in
respect to antibiotics, is that when two different acting drugs were combined the spectrum
may be extended (extended-spectrum antibiotics). Additionally, synergistic effects may result
from a combination of two different acting drugs. A positive effect often observed, is that a
combination allows to decrease the concentration of the constituents compared to
monotherapy and therefore therapy may be tolerated better in patients. Whiteside suggested
the combination of so called “sanative” pairs of drug, which do not induce cross resistance to
each other [Whiteside, E.F. (1958)]. Also, resistances are less likely to occur for drugs with a
short half life than for drugs with a long half life. Another factor which has to be mentioned in
this context is that not only the concentration of drug the parasite is exposed to, but also the
duration of exposure is of importance in developing resistance.
Within this study, in vitro resistance to drug was induced by growing trypanosomes of the
strain STIB 900 (Trypanosoma brucei rhodesiense) in rising concentration of melarsoprol or
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pentamidine, respectively. Sensitivity of these resistant strains was tested. Thereto, the
concentration at which 50% of the parasites were killed compared to the control (IC50) of
trypanosomes resistant to melarsoprol and pentamidine were tested in the Alamar Blue assay
[Raz, B. (1997)]. Additionally, cross resistance to DB 75, pentamidine resistance in
melarsoprol resistant trypanosomes and melarsoprol resistance in pentamidine resistant
trypanosomes was determined. By dividing the IC50 of a compound obtained for the resistant
strain by the IC50 of this compound obtained for the wild type, the resistance factor is obtained
[Carter, N.S. (1995)].
Since resistant trypanosomes were kept in culture conditions for several months, infectivity in
a host was checked by inoculating trypanosomes in immunosuppressed mice. After
proliferation in the mouse, stabilates were made and IC50 of trypanosomes were determined
and compared to the ones obtained for trypanosomes from culture.
Comprehension of the mechanism underlying drug resistance is of importance since gained
knowledge may help to evaluate new drug targets. The presence of cross resistance would
indicate that the drugs tested do have the same target or the same transporter.
2. Material and Methods
2.1. Trypanosomes
STIB 900 is a derivative of STIB 704 which was isolated from a male patient at St. Francis
Hospital in Ifakara/Tanzania in 1982. After several passages in rodents and a cyclic passage in
Glossina morsitans morsitans, a cloned population was adapted to axenical growth in vitro.
2.2. Medium
Trypanosomes were cultivated in Minimum Essential Medium (MEM) with Earle`s salts
(powder, GIBCO, Invitrogen, Basel, Switzerland), supplemented with 25 mM HEPES
(GIBCO, Invitrogen, Basel, Switzerland), 1 g/l additional glucose, 2.2 g/l NaHCO3 and
10 ml/l MEM nonessential amino acids (100x, GIBCO, Invitrogen, Basel, Switzerland). The
medium was further supplemented with 0.2 mM 2-mercaptoethanol, 2 mM sodium pyruvate,
0.1 mM hypoxanthine, 0.016 mM thymidine and 15% heat inactivated horse serum [Baltz, T.
(1985)].
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2.3. Drugs
DB 75 was synthesised by Dr. D. W. Boykin, Georgia State University, Atlanta, USA [Das,
B.P. (1977)]. Melarsoprol was obtained from WHO, Geneva, Switzerland donated by Sanofi-
Aventis, and pentamidine as Pentacarinat® from Rhone-Poulenc, Thalwil, Switzerland.
Endoxan® (cyclophosphamide) was purchased from Baxter, Volketswil, Switzerland and
Resazurin from Fluka, Buchs, Switzerland.
2.4. Generation of resistant strains
Trypanosomes were cultured under a subcurative dose of either melarsoprol or pentamidine.
After several subpassages, when proliferated trypanosomes showed no difference in size,
morphology and fission rate compared to trypanosomes cultured without drug, the amount of
drug applied was increased stepwise. After several of these adaptation steps, resistant strains
were obtained.
2.5. Alamar blue assay
Trypanosomes were tested for their in vitro sensitivity to melarsoprol, pentamidine and
DB 75. Thereto, trypanosomes were incubated 72 hours in serial drug dilutions of these drugs
in a 96-well plate [Raz, B. (1997)]. After addition of the viability indicator resazurin (12.5 mg
in 100 ml phosphate buffered saline), plates were read at excitation wavelength 536 nm and at
emission wavelength 588 nm using the fluorescence reader SpectraMAX Gemini XS (Bucher
Biotech AG, Basel, Switzerland). To determine the IC50, data analysis was performed with
SoftmaxPRO 3.1.2..
2.6. Proliferation of resistant trypanosomes in immunosuppressed mice
Female NMRI mice with a body weight of 18-22 g were purchased from RCC, Ittingen,
Switzerland. Mice were immunosuppressed applying 200 mg/kg Endoxan® intraperitoneally.
Resistant trypanosomes were concentrated to 5*106 trypanosomes and were inoculated
i.p. into mice. Tail blood was checked for trypanosomes. When parasitaemia was high,
stabilates were made and stored in liquid nitrogen. Trypanosomes proliferated in mice were
tested for their sensitivity using the Alamar Blue assay.
Animal use adhered to the guidelines issued by the Swiss Federal Veterinary Department
(BVET) for laboratory animals.
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3. Results
A summary of the obtained results is presented in Table 1.
3.1. Melarsoprol and pentamidine resistant STIB 900
Trypanosomes grown in melarsoprol showed an IC50 of 74.5 ng/ml to melarsoprol compared
to the wild type STIB 900 strain with an IC50 of 3 ng/ml (resistance factor: 24.8). In the case
of pentamidine, IC50 of the resistant strain was 165.8 ng/ml compared to an IC50 of 1 ng/ml
for its non resistant counterpart (resistance factor: 165.8).
3.2. Cross resistances
IC50 to pentamidine determined in the melarsoprol resistant strain was 175.6 ng/ml (resistance
factor: 175.6), and IC50 to melarsoprol in pentamidine resistant strains was determined to be
38 ng/ml (resistance factor: 12.7).
DB 75 was determined to have an IC50 of 17.1 ng/ml (resistance factor: 11.4) in the
melarsoprol resistant strain and of 20.4 ng/ml (resistance factor: 13.6) in the pentamidine
resistant strain.
3.3. Transience of resistance
Trypanosomes showing resistance were kept in culture without drug pressure. After
approximately 120 generation times (2 months = 60 days = 60*2, assuming a generation time
of 12 h), sensitivity to melarsoprol, pentamidine and DB 75 was assessed. Melarsoprol
resistant strains showed an IC50 of 77.9 ng/ml to melarsoprol (resistance factor: 26),
161.3 ng/ml to pentamidine (resistance factor: 161.3) and 19.1 ng/ml to DB 75 (resistance
factor: 12.7). Pentamidine resistant strains had an IC50 of 121.2 ng/ml to pentamidine
(resistance factor: 121.2), 17.8 ng/ml to melarsoprol (resistance factor: 5.9) and 18.5 ng/ml to
DB 75 (resistance factor: 12.3). Results showed that a low cross resistance to both resistant
strains was obtained for DB 75. A high cross resistance was found to pentamidine in the
melarsoprol resistant strain, whereas in the pentamidine resistant strain a low cross resistance
to melarsoprol was detected.
3.4. Infectivity
Inoculated trypanosomes lead to a moderate to high parasitaemia within a few days.
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3.5. Selection in mice
Resistant trypanosomes proliferated in mice underwent several passages in culture medium
before they were tested in the Alamar Blue assay.
Melarsoprol resistant trypanosomes isolated from mice showed an IC50 of 64.7 ng/ml to
melarsoprol (resistance factor: 21.6), an IC50 of 118.5 ng/ml to pentamidine (resistance
factor: 118.5) and an IC50 of 23.7 ng/ml to DB 75 (resistance factor: 15.8).
IC50s for pentamidine resistant trypanosomes isolated from a mouse were shown to be on
average 140.3 ng/ml to pentamidine (resistance factor: 140.3), 30.4 ng/ml to melarsoprol
(resistance factor: 10.2) and 19.1 ng/ml to DB 75 (resistance factor: 12.7).
Cross resistance to DB 75 was low in both melarsoprol and pentamidine resistant strains. The
melarsoprol resistant strain showed a high cross resistance to pentamidine, whereas low cross
resistance to melarsoprol was found in the pentamidine resistant strain.
4. Discussion
Cross resistances between melaminophenyl arsenicals and diamidines in laboratory strains
had been reported several times [Barrett, M.P. (2003)]. The reason for this cross resistance
had been attributed to the loss of the P2 transporter, which transports both classes of drugs
inside the parasite, since the mode of action of the two classes of drugs is assumed to be
different [Barrett, M.P. (1999)], [de Koning, H.P. (2001)]. The proposed mode of action of
arsenicals is an interaction on energy metabolism and on membrane integrity, whereas
diamidines were thought to interact with negatively charged molecules like nucleic acids,
and/or membrane phospholipids [Barrett, M.P. (1999)].
However, to draw a conclusion referring to a possible cross resistance between an arsenical
and a diamidine is not easy, as observations showed [Barrett, M.P. (1999)], [Matovu, E.
(2001)]. One reason may be that drug uptake into the trypanosome may be additionally
mediated by several transporters other than the P2 transporter.
Theoretically, loss or mutation of P2 transporter would induce high levels of resistance to
melaminophenyl arsenicals and very low levels of resistance to pentamidine due to the
amount of transporters the drug relies on.
In this experiment melarsoprol and pentamidine resistant strains both showed only a slight
cross resistance to DB 75 (resistance factor 12.5). This indicates that the P2 transporter plays
a certain but not exclusive role in uptake of DB 75. Recent studies on transport of DB 75
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suggested also the P1 transporter to be involved [Brun R., personal communication]. A 
possible interplay between P1 and P2 transporters was suggested to have a key function in 
uptake of adenosine in a way that overexpression of the P1 compensated for lack of the P2 
transporter [Geiser, F. (2005)]. A similar behaviour may occur when mutation of the P2 
transporter decreases the uptake of adenosine, which may then be taken up via P1 transporter. 
The ribose moiety of adenosine, to be more precise two hydroxylgroups of the ribose 
molecule, serve as recognition motif for the P1 transporter [de Koning, H.P. (1999)]. The 
possible recognition motif for DB 75, if at all transported by P1, is not elucidated to date. 
 
Interestingly, cross resistance of melarsoprol resistant strains to pentamidine was very high 
(average resistance factor 150), whereas pentamidine resistant strains showed low cross 
resistance to melarsoprol (average resistance factor 9.6). These results were in a way 
surprising as cross resistance of pentamidine resistant strains were thought to result also in a 
high resistance to melarsoprol. It was hypothesised that mutations occurring in the three 
transporters (P2, High affinity pentamidine transporter: HAPT, low affinity transporter: 
LAPT) involved in pentamidine uptake, had a higher impact on cross resistance to 
melarsoprol which is transported only by two transporters (P2 and a yet unidentified 
transporter [de Koning, H.P. (2004)]). 
These results may indicate that the mutation of the P2 transporter plays a minor role when 
resistance is induced by pentamidine, and/or that overexpression of another drug transporter 
compensates for drug uptake of melarsoprol in the pentamidine induced resistant trypanosome 
strain as described for P1/P2 transporters in uptake of adenosine. 
 
Stability of resistance 
Resistance to drug did not decrease within approximately 120 generation times in culture 
when drug pressure was absent, neither for melarsoprol nor pentamidine resistant strains. 
Compared to the regained chloroquine resistance in Malawi, sensitive trypanosomes are not 
assumed to survive 120 generation times under drug pressure and therefore are not likely to 
re-spread again after cessation of the drug. Regaining sensitivity to a drug to which 
trypanosomes were resistant to may be caused by mutation reversals. Since spontaneous 
mutations are likely to occur every 1 of 109 bases when DNA is replicated [Alberts, B. 
(1994)], a lot of time and trypanosomes were needed to receive the mutation reversal exactly 
at the position were the mutation had been taken place before. The P2 transporter in  
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melarsoprol resistant trypanosomes was shown to have 6 mutated nucleosides in the TbAT1 
gene, which referred to a change in the amino acid sequence [Maser, P. (1999)]. Mutations at 
other sites leading to a decrease in sensitivity are also possible. When these trypanosomes 
additionally show a shorter generation time, IC50 of the trypanosome population will decline 
as the amount of these trypanosomes increases. 
 
Mouse passage 
Since trypanosomes isolated from mice did not show any differences in their sensitivity 
profile to the corresponding resistant strain obtained in vitro, mouse passage did not have a 
selective effect for or against resistant trypanosomes. 
 
Generally, IC50 of melarsoprol, pentamidine and DB 75 did not change substantially in 
resistant strains after cessation of drug nor mouse passage compared to the original resistant 
strain. Also, both resistant strains showed the same sensitivity to DB 75. Interestingly, the 
same IC50 for pentamidine was determined in melarsoprol and pentamidine resistant 
trypanosomes. Differences in sensitivity to melarsoprol seemed to be little lower in the 
pentamidine induced resistant strain. Since the obtained IC50s represent average values, these 
differences monitor a certain trend to a lower sensitivity to melarsoprol in the pentamidine 
resistant strain. 
 
5. Conclusion 
In vitro resistance was induced successfully in trypanosomes of the strain STIB 900 and was 
stable after mouse passage. Resistance seems not to be transient since no decrease in 
sensitivity was obtained when drug pressure was absent. Sooner or longer mutations reversals 
are expected to occur leading to more sensitive trypanosomes. 
Good news were obtained referring to the cross resistance of these mutated trypanosomes to 
DB 75, since only a low cross resistance resulted.  
With the aid of these resistant strains a system was created to test upcoming new drugs for 
their cross resistance to melarsoprol and pentamidine. This system may be an important tool 
when decisions regarding further development of certain drugs have to be made. A drug 
making its way to market, preferably shows no or only little cross resistance to drugs already 
on the market. 
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Table 1: IC50 and resistance factors of tested trypanosome strains 
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Pharmacokinetic studies of selected DB compounds in trypanosome
infected and uninfected mice
Abstract
A drug discovery and development project of a consortium funded by the Bill and Melinda
Gates Foundation revealed highly active pentamidine analogues against Trypanosoma
brucei ssp. Corresponding orally active prodrugs of these compounds were synthesised. To
assess the influence of a present acute infection on the pharmacokinetics of a drug,
trypanosome infected and uninfected mice were treated with those active drugs
(intraperitoneally) and prodrugs (orally). Additionally, the effect of intraperitoneal vs.
subcutaneous application was determined for DB 75 and DB 820.
Blood from mice (infected and uninfected) was harvested at selected times and plasma
prepared. After precipitation of the plasma proteins, drug levels were determined using
HPLC/MS/MS techniques. Evaluation of the pharmacokinetic profile was performed with two
drugs (DB 75, DB 820) and their corresponding prodrugs (DB 289, DB 844), which differ
structurally only within the spacer region, where a phenyl ring is replaced by a pyridyl moiety
in case of DB 820/DB 844.
Plasma levels of infected animals were shown to be influenced by two different mechanisms:
accumulation of active drug in trypanosomes and inhibition of metabolism due to infection or
drug itself. The impact of those mechanisms was different for each of the analysed structures.
Generally, inhibition of metabolism seemed to be more important for DB 820/DB 844,
whereas accumulation of active compound had a bigger influence on the plasma levels of
DB 75/DB 289. When comparing i.p. vs. s.c. administration, higher bioavailability was
obtained after s.c. compared to i.p. application.
1. Introduction
Sleeping sickness still is one of the most life-threatening diseases for humans in Sub-Saharan
Africa. It is estimated that each year 350´000 people get infected, and another 60 millions in
36 countries are at risk of infection. In some regions, where the prevalence of HAT is 20% to
50%, sleeping sickness is the first or second cause of mortality ahead of HIV/AIDS
[www.who.int/mediacentre/factsheet/fs259/en/]. The causative agents of the disease are
protozoan parasites of the genus Trypanosoma, namely Trypanosoma brucei rhodesiense
CHAPTER 5: Pharmacokinetic studies of selected DB compounds in trypanosome infected and uninfected mice
__________________________________________________________________________________________
120
(T. b. rhodesiense) and Trypanosoma brucei gambiense (T. b. gambiense). The area in which
human African trypanosomosis (HAT) occurs is restricted to the natural habitat of the tsetse
fly, since parasites are transmitted by the bite of this fly.
Untreated trypanosomosis is always fatal. Different drugs are used for treatment depending on
the stage of infection. During first stage, when parasites are present in the blood and
lymphatic system, pentamidine and suramin are administered. Later, when trypanosomes have
invaded the central nervous system (stage 2) the highly toxic arsenical compound melarsoprol
is the most frequently used drug. Unfortunately, melarsoprol may cause encephalopathic
syndromes, occurring in around 10% of all treated patients and leading to death in 10-50% of
those cases [Blum, J. (2001)]. Eflornithine (DMFO), the sole alternative to treat second stage
trypanosomosis, is effective against T. b. gambiense only. Since currently used drugs show
severe adverse drug reactions and resistances to the applied drugs are not unusual, new drugs
for the treatment of HAT are needed urgently.
An international consortium, the “UNC lead consortium to discover new drugs for the
treatment of parasitic diseases”, was founded in 1999 with the aim to develop a new drug to
treat first stage HAT. New compounds were modelled based on their analogy to pentamidine.
Screening activities in vitro revealed highly active pentamidine analogues: two of them,
DB 75 and DB 820, showed promising results in vitro and in vivo in mice. Since these
compounds are not orally active, their corresponding methoxyamidines (DB 289, DB 844)
were synthesised by D. W. Boykin [Boykin, D.W. (1996)], [Anbazhagan, M. (2003)], [Ismail,
M.A. (2003)]. By masking the diamidine groups with methoxy moieties, orally applicable
molecules, which can be converted by enzymatic activation to the original compound, are
obtained. Excellent activity and efficacy after oral administration was demonstrated for these
methoxyamidine prodrugs.
The compounds were tested in vivo to estimate their toxicity and efficacy in mice. DB 75 was
not toxic in mice when 50 mg/kg was applied i.p., as was DB 289 after oral administration of
100 mg/kg. However, after application of 100 mg/kg DB 75 i.p. all mice died. In the case of
DB 820 i.p., DB 844 p.o. respectively, 100 mg/kg was tolerated well without showing any
signs of intoxication.
Efficacy in the acute mouse model was shown after application of active compound at a
dosage of 4 x 20 mg/kg. Treatment with 4 x 20 mg/kg DB 820 i.p. cured 4 out of 4 mice.
Results for DB 75 were not as promising, since no mouse could be cured. However, a positive
effect on the infection clearly was noticeable, resulting in a prolongation of the mean survival
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days. Control mice died within 6 days after infection, whereas DB 75 treated mice
(4 x 20 mg/kg i.p.) survived at least up to day 52.
In the acute mouse model oral application at 4 x 50 mg/kg DB 289 resulted in a cure of 3 out
of 4 mice. After oral DB 844 application at 4 x 5 mg/kg all mice were cured.
When tested in the chronic mouse model, application of DB 844 at 6 x 100 mg/kg p.o. led to
100% cure, whereas only 3 out of 5 mice could be cured with the same treatment schedule
when DB 289 was applied. These findings indicated that both prodrugs were able to cross the
blood brain barrier (BBB) to a certain extent, otherwise no cure of mice would be observed.
We anticipate DB 844 as new lead compound for second stage trypanosomosis.
Recently, DB 289 has completed phases IIa and IIb clinical trials quite successfully and is
undergoing phase III now. Further derivatives of the diverse diamidines, like DB 844, are
under investigation for activity in the late stage HAT at the moment.
In this study, pharmacokinetic profiles of active compounds (DB 75, DB 820) and prodrugs
(DB 289, DB 844) were determined in infected and uninfected mice. We will report on
differences in the pharmacokinetics due to the presence of parasites. Additionally, a possible
influence of the parasites on the conversion of the prodrug to the active compound will be
demonstrated. Furthermore, the reason for the superiority of DB 844 versus DB 289 in the
chronic model will be explainable by the collected data.
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2. Material and Methods
2. 1. Compounds and chemicals
DB 75 DB 289 DB 820 DB 844
active compound prodrug active compound prodrug
salt dihydrochloride monomaleate diacetate trihydrochloride
formula C18H16N4O/
2 HCl
C20H20N4O3/
C4H4O4
C17H15N5O/
2 CH3COOH/ 2.2 H2O
C19H19N5O3/
3 HCl / 1H2O
MW
(salt)
304.35
(377.267)
364.41
(480.47)
305.34
(490.705)
365.33
(492.783)
pKa: * 11.8
10.41
4.09
2.53
11.91
10.45
3.71
2.49
log P    *
(neutral form)
2.681 3.78 1.20 ± 0.4⊗ 3.2
log D    ⊗
pH 1
pH 4
pH 7
pH 8
pH 10
* pH 7.4
-2.88
-2.88
-2.80
-1.93
+1.43
> -2.0
-0.67
+3.37
+4.28
+4.28
+4.28
+3.78.
-3.99
-3.80
-3.37
-1.87
+0.81
n.d.
-1.36
+2.85
+3.35
+3.35
+3.35
3.2
* data determined by Saulter J. [Saulter, J.Y. (2005)]
⊗ calculated with ACD software
n.d.: not determined
2.1.1. Compounds
DB 75 and DB 289 were synthesised using methods previously described [Das, B.P. (1977)],
[Boykin, D.W. (1996)]; DB 820 and DB 844, which show an alteration of the 2,5-phenyl
group replacing the phenyl group by a pyridyl group according to Ismail [Ismail, M.A.
(2003)].
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2.1.2. Internal standards
d8-labelled DB 75 and d8-DB 289 were synthesised by D. W. Boykin as described previously
[Stephens, C.E. (2001)]. Deuterium labelled d4-820 and d4-844 were synthesised according to
Ismail [Ismail, M.A. (2004)].
2.1.3. Chemicals
DMSO and NaCl were purchased from Merck (Dietikon, Switzerland), potassium fluoride
from Sigma Aldrich (Basel, Switzerland), heparin from Fresenius (Stans, Switzerland).
HPLC- grade acetonitrile, methanol, water and formic acid were obtained from Fisher
Scientific (Chicago, IL, USA), ammonium formate and trifluoroacetic acid (TFA) from
Sigma-Aldrich (St. Louis, MO, USA).
2.2. Drug solutions
2.2.1. Drug solutions for treatment of mice
The calculated amount of drug was weighed (either 2 mg/ml for active compounds or
10 mg/ml for prodrugs), dissolved in 10% DMSO, then water was added to the final volume.
2.2.2. Standard curves
20 mM stock solutions of prodrugs in methanol and 10 mM stock solutions of active
compounds in methanol/water (1:1) were prepared and stored at –20° C. Dilutions were
prepared the day the samples were analysed containing 5, 10, 25, 50, 100, 250, 500, 1000 and
10000 nM of the corresponding drug.
2.2.3. Internal standards
Stock solutions containing 10 mM deuterium labelled drug in water (active compounds) and
methanol (prodrugs), respectively, were prepared and stored at –20° C. Further dilutions to
concentrations of 25 nM of labelled prodrug (d8-DB 289, d4-DB 844) in acetonitrile and
125 nM of deuterium labelled active drug (d8-DB 75, d4-DB 820) in
methanol/HCl 0.1N (8:1 v/v) were freshly prepared.
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2.3. Animal experiment
2.3.1. Mice
In all experiments female NMRI mice with a bodyweight from 22 to 31 g were used. Mice
were divided into 10 groups (as described in the table below), consisting of 24 mice each
(3 mice per time point, 7 time points, 1 control group).
2.3.2. Administration of active compounds
20 mg/kg of DB 75, DB 820 respectively were administered intraperitoneally to infected and
uninfected mice (groups B, G and A, F) and additionally subcutaneously to uninfected mice
(groups C, H).
2.3.3. Administration of prodrugs
The prodrugs DB 289 and DB 844 were administered per os at 100 mg/kg to infected and
uninfected mice (groups E, J and groups D, I).
2.3.4. Infection and animal care
Mice were infected with 5*103 trypanosomes of the strain STIB 900 (T. b. rhodesiense)
3 days prior treatment. The animals showed a parasitaemia of 105 to 106 trypanosomes per ml
the day the drug was applied.
The animal use adhered to the guidelines issued by the Swiss Federal Veterinary Department
(BVET) for laboratory animals.
DB 75 / DB 289 DB 820 / DB 844
group compound route of
administration
status of
infection
group compound route of
administration
status of
infection
A DB 75 i.p. uninf. F DB 820 i.p. uninf.
B DB 75 i.p. inf. G DB 820 i.p. inf.
C DB 75 s.c. uninf. H DB 820 s.c. uninf.
D DB 289 p.o. uninf. I DB 844 p.o. uninf.
E DB 289 p.o. inf. J DB 844 p.o. inf.
2.3.5. Harvesting of blood
Blood was harvested after decapitation at seven different timepoints. For the active
compounds the following timepoints were chosen: 15 min, 30 min, 1 hr, 2 hr, 4 hr, 8 hr and
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24 hr. Blood from prodrug-treated mice was collected 30 min, 1 hr, 2 hr, 4 hr, 6 hr, 8 hr and
24 hr after drug application. Each timepoint is represented by the average obtained from data
of three mice (± standard deviation).
As anticoagulant a concentrated heparin solution with potassium fluoride (2.5%) as stabiliser
in NaCl solution (0.85%) was used to obtain a final concentration of 400 U/ml heparin.
2.3.6. Plasma preparation
Plasma was obtained after centrifugation at 5000 rpm for 5 min (Eppendorf centrifuge 5415,
Vaudaux-Eppendorf AG, Schönenbuch/Basel, Switzerland) and frozen at –80° C.
2.4. Sample preparation
2.4.1. Standard curves
Calibration curves were prepared by spiking blank mouse plasma with varying amounts of
drug. The range of the calibration curve was 5 nM to 10000 nM. 25 µl of the spiked plasma
samples were transferred into Q-glass vials and treated as described below (sample
preparation).
2.4.2. Sample preparation
2.4.2.1. Determination of prodrugs by triple quadrupole MS
After thawing, 25 µl aliquots of each sample were transferred to Q-glass vials loaded in a 96
well LC/MS plate. 100 µl of a 25 nM IS (d8-289, d4-844) solution in acetonitrile was added to
each sample to precipitate the proteins. Vials in the plate were covered tightly with a
polypropylene mat cap, and vortexed briefly at moderate speed on a microplate vortexer. The
plate was centrifuged using a swinging bucket rotor equipped with microplate adaptors at
2600 g for 5 min at 4° C and loaded for MS analysis.
2.4.2.2. Determination of active compounds by iontrap MS
100 µl of 125 µM IS (d8-75, d4-820) in 8:1 methanol: HCl 0.1 N (v/v) was added to a 25 µl
plasma aliquot. Samples were vortexed gently and spun using a swinging bucket rotor
equipped with microplate adaptors at 2600 g for 5 min at 4° C. The supernatants were
transferred to 1.5 ml eppendorf tubes and evaporated under 7 psi nitrogen at 45° C for 20 min
in a Zymark TurboVap LV equipped with a 1.5-ml tube rack. Samples were reconstituted
using 100 µL of a solvent consisting of 15 mM ammonium formate and 30 mM formic acid in
water of HPLC quality.
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Reconstituted samples were vortexed at high speed for 15 s and then centrifuged at 4000 rpm
for 5 min at room temperature. The supernatants were transferred to a 200 µl polypropylene
vial insert, and placed inside a 2.0-ml glass HPLC vial. Vials were capped and loaded onto the
MS sample tray.
2.5. Instruments
2.5.1. Triple Quadrupole HPLC/MS/MS
Plasma concentrations of the prodrugs DB 289 and DB 844 were determined using reversed-
phase HPLC with tandem triple quadrupole mass spectrometry (HPLC/MS/MS).
The analytical system consisted of an Agilent 1100 binary pump (Palo Alto, CA, USA), a
thermostatic CTC PAL Leap autosampler (Hamilton Co., Reno, NV, USA), Valco solvent
divert valve (Houston, TX, USA), and an Applied Biosystems API 4000 triple quadrupole
mass spectrometer equipped with a TurboIon Spray® interface (MDS Sciex, San Fransisco,
CA, USA) and PEAK nitrogen generator (Punta Gorda, FL, USA).
The equipment was controlled using Analyst 1.3 software (Applied Biosystems, Foster City,
CA, USA).
DB 289 and d8-DB 289 or DB 844 and d4-DB 844 were eluted at room temperature using a
Bonus RP 2.1 x 50 mm 3.5 µm analytical column. The flow rate was 500 µl/min.
Initial gradient conditions of 90% solvent A were held for 60 s. During this time, the column
eluent was diverted from the mass spectrometer to waste. After these initial 60 s, the column
eluate was directed to the mass spectrometer and the amount of solvent B (100% methanol)
was increased linearly during 120 s until it reached 90%. The mobile phase composition was
held constant (10 : 90, solvent A : solvent B) for the following 60 s. Initial conditions were
reintroduced in a linear fashion over the next 60 s.
Samples were kept chilled (6º C) in covered 96-well plates with sample inserts.
Injection volume was 5 µl. After each injection, the syringe was washed once with wash
solvent 1 (50/50 methanol and water (v/v)) and wash solvent 2 (100% methanol). The injector
valve and loop were washed three times with wash solvent 1 and three times with wash
solvent 2.
Mass spectrometric conditions (user controlled voltages, gas pressures, and source
temperature) were optimised for the maximum detection of either DB 289 and d8-DB 289 or
DB 844 and d4-DB 844 using direct infusion of each compound in the manual tuning mode of
Analyst 1.3.
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solvents:
Solvent A: 10 mM ammonium acetate, 90% water (HPLC quality), 10% propanol
Solvent B: 100% Methanol
gradient:
% of A % of B time
90 10 0 – 1 min
10 90 3 – 4 min
90 10 4 – 5 min
flow rate: 0.5 ml/min.
2.5.2. Iontrap MS
Concentrations of the active compounds DB 75, DB 820 respectively were determined using
reversed-phase HPLC with an HP API-ESI LC/MSD system (Palo Alto, CA, USA). The
analytical unit consisted of an Agilent 1100 equipped with a binary pump (Palo Alto, CA,
USA). Control of the equipment and calculation of the data was done using ChemStation
Software (Agilent, Palo Alto, CA, USA).
The compounds were eluted through an Agilent Zorbax SB-CN column (2.1x 50 mm
5 µm particle) fitted with a guard column (Agilent 300SB-C3 2.1x 12.5 mm) holding a flow
rate of 0.4 ml/min. Initial conditions with 25% solvent B was held for 5 min. Within 0.1 min
the solvent B was raised to 100% and held up to 6 min. Then the gradient changes to 0% B
immediately and continue into post-run time for 4 min (see table below). Selected ion
monitoring (SIM) parameters were set as shown in the table below using the positive ion
mode. Samples were kept chilled. Injection volume was 5 µl.
SIM Ion Fragmentor Gain EMV SIM Resol. Actual Dwell
305 150 1.0 62 62
306 150 62 62
310 150 15 15
313 150 15 15
solvents:
Solvent A: 5% acetonitrile, 95% water (HPLC quality), 0.025% TFA
Solvent B: 5% water (HPLC quality), 95% acetonitrile, 0.025% TFA
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gradient:
% of A % of B time
75 25 0 – 5 min
100 5.0 – 5.1 min
100 5.1 – 6 min
post run – 10 min
flow rate: 0.4 ml/min.
2.6. Data analysis
2.6.1. Prodrugs
Data acquisition was performed using multiple reaction monitoring m/z parent → m/z product
of [DB 289+H] (365→334) and [d8-DB 289+H] (373→342) or [DB 844+H] (366→319), and
[d4-DB 844+H] (370→323). Post-acquisition quantitative analyses were performed using
Analyst 1.3.1. software.
Unknown sample concentrations of DB 289 were calculated from the weighted (1/x)
quadratic curve, determined by the least-squares regression, constructed from the peak area
ratios of DB 289 to d8-DB 289, versus DB 289 concentration.
Unknown sample concentrations of DB 844 were calculated in a similar way using the
weighted regression of the calibration curve constructed from the peak area ratios of DB 844
and d4-DB 844.
2.6.2. Active compounds
Molecular ions of DB 75, DB 820 and their isotopic standards were monitored to determine
the concentrations of the active compounds.
Concentrations of drugs were determined by matching peak area responses against a
calibration curve of peak area responses of the internal standard.
Peak detection, peak area integration, peak area ratio calculation, calibration curve fitting
(least-squares regression with weighting) and calculation of sample concentrations were
carried out with ChemStation software.
The internal standard corrected for variation in the sample preparation steps used in the
analysis of the plasma samples for the prodrugs as for the active compounds.
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Data is represented as average concentration of plasma samples ± standard deviation obtained
from three mice.
2.7. Determination of pharmacokinetic parameters
Values for Cmax, tmax were obtained by visual analysis of the graphs.
To determine the AUC, AUMC, MRT, t1/2 and kel EXCEL software was used: AUC was
calculated using the linear trapezoidal method. To determine the AUMC, the AUC is
weighted by the integration over time. MRT is evaluated by dividing AUMC/AUC,
t1/2 =ln2*MRT, and kel =1/MRT.
3. Results
3.1. Comparison of plasma levels in infected and uninfected mice
To estimate whether an infection with a parasite alters the plasma levels of a diamidine
compound administered intraperitoneally or the diamidine formed from the prodrug
administered orally, the same dose of drug or prodrug per body weight was applied to mice
without and with a parasite load of 105 to 106 trypanosomes per ml. The concentration of drug
in plasma was measured after appropriate preparation with HPLC/MS/MS techniques at
specific times. Plasma courses of two active compounds, namely DB 75, DB 820, and of their
corresponding prodrugs (DB 289, DB 844) were determined.
Pharmacokinetic profiles of active compounds were plotted in graphs from 0.25 hr up to 8 hr.
Since only low amounts of drug could be detected after 8 hr, these values were neglected
when representing the data graphically.
3.1.1. Active compounds
DB 75 in plasma of uninfected and STIB 900-infected mice after i.p. application (Fig. 1)
A slight difference in plasma levels and AUC could be observed between infected and
uninfected animals. In both cases, the plasma level rose very rapidly, representing a very fast
uptake of the drug from the abdominal cavity into the blood. The highest concentration could
be measured at the first time, 15 min after application.
CHAPTER 5: Pharmacokinetic studies of selected DB compounds in trypanosome infected and uninfected mice
__________________________________________________________________________________________
130
In infected animals a slightly higher Cmax, AUC and therefore a slightly higher MRT and t1/2
and a slightly lower kel value were observed (see Chapter 10, Appendix B, Table 1).
The AUMC was 46% higher in infected as in uninfected animals (Chapter 10, Appendix B,
Table 1).
DB 820 in plasma of uninfected and STIB 900-infected mice after i.p. application (Fig. 2)
This diamidine also showed a rapid uptake. Differences in plasma levels were detectable at
15 min and up to 2 hr after application with higher plasma levels and a less rapid elimination
in infected mice. Highest drug concentration was found after 15 min whether an infection was
present or not. At this time, around 30% more drug was found in the plasma of infected
animals. The AUC showed a remarkable increase whereas the AUMC displayed only a slight
rise (Chapter 10, Appendix B, Table 2).
3.1.2. Prodrugs
DB 289 in plasma of uninfected and STIB 900-infected mice after p.o. application (Fig. 3)
Plasma levels in the uninfected animals were higher than in the infected animals. In
infected mice two plasma peaks at 2 and 6 hr after drug application were clearly noticeable.
Quite contrary to the time-concentration curve for uninfected animals: the highest drug
concentration (twice the amount as measured in infected animals) could be detected at the
same time when the minimum between the 2 peaks at hour 4 in the infected occurred. The
AUC and the AUMC over 24 h was nearly twice as high in the uninfected as in the infected
animal. MRT, t1/2 and kel were comparable (Chapter 10, Appendix B, Table 3).
DB 844 in plasma of uninfected and STIB 900-infected mice after p.o. application (Fig. 4)
Plasma curves of infected and uninfected animals were almost identical. Both show 2
peaks at 1 and 8 hr after application. Because the time points were defined before the drug
levels were determined it could not be assessed whether the drug level would still increase
after 8 hr. Due to the missing time points between 8 and 24 hr the curve could have a course
differing from Fig. 4.
A slight difference in AUC and AUMC was detectable (Chapter 10, Appendix B, Table 4).
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3.2. Comparison of the conversion of the prodrug to the active drug
Conversion of DB 289 to DB 75 in uninfected (Fig. 5) and STIB 900-infected (Fig. 6) mice
after p.o. application of DB 289
In uninfected mice on average around one third of the prodrug was converted to the active
compound within 24 hr, whereas in the infected mice the amount of active compound within
the same period of time constituted only one fourth of the administered prodrug. After 24 hr,
more DB 75 than DB 289 was detectable in the blood in either case.
Conversion of DB 844 to DB 820 in uninfected (Fig. 7) and STIB 900-infected (Fig. 8) mice
after p.o. application of DB 844
Comparing the plasma levels within 24 hr, on average 14% of the prodrug was converted to
the active compound in infected mice. Slightly less, on average 10%, was activated in
uninfected mice.
Converted DB 75 in uninfected vs. STIB 900-infected mice after orally administered
DB 289 (Fig. 9)
DB 75 levels were determined after oral DB 289 application. The infected animals showed
a lower drug level over the whole assessment period than the uninfected animals. Two weak
peaks after 4 and 6 hr were identifiable in infected mice, whereas the uninfected animals
reached their highest plasma concentration after 4 hr and no second peak could be detected.
This pattern was already observed when DB 289 levels were measured. There too, the time
point with the highest drug concentration between infected and uninfected animals differed
and the number of peaks within the plasma course were not the same.
AUC and AUMC were around 30% lower in the infected animal (Chapter 10, Appendix B,
Table 5).
Converted DB 820 in uninfected vs. STIB 900-infected mice after orally administered
DB 844 (Fig 10)
Plasma curves of either infected and uninfected animals showed a similar pattern. No
difference between both courses was clearly detectable: tmax occurred at the same time, AUC,
AUMC, MRT, t1/2, and kel were within the same range (Chapter 10, Appendix B, Table 6).
There was a not significant trend to higher values in the infected mice.
CHAPTER 5: Pharmacokinetic studies of selected DB compounds in trypanosome infected and uninfected mice
__________________________________________________________________________________________
132
3.3. Comparison of analogues
This analysis was performed to assess differences in the pharmacokinetic parameters when
the structure of the compound is modified slightly and therefore changes in the physical-
chemical properties are obtained. Knowledge gained from this part of the study is of major
importance for further drug development.
3.3.1. Active compounds
DB 75 vs. DB 820 in plasma of uninfected mice after i.p. application (Fig. 11)
Uptake of drug took place to a higher extent within the first 15 min if DB 820 was applied.
From 30 min on, already, plasma concentration in DB 75 and DB 820 treated mice were
comparable. Other pharmacokinetic parameters like AUMC, MRT, t1/2 and kel differed
slightly, whereas no difference in AUC could be assessed (Chapter 10, Appendix B, Table 7).
DB 75 vs. DB 820 in plasma of STIB 900-infected mice after i.p. application (Fig. 12)
Also, in infected mice a higher amount of drug available in the plasma was obtainable within
the first 15 min after DB 820 administration. Over a period of 24 hr DB 75 was eliminated
slightly slower resulting in a higher plasma level after 24 hr compared to DB 820. The AUC
of infected DB 820 treated mice was around 30% higher, whereas the AUMC (~ 30%), MRT,
and t1/2 was decreased by around 40% compared to DB 75. A difference in the kel value
clearly was detectable, as it was 80% higher in DB 820 treated animals (Chapter 10,
Appendix B, Table 8).
3.3.2. Prodrugs
DB 289 vs. DB 844 in plasma of uninfected mice after p.o. application (Fig. 13)
In general, DB 844 drug levels were higher than levels of DB 289, except at the trough at
4 hr between the two peaks (at 1 and 8 hr). At this time the DB 289 course showed the highest
drug concentration over the observed 24 hr period. Interestingly, the times where the Cmax was
detected differed completely: 1 hr for DB 844 and 4 hr for DB 289. Comparing the
pharmacokinetic parameters, the highest measured plasma level was 4,5 times higher in
DB 844, which was reflected in an AUC and an AUMC 3,5 times higher. No differences were
detectable in MRT, t1/2 and kel (Chapter 10, Appendix B, Table 9).
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DB 289 vs. DB 844 in plasma of STIB 900-infected mice (Fig. 14)
During the whole observation period, except at the 6th hr, clearly more drug could be detected
after DB 844 administration. The time of the highest measurable plasma level differed in the
infected mice, too. Interestingly, a trough was observable in the DB 289 as well as in the
DB 844 treated animals. Compared to the trough at hour 4 in the DB 289 treated animal the
one in the DB 844 treated mice was delayed, occurring at hour 6.
An eight fold higher plasma level could be detected in DB 844 treated animals, what resulted
in a five times higher AUC and AUMC. No differences in MRT, t1/2 and kel were assessable
(Chapter 10, Appendix B, Table 10).
3.3.3. Converted analogues
Converted DB 75 vs. converted DB 820 in plasma of uninfected mice after prodrug
application p.o. (Fig. 15)
No difference in levels of DB 75 and DB 820 were detected over a period of 24 hr after
application of 100 mg/kg p.o. of the corresponding prodrug. Pharmacokinetics differed, since
Cmax did not occur at the same time (Chapter 10, Appendix B, Table 11).
Converted DB 75 vs. converted DB 820 in plasma of STIB 900-infected mice after prodrug
application p.o. (Fig. 16)
Around 60% more converted DB 820 was available in infected mice compared to
converted DB 75. Differences in the elimination process were not detectable. As described for
uninfected animals, tmax differed clearly (Chapter 10, Appendix B, Table 12).
3.4. Comparison i.p. – s.c. application in uninfected animals
Plasma levels of drugs applied via i.p. and s.c. route were determined to show the difference
of the retarding effect based on different application routes.
DB 75 in plasma of uninfected mice i.p. vs. s.c. application (Fig. 17)
In both cases the Cmax was achieved at 15 min, the first time point. In general, plasma levels
after subcutaneous administration were higher than after intraperitoneal application. The
difference between the Cmax was around 30%. AUC and AUMC were 3 times higher after
subcutaneous administration (Chapter 10, Appendix B, Table 13).
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DB 820 in plasma of uninfected mice i.p. vs. s.c. application (Fig. 18)
Clearly higher plasma levels could be observed after subcutaneous injection of DB 820
compared to its intraperitoneal application. Highest measured level of DB 820 s.c. was about
two times the i.p. value. Also AUC and AUMC were 4 to 5 times higher, whereas no
difference in MRT, t1/2 and kel was observed (Chapter 10, Appendix B, Table 14).
DB 75 s.c. vs. DB 820 s.c. in plasma of uninfected mice (Fig. 19)
Within the observation period of 24 hr plasma levels and AUMC of DB 820 were always
higher as compared to the ones of DB 75. The AUCs differed more than 60%, and the AUMC
in DB 820 was around 40% higher. MRT, t1/2 and kel were within the same range (Chapter 10,
Appendix B, Table 15).
4. Discussion
Pharmacokinetics helps to understand the dynamic movement of the drug within the body. It
characterises the relationship of the drug concentration to dose, time and characteristics of the
individual body to which the drug was applied. So, the optimal dosage -efficient but not yet
toxic- can be determined. From pharmacokinetic parameters quantitative information about
the disposition of drug can be gained, but no answer is obtained in the way the drug acts and
how the body responds to the drug.
Important processes in pharmacokinetics are the adsorption of the drug from the application
site, the distribution within the body, its metabolism concerning the transformation of the drug
and its excretion. Key parameters to describe the fate of the drug in the body are the half-life
(t1/2), the AUC, Cmax and tmax.
In this study Cmax, tmax, AUC, AUMC, MRT, t1/2 and kel were calculated from measured
plasma levels. The plot of the plasma drug concentration versus time represents its
pharmacokinetic profile. The highest plasma level observed within the assessment period is
represented by the peak concentration Cmax at the time tmax. The extent of drug availability and
exposure following a dose is reflected by area under the curve (AUC). This is a measurement
for the total amount of drug absorbed. By plotting concentration-time versus time the area
under the first moment curve (AUMC) is obtained. The ratio of AUMC and AUC results in
the mean residence time, MRT. This value represents how long in average molecules of the
applied compound stay in the body without being modified. This constant is rather not a
pharmacokinetic constant than a constant for the in vivo liberation of the drug from its matrix.
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Parameters which are useful to describe the elimination of the drug are rate constant of
elimination (kel) and the half-life (t1/2), the time which is required to reduce the amount of
drug in the plasma by half. This parameter is generally used to determine dosing intervals of
drugs.
Method:
Two different methods of preparing the plasma samples were used to analyse the
concentration in the plasma samples due to the different properties of the drugs to dissolve in
liquids. Both methods have in common that the proteins of the plasma were precipitated either
with acetonitrile or with acidic methanol and the compounds in the supernatant were
measured after a conditioning process with HPLC/MS/MS techniques. Since a valid analytic
method for the determination of the active compound was not yet established for the triple
quadrupole MS, plasma samples were assessed using iontrap MS.
The pharmacokinetic profiles represent the result of all the processes considering the fate of a
drug in the body from its absorption to its elimination. Different effects contribute to the
observed courses. The following discussion is an attempt to explain these courses.
4.1. Plasma levels of infected and uninfected mice
Active drugs
DB 75 treatment yielded slightly higher plasma concentrations in infected than uninfected
animals. Plasma levels in infected and DB 820 treated mice were higher than in their
uninfected counterparts during the first two hours after application, whereas afterwards no
difference between uninfected and infected plasma levels could be seen.
Accumulation of active compounds in trypanosomes is well known for DB 75 as well as for
DB 820. Like pentamidine, transport of diamidines is mediated via a saturable P2 transporter.
In vitro experiments showed an inverse proportional relationship between the drug level
outside of the trypanosome and the accumulation factor. E.g., in vitro an average
accumulation factor of around 100 000-fold for DB 75 after 4 hr incubation time with
compound ranging from 250 ng/ml to 10000 ng/ml could be determined. In vivo an
accumulation factor of around 57000 for DB 75 and around 38000 for DB 820 was found in
trypanosomes (strain S427, T. b. brucei) after treatment of mice with 7.5 µmol/kg i.v. after
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24 hours (corresponding to 2.8 mg/kg DB 75 dihydrochloride and 3.68 mg/kg DB 820
diacetate) [Mathis M. A., personal communication].
Interestingly, the effect of this accumulation on plasma concentrations could not be observed
in either case. Probably, the absorption processes were so extensive and therefore effects of
the accumulation processes in trypanosomes on plasma concentrations simply are not visible.
Another issue that has to be taken into account is, that infection inhibits metabolism.
Shertzer H. G. et al. reported a reduced capability of host mixed-function oxidases to
metabolise drugs during infections [Shertzer, H.G. (1981)]. By decreasing the rate of
metabolism, drugs are transformed to a lesser extent and so plasma levels decline slower. The
inhibition could be observed in the elimination process of DB 75 in infected animals showing
a prolongation, which was not found for DB 820. A possible explanation could be that this
effect is just not detectable in the case of DB 820, because other effects like an accelerated
elimination process are stronger. It can be assumed that the elimination process will be
accelerated similarly to the adsorption process. In the same matter as the drug is absorbed
quickly from the application site, it also will be absorbed quickly from the excretory organs
and eliminated rapidly.
Prodrugs
In the case of DB 289 approximately twice the amount of prodrug (represented by the AUC)
was available over the whole observation period if animals were uninfected. Interestingly, the
pharmacokinetic profile looked completely different, and plasma peaks occurred at totally
different times when uninfected mice were compared to infected mice. The reason for the
change in the pharmacokinetic profile after DB 289 treatment is not known.
After DB 844 treatment neither a different pharmacokinetic profile nor differences in the
occurrence of plasma peaks could be detected. However, a small surplus in the total amount
of drug detected was also assessable in uninfected animals.
Accumulation processes may be the reason for lower plasma levels in infected animals.
However, accumulation of the prodrug itself in trypanosomes is rather inconsiderable, since
prodrugs are not known to be concentrated within the parasite. Since a massive accumulation
of active compound after low dose treatment was observed in trypanosomes in vivo and in
vitro, the plasma concentrations of the prodrug will be reduced by shifting the balance of the
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transformation process from the prodrug to the active compound, and therefore lower plasma
levels of the original prodrug are obtained.
Since uptake of DB 820 by trypanosomes was observed to be less excessive than uptake of
DB 75, one would expect differences also– but to a lesser extent- in the plasma concentrations
of DB 844. Indeed, this difference was detectable, but not as big as expected. The reason for
this rather unexpected small difference may be the inhibition of the metabolism resulting in a
higher amount of the original, non-metabolised drug.
Transformation of the prodrug to the active drug
In general, the ratio of active compound to non-converted prodrug differed obviously between
the analogues. One third to one fourth was metabolised from DB 289 to DB 75, whereas only
an inconsiderable fraction was metabolised from DB 844 to DB 820. However, more DB 844
compared to DB 289 was found in the plasma.
After treatment with DB 289 the total amount of DB 75 in the blood was around one third
smaller in infected as compared to uninfected mice, whereas no significant difference of
DB 820 levels after DB 844 treatment between infected and uninfected animals could be
detected.
There is evidence that infection lowered the plasma level of DB 75 in infected DB 289-treated
animals by accumulation of the converted DB 75 in trypanosomes. Plasma concentrations of
DB 820 after DB 844 treatment were more or less the same as in infected animals showing a
trend to higher levels of active drug in infected mice. A better uptake of DB 844 compared to
DB 289 from the application site was observed, which led to the expectation that an increased
conversion of DB 844 molecules to DB 820 would take place and accumulation of the active
compound in the trypanosome would occur. Interestingly, only a trend to higher plasma levels
of DB 820 but no significant elevated conversion of DB 844 was observed as the plasma
concentrations in uninfected mice show (Fig. 10). Additionally, it must be considered that the
accumulation factor for DB 820 is lower than for DB 75, and will decrease additionally, when
the concentration of drug increases.
Here again, the inhibition of metabolism must make a considerable contribution to the plasma
concentrations of DB 820 in infected mice, otherwise bigger differences would be expected.
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Analogues
Modifications of drug structures result in changes of physicochemical properties of the
original compounds. By using ACD Scholar software, predictions about distribution and
membrane permeability can be done. This program is able to estimate the partition coefficient
(P, respectively log P) and the distribution coefficient (D, respectively log D) at different pH
values based on the chemical structure. This program uses partial structures of the molecule to
estimate these values. Good correlation between prediction and actual measured values were
obtained for neutral drugs, but not for drugs like diamidines showing high pKas. Recently,
Saulter determined pKa, log P and log D values for DB 75, DB 820, DB 289 and DB 844
[Saulter, J.Y. (2005)].
In general, a drug should be hydrophilic enough to get distributed by the bloodstream and also
lipophilic enough to pass membranes. Too lipophilic drugs stick to membranes and are not
able cross to them. Depending on the compartment in which a drug should act, different
requirements have to be met. To treat second stage trypanosomosis penetration of the blood
brain barrier would be essential.
Optimal log P values differ from organ to organ and from application route to application
route. Assuming passive adsorption, best log P values to achieve CNS penetration are around
2 ± 0.7. For excellent oral absorption log P should be around 1.8
[www.raell.demon.co.uk/chem/logp/logpka.html].
Active drugs
Except for the first 15 min, plasma levels of DB 75 and DB 820 treated mice were
comparable in uninfected animals. Infection created a difference between the two drugs. Up to
1 hr DB 820 treated animals displayed higher levels of the diamidine. After this period,
elimination of DB 75 occurred less rapidly than in the DB 820 treated mice, resulting in
higher drug levels. In vivo plasma levels above 250 nM DB 75 and above 180 nM were
measured during the 24 hr observation period. In vitro data showed that the IC50 for DB 75 is
4 nm and 7 nM for DB 820.
Physicochemical properties of DB 820, a slightly more polar molecule, seemed to favour
adsorption processes. Better membrane permeability could be observed during the absorption
process from the application site into the blood, as well as in the membrane passage into
excretory organs, as is indicated by the amount of absorbed drug and by the slopes of the
curves.
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Prodrugs
Pharmacokinetic profiles of DB 289 and DB 844 looked quite similar. Except for DB 289 in
uninfected mice, all pharmacokinetic profiles showed two peaks and a minimum in between.
These highs and this minimum did not correspond chronologically at all when DB 289 was
compared with DB 844. Additionally, the ratio of the first to the second peak differed clearly:
after DB 289 treatment both peaks were more or less of equal height, whereas in the case of
DB 844 the first peak dominated.
The absorption of DB 844 compared to DB 289 was favoured by far, independent of the
infection status. Differences in the physicochemical properties may be the reason for different
pharmacokinetic profiles, showing peaks and the minimum not at the same time.
Converted active drugs
Since no difference was detectable in the amount of converted drug in uninfected animals, it
was concluded that the converting enzyme(s) did not favour the structure of one prodrug over
the other. In infected animals, higher levels of DB 820 were obtained, possibly because of the
better accumulation of DB 75 in the parasites (higher accumulation factor) and/or because
inhibition of metabolism was stronger by DB 844, DB 820 respectively.
Application routes: i.p. vs. s.c.
Both routes of administration, i.p. and s.c., had a certain slow release effect. Drug was stored
at the application site and released slowly from there. In either case, DB 75 and DB 820, more
drug was released via the s.c. route and plasma levels stayed longer on a higher level. This
effect was based only on the site of application. The formulation of the drug was equal
referring to the slow release effect. The pharmacokinetic profiles showed a dominant
absorption particularly within the first 2 hr for DB 844 compared to DB 289 regardless of the
route of administration.
5. Conclusion
The graphs representing the pharmacokinetic profile of each compound showed a high
variability. The reason for this variability originates from the non-serial sampling method in
mice which had to be used to perform this experiment. The big differences concerning the
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standard deviation represent the inter-individual variability. Each mouse had a different
genetic background as well as polymorphisms of single genes may occur.
Different factors are involved from the point when a drug is applied to the body till its
excretion: below this factors will be discussed in a more general matter:
From in vitro experiments DB 75 was expected to be slightly more potent with an IC50 of
1.7 ng/ml as compared to DB 820 with an IC50 of 3.3 ng/ml. Unexpectedly, in vivo DB 820,
DB 844 respectively, seemed to be more active than DB 75 or DB 289. In the acute mouse
model 4 x 20 mg/kg DB 820 i.p. cured 4 out of 4 mice, after DB 75 application 0/4 mice were
cured at the same dose, but the mean survival time was prolonged by at least 44 days
compared to control mice. In the chronic model a cure of 5 out of 5 mice was achieved with
6 x 100 mg/kg DB 844 p.o., whereas after application of the same dose of DB 289 only 3 out
of 5 mice could be cured. The reason for this discrepancy in vitro versus in vivo must be a
better availability of the compound within the mouse.
5.1. Uptake of drug
5.1.1. Adsorption of drug from the application site
Transport proteins, like P-glycoprotein, are not yet known to transport diamidines from the
abdominal cavity or the lumen of the intestine into the blood. So passive diffusion plays an
important role in drug uptake. Membrane passage is a major obstacle for drugs to get to the
site where they can act. First of all, membranes have to be crossed for the drugs to be
distributed within the body by the blood stream. Therefore, physicochemical properties of
compounds may be a limiting factor. As mentioned above, log P values characterise the
distribution of a compound as neutral molecule between an immiscible solvent and an
aqueous phase. Ideal log P values for penetrating the intestinal membrane are around 1.35.
Calculated log P values for DB 75 and DB 820 are 2.681 and 1.2 ± 0.4, respectively.
For oral absorption best log P values are around 1.8. Therefore, DB 844 will cross membranes
easier with a log P value of 3.2 compared to log P of 3.78 for DB 289. Taking these calculated
values into account, it is quite easy to predict, which of those molecules will pass the blood
brain barrier to a bigger extent. Optimum log P value for CNS penetration are around 2 ± 0.7.
And indeed, DB 844 was observed to cross the blood brain barrier in a sufficient amount and
therefore was able to cure second stage trypanosomosis in mice better than DB 289.
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Different routes of passing membranes were observed in vitro experiments comparing DB 75
to DB 289. DB 75 was considered to be transported predominantly paracellular across a
CACO-2-monolayer. This monolayer mimicks the human gastro-intestinal epithelium.
Masking the diamidine group with methoxy moieties resulted in a higher uptake
predominantly via a transcellular transport [Zhou, L. (2002)]. Transport of DB 820 and DB
844 is expected to behave in the same manner.
5.1.2. Transport of compound within the body
After crossing the membranes, a certain amount of the drug binds to plasma proteins. Basic
drugs like diamidines are expected to bind on either lipoproteins or on alpha-1-acid
glycoprotein (α-AGP). So far, it is not known to which plasma protein diamidines do bind.
α-AGP belongs to the acute phase proteins which are known to be increased during an acute
infection or inflammation [Piafsky, K.M. (1980)], [Baumann, H. (1994)]. It is assumed that a
trypanosome infection increases the amount of α-AGP, and therefore higher plasma levels for
DB 75 are expected in infected animals since the total amount of drug, free and bound, is
estimated using this determination method.
Active drugs were bound to 70-75%, whereas protein binding of prodrugs was 99%. Whether
prodrugs also bind to α-AGP and therefore plasma concentration would be higher in infected
animals has to be clarified. It could also be possible that another protein which is not
increased by an infection is involved in drug transport and thus no increase in plasma
concentration would be detected.
5.2. Status of infection
5.2.1. Accumulation
Infection may influence the plasma concentration of active drugs, since trypanosomes are able
to transport and store diamidines in their organism. The P2 transporter is one of the
transporters who is considered to be involved in this process, besides LAPT (low-affinity
pentamidine transporter) and HAPT (high-affinity pentamidine transporter) [de Koning, H.P.
(2001)].
Accumulation factors were assessed in a similar mouse model for DB 75 and DB 820 in mice
infected with trypanosome strain S427. With the aid of these values and the grade of
parasitaemia determined microscopically by tail blood examination, it is possible to estimate
the amount of accumulated drug in infected animals roughly. At the day the experiment was
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performed two thirds of the mice showed a parasitaemia of 105 trypanosomes/ml and one
third of the animals even had 106 trypanosomes/ml. Assuming an infection with
105 trypanosomes/ml, 57 nM of DB 75, respectively 38 nM of DB 820 per 100 nM DB
measured could be withdrawn in infected animals compared to uninfected.
5.2.2. Inhibition of metabolism
Drug metabolism consists of two major steps performed by the liver. In a first step, molecules
are made more hydrophilic by introduction or by liberation of functional groups with the aid
of enzymes. Processes which take place within this step are oxidations, reductions or
hydrolysis reactions. Hydrolysis often is catalysed by specific or unspecific esterases, whereas
the other mentioned reactions are performed by mixed-function oxidases. These enzymes are
called mixed-function oxidases, because one atom oxygen of the O2 molecule is transferred to
the substrate (in this case to the drug to metabolise) and the other is transferred to hydrogen
atoms to produce water.
It could be shown that a present trypanosome infection was able to lower metabolism by
decreasing the activity of those mixed-function oxidases. In addition, drugs used to treat
trypanosomosis like melarsoprol or suramin were shown to inhibit these oxidases in vitro, too
[Shertzer, H.G. (1981)]. If diamidines per se are also potent oxidase inhibitors has to be
subject of further investigations. Taking the data of this study into consideration, one would
expect that DB 820, DB 844, respectively exhibits a bigger inhibitory effect on metabolism
than DB 75, DB 289 respectively.
The second phase of metabolism is the so called conjugation. Molecules obtained in Phase I
get linked with highly polar, mostly inactive molecules for rapid elimination. Glucuronic acid
is one of those polar molecules to which the activated Phase I molecules can bind. It is
known, that DB 844, DB 820 and all intermediates are conjugated intensively during phase II
metabolism and therefore are no longer available for the organism. This may explain the low
rate of the converted active compound found after prodrug application. A certain amount of
prodrug got lost through conjugation and was eliminated without being subject to metabolism.
5.2.3. Conversion of prodrugs to active compound
Differences in metabolism of the conversion DB 289 and DB 844 to their active compounds
are expected. DB 844, as an asymmetric molecule, shows a more complex metabolism, since
O-demethylation can occur on the methoxyamidine related to the phenyl or to the pyridyl
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group first. Seven different phase I intermediates are obtained during the metabolism of
DB 844, whereas only four different intermediates occur during the metabolism of DB 289 to
DB 75 [see metabolic pathways of DB 289 (Fig. 20) and DB 844 (Fig. 21)].
To round up, pharmacokinetic profiles are the sum of complex interactions ranging from
absorption processes, differences in physicochemical properties of the drug, status of infection
associated with a possible accumulation of compounds in trypanosomes, inhibition of
metabolism and differences in excretory processes.
In this study we could show that there is a difference between plasma levels in infected and
uninfected mice.
Although accumulation of diamidines in trypanosomes may lower the plasma level, the
inhibition of metabolism seems to be more relevant for plasma levels of the drugs analysed in
this study. Probably, these compounds themselves show inhibitory effects on metabolism.
When comparing two different compounds under the same conditions (route of application,
status of infection) differences were obtained from the physical-chemical properties of the
drugs and their influences.
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Fig. 1: DB 75 in plasma of uninfected and STIB 900-infected
mice after i.p. application
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Fig. 2: DB 820 in plasma of uninfected and STIB 900-infected
mice after i.p. application
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Fig. 3: DB 289 in plasma of uninfected and STIB 900-infected
 mice after p.o. application
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Fig. 4: DB 844 in plasma of uninfected and STIB 900-infected
 mice after p.o. application
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Fig. 5: Conversion of DB 289 to DB 75 in uninfected mice
 after p.o. application of DB 289
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Fig. 6: Conversion of DB 289 to DB 75 in infected mice
 after p.o. application of DB 289
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Fig. 7: Conversion of DB 844 to DB 820 in uninfected mice
after p.o. application of DB 844
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Fig. 8: Conversion of DB 844 to DB 820 in infected mice
 after p.o. application of DB 844
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Fig. 9: DB 75 in plasma of uninfected and STIB 900-infected mice
 after treatment with DB 289 p.o.
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Fig. 10: DB 820 in plasma of uninfected and STIB 900-infected mice
 after treatment with DB 844 p.o.
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Fig. 11: DB 75 and DB 820 in plasma of uninfected mice
 after i.p. application
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Fig. 12: DB 75 and DB 820 in plasma of STIB 900-infected mice
 after i.p. application
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Fig. 13: DB 289 and DB 844 in plasma of uninfected mice
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Fig. 14: DB 289 and DB 844 in plasma of STIB 900-infected mice
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Fig. 15: Converted DB 75 and DB 820 in plasma of uninfected mice
 after orally administered prodrug
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Fig. 16: Converted DB 75 and DB 820 in plasma of STIB 900- infected
mice after orally administered prodrug
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Fig. 17: DB 75 in plasma of uninfected mice i.p. vs. s.c.
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Fig. 18: DB 820 in plasma of uninfected mice i.p. vs. s.c.
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Fig. 19: DB 75 vs. DB 820 s.c. in plasma of uninfected mice
0 1 2 3 4 5 6 7 8
5000
15000
25000
35000
45000
DB 75-Uninfected s.c.
DB 820-Uninfected s.c.
Time
co
nc
. o
f D
B
 [n
M
]
CHAPTER 5: Pharmacokinetic studies of selected DB compounds in trypanosome infected and uninfected mice
__________________________________________________________________________________________
153
Fig. 20: Metabolism of DB 289
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Fig. 21: Metabolism of DB 844
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Accumulation of DB 75 in trypanosomes in vitro
Abstract
Accumulation of DB 75 in trypanosomes was assessed in vitro. Thereto, solutions containing
various numbers of trypanosomes were incubated with different concentrations of DB 75 for
1, 2 and 4 hours. After the incubation period, trypanosomes were separated from supernatant
by centrifugation. The concentration of remaining drug in the supernatant was determined
using a fluorescence reader. The obtained fluorescence signal was converted to a DB 75
concentration with the aid of a calibration curve for DB 75. Differences between the amount
of drug in solution before trypanosomes had been added and the concentration determined in
the supernatant, represented the amount of DB 75 taken up by trypanosomes.
Accumulation of DB 75 in trypanosomes was observed to be inverse linear to the number of
trypanosomes and direct linear to the amount of drug present. With the aid of this study it
could be shown that the differences between plasma levels of DB 75 in uninfected and
infected mice after conversion of DB 289 to DB 75 seen in “Pharmacokinetic studies of
selected DB compounds in trypanosome infected and uninfected mice” could be explained by
the accumulation of the drug in the trypanosome.
1. Introduction
When designing new compounds acting against parasites, one strategy to prevent severe
adverse effects on the host but exhibiting an excellent activity on the parasite is to select
molecules which interfere particularly with the metabolism of the parasite and not of the host.
One of many examples for such selectivity is the antimalarial Fansidar® (sulfadoxine +
pyrimethamine), that acts on the folate pathway, which exists only in the parasite. A similar
selectivity was found for the antitrypanosomal pentamidine, which accumulates up to
millimolar concentrations in African trypanosomes but not in mammalian host cells [Berger,
B.J. (1995)], [Damper, D. (1976)]. The uptake of pentamidine into trypanosomes was shown
to be mediated by three distinct transporters [de Koning, H.P. (2001b)]. These transporters are
necessary for the uptake of nucleobases. In contrasts to humans, trypanosomes have to rely on
salvage pathway of nucleobases, since they are not able to synthesise them de novo.
Therefore, drugs containing the same recognition motif as nucleobases, like
melaminoarsenicals and diamidines such as pentamidine, are transported into the
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cell by the same carriers. After internalisation of the drug, pentamidine is stored by binding to
specific sites in the parasite and is therefore no longer available free in the cell plasma. This
leads to further drug uptake until an equilibrium is reached.
The complete mode of action of pentamidine is not revealed yet, but binding to trypanosomal
DNA is proposed to be one of multiple cellular targets [Pepin, J. (1994)], [Nok, A.J. (2003)].
Additionally to the accumulation of the compound, the curvature and AT content of the
trypanosomal DNA differs from the human one and therefore binding to trypanosomal DNA
is favoured over binding to human DNA.
Not seldom, adverse effects like irritations at the application site, hypoglycaemia, renal
failure, acute pancreatitis, hypotension and rarely cardiac arrhythmias were reported after i.v.
or i.m. application of pentamidine [Pharmaceutical information “Pentamidine Isethionate”
Rhône-Poulenc Rohrer]. The “UNC lead consortium to discover new drugs for the treatment
of parasitic diseases” was funded with the aim to develop pentamidine analogues which
exhibit the same or even better activity against parasites but exert less toxicity and are orally
bioavailable. One of those analogues synthesised within this project, namely DB 75, showed
an excellent activity in vivo and in vitro. Additionally, fewer adverse effects were reported for
the orally applicable prodrug DB 289 (which is metabolised to the active compound DB 75)
in clinical trials phase I and II compared to pentamidine [C. Burri, personal communication].
In mice, 50 mg/kg DB 75 administered i.p. was as well tolerated as the same dose of
pentamidine.
Due to structural similarities, transport and accumulation processes are expected to be similar
for DB 75 compared to pentamidine. An important tool to visualise the distribution of DB 75
is its fluorescent property. Studies may be performed, tracing the path of the drug from the
application site through the body to the target: the parasite. Additionally, studies concerning
uptake and distribution within the parasites are also easily possible due to this innate
fluorescence.
DB 75 - Way through the body:
Investigations were performed for DB 75 itself and its prodrug DB 289 to estimate the
penetration through cells imitating the intestine epithelium (CACO-2 cells). Within these
studies two ways of crossing were observed: transcellular for DB 289 and paracellular
crossing events for DB 75 [Zhou, L. (2002)].
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Under physiological conditions, the diamidine groups of DB 75 are both protonated
(pKa: 11.8 and 10.4 [Saulter, J.Y. (2005)]) and therefore the dicationic compound is very
polar. Generally, uptake of polar compounds through membranes representing lipophilic
barriers is expected to be very little. Accumulation of polar drugs may therefore only occur
when one or even several specific transporter/s and/or an extensive intracellular binding site
is/are present.
Import and storage of DB 75 in trypanosomes
Transport processes for DB 75 are not yet fully elucidated. So far, the P2 transporter, one of
the nucleobase transporters, was shown to be involved in the uptake of this diamidine [De
Koning, personal communication]. In vitro studies using a DNA dodecamer representing the
minor groove DNA demonstrated that DB 75 is a potent minor groove binder [Laughton, C.A.
(1996)], [Trent, J.O. (1996)]. The enhanced DNA affinity to the minor groove is in large part
due to nonbonded interactions between the furan group and the walls of the narrow AT-rich
minor groove [Trent, J.O. (1996)]. Additionally, strong binding effects of an intercalating
nature were shown for GC and GC/AT rich sequences of the DNA and RNA [Wilson, W.D.
(1993)]. To date it is not known, if the intercalation with GC/AT mixed sequences of DNA
and intercalation with RNA is of big importance for the mode of action of DB 75 or not, since
the complete mode of action is not revealed yet.
When inspected under a fluorescence microscope, several structures were observed after an
incubation period of trypanosomes with DB 75. It is possible to visualise organelles
containing DNA like the nucleus and kinetoplast (blue fluorescence), and also organelles
showing yellow fluorescence which were identified as acidocalcisomes [Docampo, R. (1999)]
(Fig. 1). These organelles are cytoplasmic vacuoles containing very high concentrations of
releasable Ca2+ and a Ca2+-H+ translocating ATPase activity. They further contain high
concentrations of phosphorus as polyphosphates for possible energy storage, Mg2+, Na+, Zn2+
and very little of Cl-, K+ and sulfur.
In vivo observations
In mice, lower plasma levels of DB 75 were observed in infected animals compared to
uninfected animals when a low dose of DB 75 was administered, or when DB 75 had been
converted after application of the prodrug DB 289. It is possible that the accumulation of
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DB compound in trypanosomes may be the reason for diminished plasma levels in parasitised
animals. Possible consequences may be treatment failures and generation of resistant
trypanosome populations due to unintended underdosing. To prevent this and to estimate the
amount of active compound which may be accumulated in a trypanosome during treatment,
the amount of drug bound by trypanosomes was determined in vitro and based thereon,
accumulation factors of DB 75 in trypanosomes were calculated.
2. Materials and methods
2.1. Compounds and chemicals
2.1.1. DB 75
DB 75 was obtained from Dr. D. W. Boykin, Georgia State University, USA.
2.1.2. Culture medium (BMEM)
Trypanosomes were cultivated in Minimum Essential Medium (MEM) with Earle`s salts
(powder, GIBCO, Invitrogen, Basel, Switzerland), supplemented with 25 mM HEPES
(GIBCO, Invitrogen, Basel, Switzerland), 1 g/l additional glucose, 2.2 g/l NaHCO3 and
10 ml/l MEM nonessential amino acids (100x, GIBCO, Invitrogen, Basel, Switzerland). The
medium was further supplemented with 0.2 mM 2-mercaptoethanol, 2 mM sodium pyruvate,
0.1 mM hypoxanthine, 0.016 mM thymidine and 15% heat inactivated horse serum [Baltz, T.
(1985)].
2.2. Drug dilutions
A stock solution of 1 mg/ml DB 75 in water was prepared. By diluting the stock solution with
the appropriate amount of culture medium (BMEM), a calibration curve containing two times
the final drug concentration was obtained. This calibration curve ranged from 500 to 20000 ng
(1325 – 53000 nM) DB 75 per ml without any further dilution. By adding trypanosome
solutions of various concentrations 1:1, dilutions containing 250, 500, 1000, 2500, 5000 and
10000 ng/ml DB 75 in culture medium were obtained.
2.3. Trypanosome solutions
Solutions containing trypanosomes of the strain STIB 900 (Trypanosoma brucei rhodesiense)
in 3 different concentrations were prepared. Thereto, the density of trypanosomes from
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culture was determined with the Neubauer chamber and solutions containing 1*105, 2*106 and
1*107 parasites per ml in culture medium (2x final trypanosome density) were prepared.
2.4. Plate layout
For each incubation time one 96-well plate was used and an additional one for the calibration
curve. Analysing three different incubation times (1, 2 and 4 hr), four plates in total were
needed.
2.4.1. Plate layout for plates representing one incubation period (Fig. 2)
Into each 96-well plate, 100 µl of the drug solution containing the highest concentration of
DB 75 (20000 ng/ml) was added to wells of row A, B and H of column 1. The second highest
drug dilution (10000 ng/ml) was pipetted into wells of row A, B and H of column 2 as
described for the highest drug concentration. The same was done with the other drug
dilutions. BMEM without DB 75 was added into wells of column 7 row A, B, and H.
To wells of row A (column 1-7), 100 µl of the trypanosome solution with the lowest number
of parasites was added. The solution containing 2*106 parasites per ml was placed into wells
of row B column 1-7, and the trypanosome solution containing the highest parasite density
was pipetted into wells of row H column 1-7.
This arrangement of the plate was chosen, because it easily allowed removal of the
supernatant after centrifugation.
All plates were mixed well for 2 min using a plate shaker (IKA MTS 2/4 digital, VWR
International, Dietikon, Switzerland) performing 600 shakes/min and were incubated at 37° C
and 5% CO2 for 1, 2 or 4 hr, respectively.
2.4.2. Plate layout calibration curve and transferred supernatants (Fig. 3: column 1)
100 µl of each drug solution (2x the final drug concentration) was pipetted into wells of
column 1, starting with the highest concentration in row A and descending down to row E. In
row F screening medium without DB 75 was added. To achieve the same drug dilution (1:1)
as in the plates representing an incubation period, 100 µl BMEM was added to each well
containing already the drug solutions and additionally to the well with the blank medium.
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2.5. Sample preparation (see Fig. 3)
After being incubated 1, 2 or 4 hr, plates were centrifuged at 2750 rpm (Jouan CR 4 11,
Johnson Controls, Basel, Switzerland) and 150 µl supernatant was transferred into wells of
the plate containing the calibration curve: supernatants obtained after an incubation period of
1 hr were placed into the wells of column 2-4: the supernatants of the wells with the lowest
number of trypanosomes were transferred into wells of column 2, the supernatants of the
wells containing the second highest number of trypanosomes were transferred to column 3
and the supernatants of the wells containing the highest trypanosome concentrations were
transferred to row 4. Supernatants obtained after a 2 hr incubation were transferred into wells
of column 5-7 and supernatants obtained after a 4 hr incubation period were transferred into
wells of column 8-10. All supernatants were arranged in a way, that the highest drug
concentration was placed in row A, the second highest drug concentration was in row B and
so on.
2.6. Instruments and data analysis
Plates were read with the fluorescence reader (SpectraMAX Gemini XS, Bucher Biotech AG,
Basel, Switzerland) at excitation wavelength 370 nm and emission wavelength 460 nm. Data
analysis was performed with SOFTmaxPRO 3.1.2 and EXCEL.
Reduction of the fluorescence signal of a solution of DB 75 when incubated with
trypanosomes was determined (= fluorescence signal of calibration curve – fluorescence
signal of supernatant). The accumulation factor resulted from the ratio of the concentration of
DB 75 bound by trypanosomes to the ratio of concentration in the solution taking the
corresponding volume into account. To assess the magnitude with which the drug got
concentrated in trypanosomes, the following equation was used:
f = (voltot - voltryps) * conctryps / (conc * voltryps)
f: accumulation factor
voltot: total volume
voltryps: volume of trypanosomes (*)
conc: measured concentration of DB 75 in solution
conctryps: calculated concentration of DB 75 in trypanosomes
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(*) volume of 1 trypanosome = 37.4 fl, data obtained from “ Studies of kinetics of parasitaemia
and trypanosome disappearance after drug treatment of first infection and relapses”
3. Results
The experiment was performed three times independently, so that the obtained values resulted
from three independent binding studies. A table showing the average concentration of DB 75
can be found in Chapter 10, Appendix C.
3.1.1. Calibration curves
The average correlation factor of the three determined calibration curves was 0.9991 with a
standard deviation of 0.000404.
3.1.2. Determination of the accumulation factor
The obtained accumulation factor ranged from around 2000 to 1`000`000-fold, depending on
the amount of drug and number of trypanosomes incubated (Table 1).
3.2. Binding of DB 75
3.2.1. Uptake of DB 75 in trypanosomes (Fig. 4)
The smaller the number of trypanosomes, the higher was the uptake of DB 75 per
trypanosome independent of the amount of DB 75 present. Trypanosomes exhibiting a density
of 5*104 trypanosomes/ml incorporated almost 20 times more DB 75, than trypanosomes of a
density of 1*106 trypanosomes/ml, which took up around five times more DB 75 than
trypanosomes of a density of 5*106 trypanosomes/ml.
3.2.2. Kinetics of the uptake (Fig. 5)
Independent of the numbers of trypanosomes, highest concentrations of DB 75 in
trypanosomes were achieved after 2 hr. After 4 hr, levels of bound drug dropped below the
1 hr values in the case of 5*104 and 1*106 trypanosomes per ml. Interestingly, in  the solution
containing the highest trypanosome concentration accumulation of DB 75 after 1 hr was lower
than after 4 hr.
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3.3. Accumulation factors
3.3.1. Dependence of the accumulation factor on the trypanosome density (Fig. 6)
Independent of the duration of the incubation period, it could be shown that the higher the
numbers of trypanosomes, the lower the accumulation factor was. The decrease of the value
of the accumulation factor correlates with the increase of the number of trypanosomes.
3.3.1. Dependence of the accumulation factor on the amount of DB 75 present (Fig. 7)
Regardless of the number of parasites, the following observation was made: the higher the
concentration of DB 75 present, the lower the accumulation factor was.
4. Discussion
The fluorescent property of DB 75 facilitated the assessment of the amount of drug
accumulated in trypanosomes compared to other uptake studies performed with pentamidine,
also a diamidine. First of all, no radiolabelled counterpart had to be synthesised de novo.
Additionally, one could circumvent all the critical aspects and handling with radioactive
material. No other indicators were needed, because of the ability to measure the presence of
the compound directly due to the native fluorescence.
The proportionality between the measured intensity of the fluorescence signal and the
concentration within the selected range of 250 ng/ml to 10000 ng/ml was given, what was
represented by the correlation factor of the calibration curve of nearly 1 and its small
deviation. Therefore, reproducible and accurate results were granted when determination of
drug concentrations in a sample of unknown DB 75 concentration was performed by
fluorescence spectroscopy.
Binding of DB 75
Uptake of DB 75 could be shown to be an inverse linear process. Trypanosomes of the lowest
density (5*104 trypanosomes/ml) bound around 20 times (mean: 18.33, stand. dev.: 1.26)
more DB 75 compared to the solution containing 20x more trypanosomes (1*106
trypanosomes/ml). The same applied for the solution containing 1*106 trypanosomes/ml
where around 5x (mean: 6.11, stand. dev.: 1.16) more bound drug could be detected compared
to the solution with the highest trypanosome density which contained 5*106 trypanosomes/ml.
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Generally, the more drug present, the more drug bound. Graphs representing the uptake of
DB 75 versus the drug concentration in the solution (Fig. 5), showed the characteristics of a
saturated processes with a curve represented by a steep rise at low concentrations changing to
a small slope and finally ending in a plateau at high concentrations. This is explainable by the
fact, that the more compound is available for transport, the higher the chance for each single
molecule to get transported into the cell.
Since the highest concentration at which the uptake was studied was 10000 ng/ml, the value at
which the plateau was reached could be little higher than determined in this study. Higher
concentrations of drug solutions were excluded from this study, since a killing effect on
trypanosomes was expected.
Accumulation factors
Trypanosome suspensions of lower densities were observed to take up higher amounts of drug
compared to trypanosome suspensions of higher densities. This may be explainable by the
probability with which molecules were taken up. If there are fewer trypanosomes in a solution
of DB 75 of a given concentration, the possibility for each molecule to be taken up is higher,
than if a lot of trypanosomes compete for transport of this molecule. This only applies for
solutions in which drug is not present to excess. Since the accumulation factor is based on
both uptake and the amount of drug remaining outside the trypanosome, a higher
accumulation factor is expected, when the trypanosome concentration is low.
The decrease in the value of the accumulation factor when the amount of drug present
increases is not surprising since the accumulation factor represents the ratio of the
concentration in trypanosomes to the amount of drug outside the trypanosomes. Assuming
that trypanosomes accumulate always the same amount of drug, the ratio between the amount
of drug accumulated in trypanosomes and the amount of drug remaining in the solution would
be higher if the drug concentration of the solution is low than if the amount of drug in the
solution is high.
Another reason for the decrease of the accumulation factor could be that the higher the
concentration of drug present, the more damaged the trypanosomes are. It is assumable that if
trypanosomes were damaged, their pumps do not work properly anymore and therefore influx
and accumulation of DB 75 would be diminished. Additionally, if trypanosomes would die
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within the incubation period and would get lysed, the amount of accumulated drug would be
freed and would be measurable therefore in the supernatant.
General aspects
Two processes play an important role, when a substrate or drug is accumulated within an
organism. First, a specific transport system is needed and second, a storage system for this
accumulated substrate has to be available.
Transporters
Transporters recognising specific structures are responsible for active transport of substrates
into the cell. One important transporter is the P2. Since Trypanosoma brucei is not able to
synthesise purines de novo, parasites have to rely on the salvage of preformed purines from
the host. Purine uptake is performed by specific nucleobase transporters. In trypanosomes, 11
nucleoside and nucleobase transporters were identified to date. The function and the
substrates of all these carriers are not known yet [Landfear, S.M. (2004)].
Which transporters are involved in the uptake of DB 75 is not revealed totally at this time.
There is strong evidence that the P2 transporter plays an important role in uptake of DB 75.
Comparing the uptake mechanisms of the drugs on the market to treat trypanosomosis,
exhibiting the same recognition motif than DB 75, conclusions are not easy to draw:
a) Melarsoprol
Uptake of melarsoprol is mediated via two transporters [de Koning, H.P. (2004)]. One of
them, the P2 transporter recognises nucleosides and nucleobases that are structurally related to
adenosine. The recognition motif of this transporter consists of a) an amidine group that may
be integrated into a pyridine or pyrimidine ring, b) an aromatic system associated or
integrated with the amidine group and c) an electronegative group attached to the aromatic
ring in para position to the amidine, that is able to contribute with a lone electron pair to the
π-system [de Koning, H.P. (1999)]. These criteria are all in agreement with the structures of
diminazene, pentamidine and the melaminophenylarsenicals.
Mutations within the P2 transporter leading to reduced uptake of substrate, what is thought to
contribute to melarsoprol resistance [Maser, P. (1999)].
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b) Pentamidine
Pentamidine, is taken up also by the P2 transporter and at least by two alternative carriers as
well [de Koning, H.P. (1999)]. Complete cross resistance between melarsoprol resistant
strains and pentamidine does not occur, because these other carriers are involved in uptake of
pentamidine: the P2 transporter, also called ASPT 1 (adenosine-sensitive pentamidine
transporter 1), showed the highest affinity to pentamidine responsible for 50-70% of the total
uptake of the drug. The other carriers show different affinities to pentamidine: the so called
HAPT (high affinity pentamidine transporter) exhibits high affinity to pentamidine, but is
saturated at very low concentrations what leads to little contribution on the total uptake of the
drug. The LAPT (low affinity pentamidine transporter) contributes little to the total uptake,
but still a considerable amount, due to its very high capacity and due to its lack of
sensitiveness to inhibitors like the diamidines propamidine, stilbamidine and diminazene
[de Koning, H.P. (2001a)].
c) Diminazene
Recent studies about uptake of diminazene into trypanosomes showed, that this compound is
more or less exclusively accumulated by the P2 transporter [de Koning, H.P. (2004)].
All these structurally related compounds show differences in their uptake into the
trypanosome. Therefore, DB 75 may be mediated also by several transporters. Further
experiments on the internalisation of DB 75 are urgently needed.
Storage of accumulated drug
Pentamidine was reported to rapidly reach high intracellular levels due to binding to
intracellular sites, such as kinetoplast DNA [Carter, N.S. (1995)]. The same was observed for
DB 75, that is stored by binding to AT rich sites at the minor groove. Additionally,
accumulated DB 75 was detected in acidocalcisomes when analysing by fluorescence
microscopy. Why this organelle is able to accumulate DB 75 is not known (binding to DNA
as a reason may be excluded, since DNA is absent from acidocalcisomes). Possibly, the
protonated drug may form complexes with negatively charged ions like chloride, sulphate or
phosphate anions. Also, it is not elicited to date what transporters are used to get the drug in
there.
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5. Conclusion
Accumulation factors determined in an in vitro system are only able to give a rough
estimation about the magnitude of accumulation that may be achieved in vivo.
Theoretically, mice showing a parasitaemia of 1*106 trypanosomes/ml would be able to bind
292 nM of administered compound based on the amount of DB 75 in pM bound by 1
trypanosome obtained in this in vitro assay at an incubation concentration of 250 ng/ml,
662.5 nM respectively DB 75 (average value for 1, 2 and 4 hr: 0.29 pM/trypanosome).
Accumulation plays a significant role only when plasma levels are low. As seen for plasma
levels of converted DB 75 after application of DB 289, a difference of about 135-170 nM
infected vs. uninfected mice were found within the first 4 hr after treatment (see
“Pharmacokinetic studies of selected DB compounds in trypanosome infected and uninfected
mice“).
In vivo, other factors have to be taken into consideration which will reduce the calculated
amount of the bound DB 75. One of them would be the protein binding of the drug that
reduces the amount of free and therefore active drug in the blood. Drug bound by plasma
proteins would not be transported into trypanosomes, if the affinity to the protein would be
higher than the affinity of the trypanosomes to the transporter. The amount of drug
determined in “Pharmacokinetic studies of selected DB compounds in trypanosome infected
and uninfected mice” represented the amount of free and protein bound drug in the plasma.
Additionally, drug levels will be reduced constantly by metabolism and therefore less DB 75
is expected to be present for accumulation in trypanosomes in vivo.
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Fig. 1: Fluorescence of trypanosomes incubated with DB 75 
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Fig. 2: Plate representing an incubation period 
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Fig. 3: Plate with calibration curve and transferred supernatant 
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Fig. 4: Binding of DB 75 in trypanosomes
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Fig. 5: Binding of DB 75 in trypanosomes
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Fig. 6: Accumulation factor of DB 75
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Fig. 7: Accumulation factor of DB 75
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Table 1: Binding and accumulation factor of DB 75 
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Investigations of plasma samples by bioassay
Abstract
To assess active metabolites in plasma samples of trypanosome infected and uninfected mice
treated with DB 75, DB 820 and their corresponding prodrugs DB 289, DB 844,
anti-trypanosomal activity of plasma samples were determined by bioassay. Activity was
evaluated as equivalent to DB 75, DB 820 respectively and compared to the concentration
determined by HPLC/MS/MS. Differences bigger than a factor of two (amount of drug
determined by bioassay to amount of drug obtained from HPLC/MS/MS) suggested the
presence of at least one additional active metabolite.
Results indicated active metabolites for each of those compounds. Interestingly, occurrence of
active metabolites differed completely among the active drugs and also among the prodrugs.
1. Introduction
With the aid of chemical, analytical methods courses of compounds in plasma can be
determined after suitable preparation steps. These methods are generally very accurate. To
assess an actual concentration of a specific compound, a calibration curve of this compound
has to be generated and a linear or other relationship between the concentration and the signal
obtained by the analytical detector has to be granted within a specified range. Thereto, probes
representing specific concentrations have to undergo the same preparation procedure as the
plasma samples which have to be analysed. After having obtained the corresponding
analytical signal to each probe of the calibration curve, it is possible to calculate the
calibration curve with the corresponding correlation factor. Then, plasma samples containing
an unknown concentration of this drug can be analysed, and concentrations may be calculated
using the determined calibration curve. The disadvantage of such an analytical evaluation
method is that only concentrations of compounds can be determined which are chemically
identified, stable and synthesisable.
Bioassays in contrast, assess the activity of all active principles (active compounds and
metabolites) that occur in a plasma sample in total. A biological principle is the basis of this
analysis, and therefore the obtained results are subjected to fluctuation.
In this case, trypanosomes cultured in vitro were used for the assessment of the anti-
trypanosomal activity of active compounds in plasma samples of mice obtained after
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treatment with DB compounds. A method similar to the bioassay described by Burri and
coworkers was used [Burri, C. (1992)]. Instead of determining the minimal inhibitory
concentration (MIC), the IC50, the concentration at which 50% of the parasites compared to a
control population were killed, was assessed. Thereto, adaptations as described by Räz were
made [Raz, B. (1997)].
Parasites were incubated in a serial dilution of DB 75 or plasma sample of unknown DB 75
concentration, and the IC50s were determined using a viability indicator. Based on the IC50s
obtained for the reference drug DB 75 and for the unknown plasma samples, the
concentrations of DB 75 in the plasma samples were calculated and compared to
concentrations obtained in the chemical, analytical method by HPLC/MS/MS (see
“Pharmacokinetic studies of selected DB compounds in trypanosome infected and uninfected
mice”). The same was done with plasma samples collected after treatment with DB 820,
where DB 820 was used as reference drug.
Since prodrugs showed a rather negligible activity in the bioassay (IC50 in the µmolar range),
it was not possible to assess their concentrations. Instead, the amount of converted active drug
was assessed.
This system based on viable organisms is very sensitive to changes in the environment
(temperature, CO2%, medium...), which may result in variations when determining the same
sample independently another time. Generally, a difference of a factor of two is acceptable
when the same plasma sample is analysed twice.
2. Material and methods
2.1. Drugs and Chemicals
2.1.1. DB compounds
DB 75 was synthesised as described by Das and Boykin [Das, B.P. (1977)], [Boykin, D.W.
(1996)], DB 820 according to Ismail [Ismail, M.A. (2003)].
2.1.2. Dilutions of reference drugs
A solution of 100 ng/ml DB 75, DB 820 respectively in BMEM was prepared (= two times
highest starting concentration).
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2.1.3. Resazurin
A solution of 0.0125% resazurin (Fluka, Buchs, Switzerland) in phosphate buffered saline
(PBS) was used to detect viability of the trypanosomes.
2.2. Plasma samples
Plasma samples were identical to the ones used for “Pharmacokinetic studies of selected DB
compounds in trypanosome infected and uninfected mice”. For further information about
trypanosomes, animal work and collection of the plasma samples, see chapter 5.
2.2.1. Dilution of the plasma samples
Based on the amount of drug determined by the HPLC/MS/MS method, suitable dilutions of
the plasma samples in BMEM were prepared, resulting in solutions containing between 50
and 30 nM active drug (= two times the highest concentration). To minimise the inhibitory
effect of the blank plasma sample on the bioassay, each plasma sample was pre-diluted at
least 1:3. Additionally, determination of the IC50 of blank plasma samples pre-diluted 1:3
(= two times the highest concentration) was performed to assess the extent of their inhibitory
effect.
2.3. Bioassay (Fig.1)
In each 96-well plate, one reference drug (DB 75 or DB 820 of known concentration) and
3 plasma samples containing the same compound as represented by the reference drug were
tested. Thereto, serial drug dilutions for each drug/plasma sample were performed in triplicate
(3 columns), starting with wells of row H, containing the highest concentration. Dilution steps
were performed (1:3) up to wells of row B. Wells of row A did not contain any drug or
plasma sample, serving as control. To two columns a trypanosome solution with a density of
3*104 trypanosomes/ml was added, whereas the volume of the other column was
complemented with medium and served as background. After an incubation period of 68 hr,
the viability indicator resazurin was added and another incubation period of 4 hr took place.
CHAPTER 7: Investigations of plasma samples by bioassay
__________________________________________________________________________________________
180
2.4. Instruments and data analysis:
The fluorescence reader SpectraMAX Gemini XS (Bucher Biotech AG, Basel, Switzerland)
was used to read the plates (excitation wavelength: 536 nm, emission wavelength 588 nm).
Data analysis was performed with SoftmaxPRO 3.1.2. and EXCEL.
The obtained IC50 of the reference drug was set in relation to the IC50 of the unknown plasma
sample (see equations below). The unknown concentration of the plasma sample was
calculated and compared with the concentration obtained from the HPLC/MS/MS studies.
Thereto, results obtained in ng/ml were transformed into nM [molecular weight DB 75
(dihydrochloride salt) 377.27 g/mol, DB 820 (diacetate salt) 490.71 ng/mol].
f: factor
IC50ref: IC50 of reference starting conc. of reference: 50 ng/ml
IC50plasma: IC50 of plasma sample starting conc. in plasma:   x ng/ml
n: pre-dilution of plasma sample
f = IC50ref/ IC50plasma
x = 50 ng/ml * f* n*2*3
Multiplication with the factor 2 and 3 takes the dilution obtained by pipetting 2x the highest
concentration and the pre-dilution 1:3 into account.
3. Results
In chapter 10, Appendix D, a table showing the concentrations of DB 75 determined by
bioassay and HPLC/MS/MS can be found.
3.1. Plasma course of DB 75 in trypanosome infected and uninfected mice determined by
HPLC/MS/MS and bioassay (Fig. 2, Fig. 3)
Results of the bioassay showed clearly, that in infected animals the amount of DB 75
determined by HPLC/MS/MS was lower than the one calculated for the bioassay. Except for
plasma samples collected at 1 and 24 hr, the ratio between the amount determined by the
analytical method and the biological determination in infected mice was bigger than 2. In
uninfected animals, this was only the case for the plasma samples collected 15 min after drug
application.
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3.2. Plasma course of DB 75 after application of DB 289 in trypanosome infected and
uninfected mice determined by HPLC/MS/MS and bioassay (Fig. 4, Fig. 5)
At 30 min, determined DB 75 concentration were manifold bigger in the bioassay than values
determined by HPLC/MS/MS independent of the status of infection (uninf: 5x, inf.:7x, both
results showed big deviations, but all obtained ratios were bigger than 2). Thereafter, values
for DB 75 obtained in the bioassay were more or less similar in uninfected animals than the
ones obtained by HPLC/MS/MS. At 4, 6 and 8 hr, plasma samples of infected animals
showed higher activity in the bioassay compared to the DB 75 concentration determined by
the analytical method.
3.3. Plasma course of DB 820 in trypanosome infected and uninfected mice determined by
HPLC/MS/MS and bioassay (Fig. 6, Fig. 7)
Interestingly, uninfected plasma samples showed higher anti-trypanosomal activities in the
bioassay compared to the amount of DB 75 found with the HPLC/MS/MS method after
0.5, 1, 8 and 24 hr, whereas plasma levels of infected animals had only slightly increased
levels of DB 820 (ratio >2) after 8 and 24 hr when determined by bioassay.
3.4. Plasma course of DB 820 after application of DB 844 in trypanosome infected and
uninfected mice determined by HPLC/MS/MS and bioassay (Fig. 8, Fig. 9)
Plasma samples of uninfected animals showed higher activity at 0.5, 6 and 24 hr when
determined by bioassay. A similar pattern of the plasma activity curve was observed in
infected animals exhibiting a ratio higher than factor 2 at 30 min and 6 hr.
3.5. Inhibitory concentration of blank plasma samples
The anti-trypanosomal activity of each five blank plasma samples - 5x infected, 5x
uninfected- were determined by bioassay. The factors calculated from the IC50 of the
reference drug to the IC50 obtained from the blank plasma sample did not differ considerably
between infected (mean: 0.49, stand. dev.: 0.23) and uninfected mice (mean: 0.37, stand. dev.:
0.07).
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4. Discussion
Influence of blank plasma on trypanosomes: background
Blank plasma samples pre-diluted 1:3 (= two times highest concentration), with an actual
plasma concentration of 16.67% (1:6) in the well of the highest concentration, showed an
inhibitory effect on trypanosomal growth. This effect was of major importance, when plasma
samples to be tested had not been further pre-diluted to reduce the amount of plasma and the
concentrations of active compounds were low.
Based on an average factor of 0.4 obtained from IC50blank_plasma/IC50ref, the inhibitory
effect would correlate with an starting concentration of 2*3*50*0.4 = 120 ng/ml
DB compound, what would be 318 nM DB 75, 244 nM DB 820 respectively. However,
concentrations below these levels were measured, indicating variations of the inhibitory
effects of the plasma.
Therefore, plasma concentrations determined by bioassay exhibiting a concentration of
DB compound below 320 nM should be interpreted with caution if they had not been further
pre-diluted than the minimum (16.67% plasma in wells of highest concentration).
Active metabolites after DB 75 treatment
Within the first 15 min, ratios of DB 75 concentrations determined in the bioassay to the ones
determined by HPLC/MS/MS were higher than factor 2 in all mice. At 30 min, only infected
mice showed ratio higher than 2. These samples were all diluted additionally more than
10-fold (most of them 30x), which decreases the amount of plasma in the well of highest
concentration to below 0.83%. Therefore, inhibitory effects based on the plasma itself can be
excluded. The obtained differences indicated, that an active metabolite may be formed very
early. Then, the ratio drops below 2 at 1 hr. Thereafter, a parallel course can be detected,
when ratios for uninfected animals were compared to infected animals. Infected animals
showed ratios higher than factor 2 from 2 to 8 hr. Especially, samples collected at 2 hr had
been further diluted. For the other samples, showing a ratio higher than 2, concentration of
active DB 75 was calculated to be by far higher than what may be achieved by the inhibitory
effect of plasma on its own. Probably, another active metabolite or even several active
metabolites were formed within this period. Since these differences were obtained only in
infected mice, one could speculate if the degradation of this metabolite/s is inhibited in
infected animals as metabolism was shown to be inhibited in parasitised animals when
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concentration of plasma samples were determined by HPLC/MS/MS. Rather unlikely, but still
possible, is the assumption that infection may cause changes in metabolic pathways and
therefore different metabolites were obtained in infected compared to uninfected animals.
Active metabolites after application of DB 289
After 30 min, a ratio higher than 2 was obtained in infected and in uninfected animals. Since
these plasma samples were not further pre-diluted and showed a low concentration of active
DB 75 when assessed by HPLC/MS/MS, the inhibitory effect of the plasma may be the reason
for these differences. After 4 hr, only infected animals showed a small increase with a ratio
higher than 2, which rose up a little bit to the 8th hr. Plasma samples collected during this
period were not diluted further, but the concentration calculated may not be caused totally by
inhibitory effects of the plasma sample.
Interestingly, ratios higher than factor 2 were mainly observed in infected animals only,
although courses of converted DB 75 determined by HPLC/MS/MS clearly showed that those
levels were lower in infected animals compared to uninfected animals.
Active metabolites after DB 820 treatment
Neither in infected nor in uninfected animals a ratio higher than 2 was obtained when
determination by bioassay to the one by HPLC/MS/MS was compared within the first 8 hr.
The peak obtained for uninfected animals at the 1st hr may be explained by one plasma sample
which showed an extremely low concentration of DB 820 when assessed by HPLC/MS/MS
and the inhibitory effect of plasma since no further dilution was performed. After 8 hr, the
ratio bioassay/HPLC/MS/MS was slightly higher than 2 in infected animals and even more
higher in uninfected animals. Inhibitory effects of plasma samples have to be taken into
account since almost all of the plasma samples were not further diluted. However, not the
total activity obtained in the bioassay may be caused by the inhibitory effect of the plasma,
therefore the presence of an active metabolite may be possible.
Active metabolites after application of DB 844
As already described for DB 75 after application of DB 289, differences were seen in the case
of DB 844/DB 820 within the 1st hr. These differences were probably due to the inhibitory
effect of the plasma and low concentration of the converted active drug.
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Remarkably, a ratio higher than 2 was obtained for uninfected animals at the 6th hr. Plasma
samples were not further pre-diluted, and differences which occurred may not totally be due
to inhibitory effect of plasma. Therefore, it is possible that an active metabolite may be
formed. The time at which this metabolite occurred indicated that it has to be a different one
than the one that may be built after DB 820 application, since it could be detected before the
possible metabolite after DB 820 treatment which was observed after the 8th hr.
Why active metabolites were only found in uninfected animals after DB 820 application,
respectively DB 844, and not in infected animals is not known to date. The same applies for
metabolites found only in infected animals after treatment with DB 75, respectively DB 289.
Possible metabolites of DB compounds based on metabolism of pentamidine (Fig. 10)
Assuming that DB compounds were metabolised similarly to pentamidine, N-hydroxylation
of the amidines could take place [Berger, B.J. (1991)], [Berger, B.J. (1992)]. In a first step,
one of the amidine moieties could be hydroxylated resulting in an asymmetric compound
(DB 75 Æ M4 (DB 835), DB 820 Æ M4A and/or M4B, metabolites identified when prodrug
DB 844 got activated to the active compound DB 820). In a second step, the other diamidine
moiety may be hydroxylated (DB 75 Æ Æ DB 290, DB 820 Æ Æ DB 821).
Another possible way of degradation would be the oxidation of the furan spacer, although
furan rings of many drugs were reported to be metabolically stable. If a metabolic cleavage of
furan is transformed, hydroxylation of the 5-position, followed by tautomerism and hydrolysis
of the 5-hydroxyfuran derivative as reported for diclofurime, a Ca-antagonist [Le Fur, J.M.
(1985)], would be imaginable.
In vitro data of possible metabolites
Some of the metabolites mentioned above were already synthesised within the project of the
“UNC lead consortium to discover new drugs for the treatment of parasitic diseases” and
tested for their in vitro activity against trypanosomes. The following IC50 values were
obtained:
active compounds:
DB 75: IC50 = 1.5 ng/ml (= 4 nM)
DB 820: IC50 = 3.25 ng/ml (= 7 nM)
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metabolites of DB 289 (Chapter 5, Fig. 20):
M1 (DB 775) IC50 = 1.16 µg/ml (= 2.6 µM)
M2 (DB 290) IC50 = 22.35 µg/ml (= 66.4 µM)
M3 (DB 810) IC50 = 0.028 µg/ml (= 0.066 µM)
M4 (DB 835) IC50 = 0.187 µg/ml (= 0.461 µM)*
*impurities with DB 75 due to synthesis
metabolites of DB 844 (Chapter 5, Fig. 21):
M1A: not determined
M1B (DB 1058) IC50 = 4.61 µg/ml (= 9.7 µM)
M2A not determined
M2B (DB 1212) 0.030 µg/ml (0.066 µM)
M3 (DB 821) IC50 = 55.4 µg/ml (= 120.2 µM)
M4A not determined
M4B not determined
Based on these in vitro results, the obtained active metabolites were not identical with DB
775, DB 290 and DB 835 in the case of DB 289; DB 810 would be possible, since a good
activity was obtained in the in vitro assay. In the case of DB 844, possible active metabolites
were not DB 821 and DB 1058; M2B would be possible due to its activity in vitro. Not yet
determined metabolites should be tested in vitro to identify possible active metabolites.
5. Conclusion
Hints for the existence of active metabolites were obtained in infected animals after DB 75 or
DB 289 treatment, respectively. In the case of DB 75, possible metabolites occurred very
early within the first 30 min and after 2 hr. Possible metabolites after treatment with DB 289
occurred only in infected animals after 4 hr and were detectable till the 8th hr. If these
metabolites were the same as the ones which were seen after DB 75 treatment has to be
clarified.
Also, metabolites may be formed after DB 820 or DB 844 application, respectively. After
DB 820 treatment, possible metabolites may be formed after 8 hr up to 24 hr, especially in
CHAPTER 7: Investigations of plasma samples by bioassay
__________________________________________________________________________________________
186
uninfected animals. 6 and 24 hr after DB 844 treatment, results of the bioassay indicated the
presence of possible metabolites in uninfected animals.
To gain more evidence on formed metabolites further studies are required. First of all,
possible metabolites after incubation with liver microsomes have to be analysed and
identified. Then a comparison with plasma samples is possible.
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Fig. 1: Plate layout bioassay
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Fig. 2: Concentration of DB 75 in plasma samples of trypanosome
infected and uninfected mice determined by HPLC/MS/MS and bioassay
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Fig. 3: Ratios of the DB 75 concentration in plasma samples
determined by HPLC/MS/MS and bioassay
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Fig. 4: Concentration of DB 75 after conversion of DB 289 in plasma
samples of trypanosome infected and uninfected mice determined by
HPLC/MS/MS and bioassay
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Fig. 5: Ratios of DB 75 concentration in plasma samples after
conversion of DB 289 determined by HPLC/MS/MS and bioassay
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Fig. 6: Concentration of DB 820 in plasma samples of trypanosome
infected and uninfected mice determined by HPLC/MS/MS and bioassay
0 2 4 6 8
0
2500
5000
7500
10000
12500
15000
HPLC/MS/MS uninf. after DB 820
bioassay uninf. after DB 820
HPLC/MS/MS inf. after DB 820
bioassay inf. after DB 820
12 16 20 24
time [h]
co
nc
. D
B
 8
20
 [n
M
]
Fig. 7: Ratios of DB 820 concentration in plasma samples
determined by HPLC/MS/MS and bioassay
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Fig. 8: Concentration of DB 820 after conversion of DB 844 in
plasma samples of trypanosome infected and uninfected mice
determined by HPLC/MS/MS and bioassay
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Fig. 9: Ratios of DB 820 concentration in plasma samples after
conversion of DB 844 determined by HPLC/MS/MS and bioassay
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Fig. 10: Possible N-hydroxylation of DB compounds 
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Pharmacokinetic studies of DB 75 and its prodrug DB 289
in Plasmodium berghei infected and uninfected mice
Abstract
In vivo observations showed that P. berghei infected mice treated with DB 75 could decrease
their parasitaemia by 87% and prolong their survival time to 23 days compared to 6-7 days
obtained for control animals. Unfortunately, when administering the prodrug DB 289,
parasitaemia was reduced only by 42% and survival days were only slightly prolonged to
15 days. Pharmacokinetic studies were performed for DB 75 and its prodrug DB 289 in
P. berghei infected and uninfected mice to reveal the reasons for those differences.
It could be shown that the rate of conversion of prodrug to its active principle was the same in
uninfected animals than in infected. Taking the plasma protein binding into consideration,
insufficient concentration of free active compound was found in infected and in uninfected
mice as the comparison with an in vitro time dose assay showed. Increase of the plasma
proteins as reported for infected animals might lead to further reduction of free active drug in
plasma. Another factor which may reduce the concentration of free active drug, may be the
accumulation of DB 75 in parasites as seen when parasites incubated with DB 75 were
inspected under the UV microscope.
This study showed that the amount of active drug after application of the prodrug in plasma
was subcurative.
1. Introduction
Today, approximately 40% of all people, mostly people living in the developing countries, are
at risk of malaria. There, this infectious disease is still one of the leading causes of morbidity
and mortality. It is estimated that infections with plasmodia cause 1.2 millions deaths per
year, of which 90% occur in Sub-Saharan Africa. Children under the age of five, as well as
pregnant women and their unborn child are particularly vulnerable to malaria
[http://www.who.int/mediacentre/factsheets/fs094/en/index.html].
Malaria is a parasitic disease caused by protozoans of the genus Plasmodium, which is
transmitted by the female anopheles mosquito. Four species are infectious to humans:
P. vivax, P. ovale, P. malariae and P. falciparum. Infections can be distinguished based on
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morphological criteria and their development in the host. P. falciparum causing malaria
tropica is by far the most life threatening disease of all plasmodial infections.
Parasites undergo a complex life cycle containing sexual and asexual reproduction and
changes of hosts. When injected by the bite of an infected mosquito, the parasites in the stage
of sporozoites invade liver cells. There, maturation to schizonts and segregation to merozoites
takes place (asexual reproduction). Merozoites are released and invade erythrocytes. In the
red blood cell, erythrocytic schizogeny takes place: merozoites develop via immature
trophozoites (ring stage) into mature schizonts which again release merozoites. Some of the
parasites differentiate to gametocytes which have to be taken up by a mosquito to complete
their lifecycle. In the insect they mature to micro- and macrogametes and fuse to a zygote
(sexual reproduction). Zygotes become motile ookinetes which invade the midgut wall of the
mosquito where they develop into oocysts which grow and release sporozoites. Sporozoites
invade the salivary glands, from where they are transmitted into a new host.
Since the plasmodium life cycle differs a lot from the human one, drug targets are manifold.
However, only about eight drugs are available for treatment of malaria [Hatz, C. (1998)].
Additionally, spreading resistance of the parasite to some anti-malarials weakened treatment
success (most important example: chloroquine resistance). Therefore, new drugs are urgently
required.
The efficacy of aromatic diamidines against human protozoal infections was known since
1930, when activity against trypanosomes was observed.
During the 1940´s anti-plasmodial activity of aromatic diamidines in monkeys infected with
Plasmodium knowlesi was demonstrated [Bell, C.A. (1990)]. However, diamidines were never
used clinically in the treatment of malaria.
Potent anti-malarial activity was reported for pentamidine, which served then as lead
compound. The parasitic DNA is considered to be the main cellular target of pentamidine and
its analogues. It could be shown, that these compounds bind to the minor groove with
preference to AT-rich sites. By this binding, an interference with DNA-interacting enzymes is
achieved. Since the plasmodium genome contains up to 80% adenine and thymidine,
compared to 50% in humans, binding to the DNA of the pathogen is favoured. Additionally,
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the curvature of the DNA double helix differs from parasite to host, and therefore molecules
show different binding capacities.
Chemical modelling and subsequent screening activities revealed highly active pentamidine
analogues against trypanosomes. One of the most promising molecules is the diphenylfuran
DB 75, which showed an excellent activity against trypanosomes in vitro and in vivo. When
tested on P. falciparum strain K1 in vitro, it exhibited a potent anti-malarial effect with an
IC50 of 5.8 ng/ml.
Testing this compound in vivo in the P. berghei mouse model, a moderate to good activity of
87% with 23 days survival was achieved after application of 4 x 50 mg/kg s.c. After oral
application of 4 x 100 mg/kg DB 289, the corresponding methoxyamidine prodrug, no
significant effect on the parasite could be demonstrated (activity 42.4%, survival days 15.2 on
average). Control mice died within 6 to 7 days after infection.
To find out, why DB 75 exhibits anti-plasmodial activity in the P. berghei mouse model and
why this is not the case when its prodrug is administered, a pharmacokinetic study was
performed. It was hoped to find a reasonable explanation for this discrepancy by studying the
pharmacokinetics of DB 75 and DB 289 in the mouse.
2. Material and Methods
2. 1. Compounds and chemicals
2.1.1. Compounds and radiolabelled internal standards
DB 75, DB 289 and their stable isotopically labelled counterparts d8-DB 75 and d8-DB 289
were synthesised using methods previously described [Das, B.P. (1977)], [Boykin, D.W.
(1996)], [Stephens, C.E. (2001)].
2.1.2. Chemicals
Tween 80 was obtained from Fluka (Buchs, Switzerland). Ethanol and NaCl were purchased
from Merck (Dietikon, Switzerland), potassium fluoride from Sigma Aldrich (Basel,
Switzerland) and heparin from Fresenius (Stans, Switzerland).
HPLC- grade acetonitrile, methanol, water and formic acid were obtained from Fisher
Scientific (Chicago, IL, USA), ammonium formate and trifluoroacetic acid (TFA) from
Sigma-Aldrich (St. Louis, MO, USA).
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2.2. Drug solutions
2.2.1. Drug solutions for treatment of mice
The calculated amount of drug was weighed (5 mg/ml DB 75 or 10 mg/ml DB 289) and
dissolved in one tenth of the final volume of 70% Tween 80/30% ethanol, which was then
10-fold diluted with water resulting in 7% Tween 80 and 3% aqueous ethanol.
2.2.2. Standard curves and internal standard
These were prepared as described previously [see “Pharmacokinetic studies of selected DB
compounds in trypanosome infected and uninfected mice”].
2.3. Animal experiment
2.3.1. Animals
In all experiments female NMRI mice with a bodyweight of 20 to 22 g were used.
2.3.2. Administration of compounds
50 mg/kg of DB 75 subcutaneously, 100 mg/kg DB 289 per os, respectively, was
administered to infected and uninfected mice.
2.3.4. Infection and animal care
Mice were infected intravenously on day 0 with the P. berghei strain ANKA. Blood from an
infected mouse was diluted with physiological saline solution till 108 parasitised erythrocytes
per ml were obtained. 0.2 ml of this solution was applied. Pharmacokinetic parameters were
determined in an early stage of the infection (day 1). A parasitemia of around 1% is expected.
Animal use adhered to the guidelines issued by the Swiss Federal Veterinary Department
(BVET) for laboratory animals.
Plasma samples were kindly provided from the MMV group at the Swiss Tropical Institute.
For information about harvesting of blood and plasma preparation, sample preparation,
description of instruments and data analysis see “Pharmacokinetic studies of selected DB
compounds in trypanosome infected and uninfected mice”.
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3. Results
3.1. Comparison of plasma levels in infected and uninfected mice
3.1.1. Active compounds
DB 75 in plasma of uninfected and P. berghei-infected mice after s.c. application (Fig. 1)
Plasma concentrations in infected and uninfected mice were similar during the whole 24 hr
observation period. No difference could be observed, neither in the amount of drug available
for the organism, nor in the elimination process between infected and uninfected animals
(Chapter 10, Appendix E, Table 1).
3.1.2. Prodrugs
DB 289 in plasma of uninfected and P. berghei-infected mice after p.o. application (Fig. 2)
Available amount of drug was twice as high in the infected animals compared to their
uninfected counterparts. The AUMC even was 4 times higher in infected animals. It took
twice the time to eliminate the prodrug from infected animals than from uninfected.
Cmax occurred at the same time point. Plasma levels of uninfected animals declined thereafter
steadily. In infected animals a minimum after 6 hr was observed, which was followed by a big
rise in the plasma concentration at 8 hr. Plasma levels declined thereafter, but a considerable
amount of prodrug still was detectable in the plasma of infected mice after 24 hr (Chapter 10,
Appendix E, Table 2).
3.2. Comparison of the conversion of the prodrug to the active drug
Conversion of DB 289 to DB 75 in uninfected (Fig. 3) and P. berghei-infected (Fig. 4) mice
after orally administered DB 289
In either case, infected and uninfected, only a small amount of around 10% prodrug was
activated to DB 75. After 24 hr, the highest plasma concentration of active compound was
detected within the whole observation period of 24 hr in infected as well as in uninfected
animals (Chapter 10, Appendix E, Table 3).
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DB 75 in plasma of infected vs. uninfected mice after treatment with DB 289 p.o. (Fig. 5)
During the first 7 hr, plasma levels of activated compound were more or less the same in
infected and uninfected animals. Within this period, plasma concentrations rose steadily.
After 7 hr, DB 75 concentration in infected animals increased to a higher extent than in
uninfected animals. This increase in infected animals led to the fact that around one fourth
more active compound was at disposal over 24 hr than in the uninfected mice.
4. Discussion
4.1. Plasma levels of infected and uninfected mice
4.1.1. Active drugs
Infected animals showed the same plasma concentration course as uninfected animals.
Accumulation of DB 75 in plasmodium was observed in vitro and in vivo at different stages
of the parasite [Schild, N. (2003)]. Since there is no difference detectable between plasma
concentrations in infected and uninfected animals it could be that this accumulation process is
rather unimportant in relation to the total amount of available drug. It is also possible that this
effect is masked by the increase of drug concentration in the plasma obtained by inhibition of
the metabolism. Shertzer reported that a trypanosome infection is accompanied by a
significantly impaired capacity of the liver to metabolise drugs via monooxygenation
[Shertzer, H.G. (1981)]. The same may apply for plasmodia infected mice.
4.1.2. Prodrugs
Relevant differences between the pharmacokinetic profiles occurred not until the 6th hr. At
this time, plasma levels dropped and rose again thereafter in infected animals but not in
uninfected. The reason for this behaviour is not known.
The large surplus of drug in infected animals compared to uninfected may be due to the
inhibition of metabolism. Since enzymes like hepatic cytochrome P 450 and associated
mixed-function oxidases may be inhibited, less of the prodrug would be converted to the
active compound and therefore more DB 289 is detectable. Accumulation processes of the
prodrug were not reported so far.
4.2. Transformation of the prodrug to the active drug
Activation of the prodrug was performed only to a small extent in either case (infected or
uninfected). Comparing the conversion to the active compound, no difference in the amount
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of drug available was visible up to 8 hr. After this time, concentration of DB 75 increased in
both cases, but stronger in infected animals.
Lower plasma levels in infected animals were expected, because accumulation of DB 75 in
the parasite may take place. The consequence of this accumulation process would be, that
more prodrug is converted to the active drug, and therefore lower plasma levels would be
assessable. As noticeable from the graphs, the opposite applied: higher plasma levels were
obtained in infected animals. This indicated that the inhibition of the metabolism may play the
more important role.
Conclusion
Plasma concentrations showed a great variability independent from the status of infection.
Since a non-serial sampling method was used, this variability was expected. Each value
represents an average of the plasma concentration obtained from three individual mice,
possessing each a slightly different genetic background. Taking serial probes by cannulating
the mice was not possible, because the amount of plasma needed for determination exceeded
the total amount of plasma in one mouse.
Various factors change during an infection. One of these is an increase of various plasma
proteins. For drug transport within the body, several classes of proteins must be taken into
consideration. Generally, albumin is responsible for the transport of acidic drugs, lipoproteins
for neutral drugs and alpha-1-acid glycoprotein (α-AGP) for bases.
An increase of plasma proteins like α-AGP would lead to higher plasma concentration of
alkaline compounds like diamidines, since bound and free drug are assessed with the
determination method of this pharmacokinetic study. Human α-AGP levels are known to be
higher in malaria patients. Hochepied (2002) reported, that in mice during an acute phase
reaction, like an infection is, concentrations of α-AGP increase 2-5 times from the normal
level of 0.2-0.4 mg/ml, leading it to one of the dominant plasma proteins. α-AGP is assumed
to bind the cationic DB 75 [Hochepied, T. (2002)]. Protein binding is known to be 70% in the
case of DB 75 and 99% in the case of DB 289 [Hall J. E., personal communication].
CHAPTER 8: Pharmacokinetic studies of DB 75 and its prodrug DB 289 in Plasmodium berghei infected
 and uninfected mice
__________________________________________________________________________________________
201
The pharmacokinetic profile was influenced by the status of infection in two ways:
1. Possible accumulation of compound in the parasite
Accumulation of diamidine compounds in infected erythrocytes is known for several years
now. In vitro, pentamidine was concentrated 500 fold by P. falciparum infected erythrocytes
within 3 hr [Stead, A.M. (2001)]. No accumulation factors are known for DB 75 and DB 289
so far, but fluorescence microscopy indicated that DB 75 is accumulated in P. falciparum and
P. berghei [Schild, N. (2003)]. The suggested mechanism of this uptake is a transport through
the new permeability pathway (NPP), that is induced in the host erythrocyte membrane by the
intracellular parasite. A pore system such as the NPP allows the equilibration of substrates,
but not an accumulation. To concentrate the drug, transporters or receptors, specific and/or
unspecific, are needed. One potential drug receptor could be ferriprotoporphyrin (FPIX), that
is generated during the digestion of haemoglobin [Francis, S.E. (1997)]. By interacting
(diamidine with FPIX), the conversion from FPIX, toxic to the parasite, to non-toxic
hemozoin is inhibited. In vitro, pentamidine was shown to bind to FPIX. This binding would
be essential for anti-malarial activity as already shown for other antimalarials like
chloroquine.
2. Inhibition of metabolism
As discussed previously [“Pharmacokinetic studies of selected DB compounds in
trypanosome infected and uninfected mice”], a decrease of metabolic activity in trypanosome
infected mice by inhibition of mixed-function oxidases was reported by Shertzer [Shertzer,
H.G. (1981)]. In a malaria infection an impaired oxidation, glucuronidation and biliary
excretion in the isolated perfused rat liver was shown by Murdoch [Murdoch, R.T. (1991)].
This pharmacokinetic study was performed, to reveal why no cure could be achieved after
administration of the prodrug DB 289 in P. berghei infected mice, whereas an activity for
DB 75 could be demonstrated. It was expected that data obtained in this experiment could
help to explain this phenomenon.
Conversion of DB 289 to its active form DB 75 also takes place in infected animals - even to
a similar extent as in the uninfected animals. A possible explanation for the insufficient
activity against plasmodium could be, that the amount of free drug in the plasma was not long
enough available or even is too low to exhibit an anti-protozoal effect. Considering a protein
binding of 70% for DB 75 less than one third of the measured amount of DB 75 is free in the
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plasma (around 25 nM up to 115 nM in infected animals) and therefore responsible for the
activity. IC50 values, determined in a time dose assay in vitro for strain K1 (P. falciparum)
showed that an incubation with at least a concentration of 132.5 nM free compound for 1 hr is
needed to be effective against 50% of the parasites [Schild, N. (2003)]. Prolonging the
incubation time up to 4 hr, an IC50 of 103.4 nM was determined in vitro. To kill 50% of the
parasites, when incubating the drug for 24 hr, 20.3 nM would be needed. In general, values
3-5 times higher than the IC50 would be needed to eliminate the parasites (minimal inhibitory
concentration: MIC), what would be 60 to 100 nM for a period of 24 hr (Chapter 9, Appendix
E, Table 4). Similar values were expected for P. berghei. Considering a plasma protein
binding of 70%, this amount was just achieved. Taking higher plasma protein levels from the
type α-AGP, which were proven to increase during a P. falciparum infection, into
consideration, the amount of free drug in the plasma declines. Therefore the actual
concentration of free drug could be below the curative dose.
Allen and co-workers reported that uptake of radiolabelled DB 75 was not observed in
P. berghei, but in P. falciparum [Poster Allen J. (2005), Congress: Medicine and Health in the
Tropics, Marseille]. They concluded that this may be the reason why no cure was achieved
after application of DB 289 in the mouse.
Fluorescence microscopy revealed blue fluorescent structures in P. berghei infected
erythrocytes extracted from a mouse treated with 40 mg/kg DB 75. These structures were
identical to structures which were obtained when stained with the conventional DNA-dye
Hoechst 33258 [Schild, N. (2003)]. Uninfected erythrocytes did not show fluorescence when
inspected. The fluorescence indicated an accumulation of DB 75. This observation contradicts
the findings of Allen and co-workers.
P. falciparum appeared to exhibit greater fluorescence than P. berghei [Schild, N. (2003)].
Probably, a lower accumulation in P. berghei infected erythrocytes occurs than in
P. falciparum infected erythrocytes. This has to be subject for further investigations.
Another observation which indicated the accumulation of DB 75 in P. berghei infected
erythrocytes is that the in vitro assay with erythrocytes isolated from a P. berghei infected
mouse showed a similar IC50 as P. falciparum in vitro did [Wittlin S., personal
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communication]. It is possible to keep P. berghei infected erythrocytes in culture for 24 hr,
therefore the duration of the performed assay was reduced to 24 hr (instead of 72 hr) for both
P. berghei and P. falciparum infected erythrocytes.
Another phenomenon which was observed during in vivo screening and which was surprising,
was that the mean survival days varied a lot after DB 289 treatment: from 8 to 25 days after
treatment with 4 x 100 mg/kg p.o, whereas the activity in % was more or less constant with
around 42%. Such variations in the survival days were not observed after application of
standard antimalarials.
Why these differences in the survival days were obtained is not known to date. It is assumed,
that since plasma levels insufficient to kill the parasites completely were achieved, the general
constitution (status of health and immune system) of the mouse may be relevant for longer
survival. The velocity with which drugs act and parasites are killed may be influence the
variability in survival days. Survival days do not spread that much when classical
antimalarials were tested in the P. berghei mouse model. The variation of the survival days
after treatment with chloroquine and artemether lies within a range of +/- 10%. Survival days
after treatment with 1 x 10 mg/kg ranged in the case of chloroquine from 8 to 10 days (mean:
8.9 days), the ones of artemether from 9 and 11 days (mean 9.7 days) [Wittlin S., personal
communication]. Both are known as fast-acting drugs.
Outlook:
In this study, we could demonstrate that the prodrug DB 289 was converted into DB 75 to the
same extent in healthy as well as in infected mice. Unfortunately, only a small fraction of
prodrug was converted to the active compound. This amount of active compound seemed to
be insufficient to kill the parasites. Since prodrug is present in excess and the amount of
converted prodrug is more or less constant over time, developing a different galenic
formulation to deliver more prodrug is not necessary. An important step to improve the extent
of conversion, for instance would be inducing the enzymes which are involved in the
activation of the prodrug to the active compound.
Metabolism of DB 289 was elucidated by Zhou (2004), revealing enzymes like cytochrome
(CYP) P 450 and cytochrome b5 to play a key role [Zhou, L. (2004)], [Ansede, J.H. (2004)],
[Saulter, J. (2005)]. The first step, the N-demethylation of DB 289 is catalysed by CYP P 450
1A2, 4F2, 4F3B. CYP 450 1A2 is known to be induced by phenobarbital, phenytoin,
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rifampicin, ritonavir, polycyclic aromatic hydrocarbons found in cigarette smoke or charcoal
broiled foods [Michalets, E.L. (1998)]. Cytochrome b5 reacts relatively insensitive to
induction by exogenous drugs and chemicals [Gibson, G.G. (1994)]. In a first step, one has to
clarify, which enzymatic reaction within the activation of the prodrug is the limiting step.
Once this is known, interaction at the level of this enzyme may be possible and therefore
higher levels of active compounds may be achieved in mice.
Conversion of prodrug to active compounds was demonstrated to be more efficient in rats.
Therefore, the P. berghei mouse model may not be ideal to assess the effectiveness of
DB prodrugs in vivo. In humans, the enzymes involved in this activation are even more
effective [Hall J. E., personal communication]. This must be the reason for the promising
results for DB 289 in the phase II trial in malaria patients, completed 2003 in Bangkok, with a
cure rate of 96% [Yeramian, P. (2005)].
It could also be, that uptake of DB 75 in P. berghei infected erythrocytes is reduced compared
to uptake in P. falciparum infected erythrocytes and that therefore insufficient levels of drug
in the parasites were obtained.
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Fig. 1: DB 75 in plasma of uninfected and
P. berghei-infected mice after s.c. application
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Fig. 2: DB 289 in plasma of uninfected and
P. berghei-infected mice after p.o. application
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Fig. 3: Conversion of DB 289 to DB 75  in plasma of
uninfected mice after orally administered DB 289
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Fig. 4: Conversion of DB 289 to DB 75 in plasma of
P. berghei-infected mice after orally administered DB 289
0 2 4 6 8
0
500
1000
1500
2000
2500
3000 DB 289
converted DB 75
12 18 24
time [h]
D
B
 in
 [n
M
]
CHAPTER 8: Pharmacokinetic studies of DB 75 and its prodrug DB 289 in Plasmodium berghei infected
 and uninfected mice
__________________________________________________________________________________________
207
Fig. 5: DB 75 in plasma of uninfected and
P. berghei-infected  mice after treatment with DB 289 p.o.
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General discussion
This Ph. D. thesis was embedded in an international project of a public-private-partnership
with the aim to develop new drugs for the treatment of human African trypanosomosis. In this
thesis, several facets of the lead compound DB 75 have been under investigation. Data at
hand, resulting from various studies, helps to draw a detailed picture of the behaviour of this
drug not only in vitro but also in vivo in mice. Additionally, findings for DB 75 and its
prodrug DB 289 may be applicable in lead optimisation. Understanding of the lead, facilitates
the selection for new compounds when a rational drug design like molecular modelling and/or
target research is performed.
This project started with an experiment which helped to understand the complex interplay
between mice, trypanosomes and drug treatment. Thereto, a mouse study was performed,
where the development of a first infection, of a first and of a second relapse parasitaemia was
observed in immunocompetent and immunodeficient mice. Additionally, parasite clearance
after drug treatment and duration of the aparasitic period was monitored in both
immunocompetent and -deficient mice. Based on the data collected a precise description of
the impact of host and parasite factors in a developing parasitaemia was possible.
Understanding the kinetics of parasitaemia in trypanosome infected mice without and with
DB 75 treatment is a pre-requisite in any study where DB 75 administered to mice is
involved. By comparing morphology, size distribution and sensitivity to selected drugs of
trypanosomes isolated from each stage like first infection, first relapse or second relapse,
changes due to interaction with the host and/or the treatment could be assessed. The obtained
results clearly showed no differences between the various trypanosome populations. The
conclusion of these results was, that reappearance of trypanosomes after drug treatment with
DB 75 was not due to surviving resistant trypanosomes, but rather due to invasion from
extravascular sites (niches). Therefore, the next step was the identification of those niches. A
method amplifying and detecting mRNA of trypanosomes was established. It was possible to
gain first results, but unfortunately, limitations in time did not allow improvements of the
evaluated method and therefore prevented the complete identification of those niches.
However, it could be shown that the method itself worked. More investments on the
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extraction method leading to an increase of the RNA yield and improvement of the sensitivity
of the detection method are required.
After having improved this method, it would also be possible to perform studies with the aim
to find out at what stage of the infection passage of the blood brain barrier is likely taking
place. This could be performed with different trypanosomes strains like the GVR 35
(T. brucei brucei) which leads to an chronic infection and is used when compounds were
tested for treatment of second stage trypanosomosis, and the STIB 900, leading to an acute
infection. Since relapses also occur in the African green monkey model, identification of
possible niches may be detected taking results of the mouse model into consideration.
Cross resistance is well documented for drugs used to treat trypanosomosis. Therefore, new
drug candidates, especially drugs which were synthesised as analogues to drugs already on the
market and from which drug resistance already had been reported, should be tested in an early
stage of their development for their cross resistance to existing drugs. Cross resistances which
may be monitored in laboratory strains may also occur in the field.
Trypanosomes to which either melarsoprol or pentamidine resistance was induced in vitro
were shown to maintain their sensitivity towards DB 75 to a certain extent. This finding is
rather surprising, since transport for DB 75 is assumed to happen via the P2 transporter.
Alterations of the P2 transporter were shown to be important in melarsoprol and pentamidine
resistant strains. The moderate cross resistance to DB 75 may indicate that additional
transporter like the P1 transporter, which do not transport pentamidine, may be responsible for
drug uptake.
Laboratory induced resistance of STIB 900 trypanosomes to melarsoprol and pentamidine,
delivers a new biological tool to check for cross resistance of newly synthesised drugs and
may therefore be an important tool in lead optimisation.
In a second approach to understand the interplay between mice, trypanosomes and drug,
pharmacokinetics of DB 75 in infected and uninfected animals was studied. To complete the
picture, the same study was performed with the corresponding prodrug DB 289 and also with
the closely related drug candidate DB 820 and its prodrug DB 844. By performing the
pharmacokinetic studies also with DB 820, DB 844 it could be shown that minor changes in
structure like the replacement of one phenyl moiety within the spacer region by one pyridyl
moiety may result in big differences referring to the pharmacokinetic profile.
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Metabolic activation of the prodrugs and reduction of plasma levels of free compound due to
host and/or parasite factors were found to play an important role. From the side of the host,
plasma protein binding of the drug has to be considered, whereas parasites interact by
accumulating active compound and/or by inhibiting metabolism. The drug itself may also
induce the inhibition of metabolism.
These studies clearly showed that predictions concerning plasma levels are not easy to make
since all mentioned factors had an influence on pharmacokinetic parameters. The extent of the
influence of these parameters depended on the host, the parasite and on drug related
properties.
In an in vitro study, the extent of a possible accumulation of DB 75 in trypanosomes was
assessed. This was done to find out, whether the difference obtained between plasma levels of
DB 75 after DB 289 application in infected mice compared to the one in uninfected mice may
be explained by accumulation of the active compound. Data obtained in this study showed
that an accumulation of DB 75 in vitro up to one million fold is possible what is sufficient to
explain the detected differences between infected and uninfected animals. When assessing the
dosage of a treatment, possible accumulation in parasites have to be considered, otherwise
application of subcurative doses would be the consequence. Not all DB compounds were
observed to accumulate to the same extent, therefore influence of infection had to be assessed
preferably for each compound.
In another study related to the pharmacokinetic studies, the presence of active metabolites
after DB 75, DB 289 and DB 820, DB 844 application was assessed using the bioassay. Anti-
trypanosomal activity was determined as equivalent of active drug and compared to the
amount of active drug obtained by HPLC/MS/MS method. For each of the compounds
applied, indications for the presence of at least one active metabolite were found. Further
studies are urgently needed to verify these results and to identify possible metabolites. May be
one of those metabolites may serve as new lead. Thereto, this metabolite has to be
synthesisable, stable and exhibit a stronger anti-parasitic activity than the parent compound.
Pharmacokinetic studies in P. berghei infected mice, were performed to find an explanation
why application of the prodrug DB 289 did not lead to a significant reduction (~ 40%
reduction) in parasites as the application of the active compound DB 75 (~ 85% reduction)
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does. Analysis of the obtained pharmacokinetic profiles revealed that the conversion of the
prodrug to the active drug was insufficient. Plasma levels of active drugs converted from
prodrugs did not reach the required therapeutical dose as a comparison with an in vitro time
dose assay showed. This result questions the P. berghei mouse model to be adequate when
testing DB prodrugs for their activity. Experiments in rats showed that the enzyme(s) which
were responsible for conversion of the prodrug to the active compound act more efficiently. In
humans, prodrug is reported to be readily converted to the active drug [Boykin, D.W. (1996)].
This may explain the high cure rate of 96% obtained in an efficacy trail for DB 289 in
P. falciparum and P. vivax infected patients conducted in Thailand [Yeramian, P. (2005)].
At time, DB 289 is undergoing phase III clinical trials for treatment of first stage
trypanosomosis at multiple sites in the Democratic Republic of Congo, Sudan, and Angola.
During the Phase III trial, it is aimed to submit for the status of the so called Treatment IND
(Treatment Investigational New Drugs) to the U.S. FDA for approval which, if granted, would
enable DB 289 to be sold for the treatment of trypanosomiasis in desperately ill patients while
the clinical trials are being completed [www.immtech-international.com/documents/news_aug
_25_2005.pdf].
In the case of malaria, enrolment for clinical trial phase II in Bangkok started in May 2005.
The trial conducted by Immtech International in collaboration with the Medicines for Malaria
Venture (MMV) will compare the effectiveness of three-day dose regimens of DB 289 given
as mono-therapy and in combination with artesunate.
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Table 1: Data hypoxanthine assay group A
mouse
tryp.
strain
replicate
IC50
DB 75
IC50
diminazene
IC50
melarsoprol
IC50
pentamidine
A NMRI K 900 1 14 50 2.16 4.18
2 20 58 2.57 5.35
3 13 44 2.18 5.31
A NMRI KR 1 13 24 3.54 11.33
2 21 39 3.34 7.61
3 12 38 2.17 5.73
A NMRI KSt 1 9 16 2.66 8.06
2 12 37 7.03 5.06
3 17 56 3.26 4.73
average 14.56 40.22 3.21 6.37
stand. dev. 3.97 13.88 1.53 2.26
mouse
tryp.
strain
replicate
IC50
DB 75
IC50
diminazene
IC50
melarsoprol
IC50
pentamidine
A SCID K 900 1 13 25 4.44 1.82
2 15 34 3.14 5.7
3 12 28 4.01 4.25
A SCID R 1 8 11 1.48 2.58
2 16 32 3.01 5.74
3 16 32 4.15 5.95
A SCID KSt 1 19 37 3.57 8.07
2 15 19 2.4 7.07
3 13 41 1.81 10.37
average 14.11 28.78 3.11 5.73
stand. dev. 3.1 9.3 1.04 2.65
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mouse
tryp.
strain
replicate
IC50
DB 75
IC50
diminazene
IC50
melarsoprol
IC50
pentamidine
A NMRI R 795 1 4 6 2.7 3.98
2 10 18 5.23 9.36
3 6 10 3.92 7.55
A NMRI KR 1 7 9 3.63 5.49
2 11 19 4.97 9.84
3 7 14 4.75 8.52
A NMRI KSt 1 3 5 2.1 4.23
2 9 16 4.61 7.81
3 6 11 4.51 7.57
average 7 12 4.05 7.15
stand. dev. 2.65 5.05 1.06 2.12
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Table 2: Data hypoxanthine assay group B
mouse
tryp.
strain
replicate
IC50
DB 75
IC50
diminazene
IC50
melarsoprol
IC50
pentamidine
B NMRI R 900 1 19 50 2.85 6.83
2 11 25 2.04 4.43
3 10 39 2.31 9.69
B NMRI St 1 17 50 4.38 7.13
2 8.54 33.71 2.18 7.43
3 22 97 3.55 7.06
B NMRI KSt 1 15 50 2.41 6.03
2 23 98 3.15 4.77
3 11.61 75 1.7 6.1
average 15.24 57.52 2.73 6.61
stand. dev. 5.32 26.55 0.84 1.56
mouse
tryp.
strain
replicate
IC50
DB 75
IC50
diminazene
IC50
melarsoprol
IC50
pentamidine
B SCID St 900 1 10 45 3.17 4.86
2 19 38 2.85 5.94
3 15 72 2.53 7.33
B SCID KR 1 12 62 3.35 4.68
2 14 66 2.63 3.88
3 19 18 3.21 7.94
B SCID KSt 1 25 80 3.12 6.2
2 10 20 2.67 4.69
3 7 25 2.78 3.34
average 14.56 47.33 2.92 5.43
stand. dev. 5.64 23.55 0.29 1.54
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Table 3: Data hypoxanthine assay group C
mouse tryp.
strain
replicate
IC50
DB 75
IC50
diminazene
IC50
melarsoprol
IC50
pentamidine
C NMRI K 900 1 14 67 4.05 4.96
2 8 53 3.51 6.25
3 10.05 28.4 2.15 5.22
C NMRI R 1 8 66 3.58 4.96
2 18 56.9 3.19 6.25
3 11 34 4.06 5.22
C NMRI KSt 1 11 41.74 4.56 7.66
2 13.84 54.6 4.03 10.47
3 12.65 62.58 3.19 9.21
average 11.84 51.58 3.59 6.69
stand. dev. 3.19 13.92 0.7 2.01
mouse
tryp.
strain
replicate
IC50
DB 75
IC50
diminazene
IC50
melarsoprol
IC50
pentamidine
C SCID K 900 1 14 33 10.62 1.9
2 19 41 2.7 4.69
3 10 16 1.68 2.57
C SCID St 1 23 64 5.61 4.91
2 12 24 2.17 3.36
3 16 19 1.89 6.46
C SCID KSt 1 11 21 1.73 3.82
2 12 46 2.18 3.9
3 17 64 2.82 3.79
average 14.89 36.44 3.49 3.93
stand. dev. 4.26 18.57 2.93 1.34
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Table 4: Data hypoxanthine assay group D
mouse
tryp.
strain
replicate
IC50
DB 75
IC50
diminazene
IC50
melarsoprol
IC50
pentamidine
D NMRI K 900 1 6 76 3 4.61
2 9 30 2.13 6.75
3 19 62 1.93 4.73
D NMRI St 1 11 88 3.71 5.03
2 16 66 2.13 9.2
3 19 84 3.26 6.42
D NMRI KSt 1 10 61 3.98 5.26
2 20 72 2.57 6.71
3 18 74 3.04 5.32
average 14.22 68.11 2.86 6
stand. dev. 5.24 16.97 0.72 1.46
mouse
tryp.
strain
replicate
IC50
DB 75
IC50
diminazene
IC50
melarsoprol
IC50
pentamidine
D SCID K 900 1 15 25 2.53 6.67
2 10 17 2.39 7.14
3 20 73 2.24 11.17
D SCID St 1 14 28 3.27 6.6
2 21 54 2.4 5.95
3 15 70 2.28 4.62
D SCID KR 1 21 37 1.84 14.25
2 11 75 2.66 4.52
3 21 55.24 2.49 8.64
average 16.44 48.25 2.46 7.73
stand. dev. 4.42 22.18 0.38 3.18
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Table 5: Data hypoxanthine assay group E
mouse
tryp.
strain
replicate
IC50
DB 75
IC50
diminazene
IC50
melarsoprol
IC50
pentamidine
E NMRI K 900 1 9 21 3.62 10.56
2 12.8 64.7 1.8 7.23
3 14.2 57.2 2.71 9.02
E NMRI R 1 23 36 2.98 7.78
2 19 85 2.92 6.85
3 21 54 1.9 3.73
E NMRI St 1 19 79 4.22 5.6
2 18.35 64.13 3.06 4.94
3 11.52 38.86 3.76 3.6
average 16.43 55.54 3 6.59
stand. dev. 4.72 20.72 0.81 2.36
mouse
tryp.
strain
replicate
IC50
DB 75
IC50
diminazene
IC50
melarsoprol
IC50
pentamidine
E SCID K 900 1 6 29 2.26 4.63
2 13 34 3.07 8.49
3 22 39 2.38 5.13
E SCID KR 1 25 33 3.35 9.08
2 14 28 2.67 5.03
3 9 47 1.52 4.18
E SCID 1 21 77 1.87 4.59
2 7 60 3.34 6.6
3 8 28 3.72 6.43
average 13.89 41.67 2.69 6.02
stand. dev. 7.15 16.91 0.74 1.77
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RAW DATA
Pharmacokinetic parameters of active compounds:
Table 1: DB 75
parameter infected mice uninfected mice inf./uninf.
Cmax [nM] 13090 10397 + 26 %
tmax [h] 0.25 0.25
AUC 26222 21523 + 21.8 %
AUMC 158506 108340 + 46.3 %
MRT [h] 6.04 5.03 + 19.8 %
t1/2 [h] 4.2 3.5 + 20 %
kel   (1/MRT) 0.17 0.2 - 15 %
Table 2: DB 820
parameter infected mice uninfected mice inf./uninf.
Cmax [nM] 21420 16607 + 29 %
tmax [h] 0.25 0.25
AUC 33889 21635 + 56.6 %
AUMC 109161 90282 + 20.9 %
MRT [h] 3.22 4.17 - 22.8 %
t1/2 [h] 2.2 2.9 - 24.1 %
kel   (1/MRT) 0.31 0.24 + 29.2 %
Pharmacokinetic parameters of prodrugs:
Table 3: DB 289
parameter infected mice uninfected mice inf/uninf.
Cmax [nM] 981 1963 - 50 %
tmax [h] 2 4 !
AUC 8996 16106 - 44 %
AUMC 48143 91889 - 48 %
MRT [h] 5.35 5.71 - 7 %
t1/2 [h] 3.7 4.0 - 7.5 %
kel   (1/MRT) 0.19 0.18 + 5.6 %
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Table 4: DB 844
parameter infected mice uninfected mice inf./uninf.
Cmax [nM] 7950 8823 - 9.9 %
tmax [h] 1 1
AUC 42717 56763 - 24.7 %
AUMC 236473 327675 - 27.8 %
MRT [h] 5.54 5.77 - 4 %
t1/2 [h] 3.8 4.0 - 5 %
kel   (1/MRT) 0.18 0.17 + 5.9 %
Pharmacokinetic parameters of active compounds after prodrug
application:
Table 5: DB 75 after DB 289
parameter infected mice uninfected mice inf./uninf.
Cmax [nM] 255.7 413 - 38.1 %
tmax [h] 4 4
AUC 4565 6681 - 31.7 %
AUMC 48688 67429 - 27.8 %
MRT [h] 10.66 10.09 + 5.6 %
t1/2 [h] 7.4 7 + 5.7 %
kel   (1/MRT) 0.09 0.1 - 10 %
Table 6: DB 820 after DB 844
parameter infected mice uninfected mice inf./uninf.
Cmax [nM] 431 371 + 16.2 %
tmax [h] 8 8
AUC 7254 6224 + 16.5 %
AUMC 71441 62070 + 15.1 %
MRT [h] 9.85 9.97 - 0.1 %
t1/2 [h] 6.8 6.9 - 1.4 %
kel   (1/MRT) 0.10 0.10
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Pharmacokinetic parameters comparing analogues:
Table 7: DB 75 - DB 820 in uninfected mice
parameter uninfected mice
DB 75
uninfected mice
DB 820
820/75
Cmax [nM] 10397 16607 + 59.7
tmax [h] 0.25 0.25
AUC 21523 21635 + 5.2 %
AUMC 108340 90282 - 16.7 %
MRT [h] 5.03 4.17 - 17.1 %
t1/2 [h] 3.5 2.9 - 17.1 %
kel   (1/MRT) 0.20 0.24 + 20 %
Table 8: DB 75 - DB 820 in infected mice
parameter infected mice
DB 75
infected mice
DB 820
820/75
Cmax [nM] 13090 21420 + 63.6 %
tmax [h] 0.25 0.25
AUC 26222 33889 + 29.2 %
AUMC 158506 109161 - 31.1 %
MRT [h] 6.04 3.22 - 46.7 %
t1/2 [h] 4.2 2.2 - 47.6 %
kel   (1/MRT) 0.17 0.31 + 82.4 %
Table 9: DB 289 – DB 844 in uninfected mice
parameter uninfected mice
DB 289
uninfected mice
DB 844
844/289
Cmax [nM] 1963 8823 x 4.5
tmax [h] 4 1 !
AUC 16106 56763 3.5 x
AUMC 91889 327675 3.5 x
MRT [h] 5.71 5.77 + 1.1 %
t1/2 [h] 4.0 4.0
kel   (1/MRT) 0.18 0.17 - 5.6 %
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Table 10: DB 289 – DB 844 in infected mice
parameter infected mice
DB 289
infected mice
DB 844
844/289
Cmax [nM] 981 7950 8 x
tmax [h] 2 1 !
AUC 8996 42717 4.7 x
AUMC 48143 236473 4.9 x
MRT [h] 5.35 5.54 + 3.6 %
t1/2 [h] 3.7 3.8 + 2.7 %
kel   (1/MRT) 0.19 0.18 - 5.3 %
Pharmacokinetic parameters of actives compounds after conversion:
Table 11: Converted DB 75 and DB 820 in uninfected mice
parameter DB 75 uninf. DB 820 uninf 820/75
Cmax [nM] 413 371 + 10.17 %
tmax [h] 4 8 !
AUC 6681 6224 6.8 %
AUMC 67429 62070 7.9 %
MRT [h] 10.09 9.97 - 1.2 %
t1/2 [h] 7 6.9 - 1.4 %
kel   (1/MRT) 0.1 0.10
Table 12: Converted DB 75 and DB 820 in infected mice
parameter DB 75 inf. DB 820 inf. 820/75
Cmax [nM] 255.7 431 1.7 x
tmax [h] 4 8 !
AUC 4565 7254 1.6 x
AUMC 48688 71441 1.5 x
MRT [h] 10.66 9.85 - 7.6 %
t1/2 [h] 7.4 6.8 - 8.1 %
kel   (1/MRT) 0.09 0.10 + 11.1 %
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Pharmacokinetic parameters comparing application routes:
Table 13: DB 75 i.p. vs. s.c.
parameter uninfected mice
i.p.
uninfected mice
s.c.
s.c./i.p.
Cmax [nM] 10397 13667 + 31.5 %
tmax [h] 0.25 0.25
AUC 21523 58390 2.7 x
AUMC 108340 312666 2.9 x
MRT [h] 5.03 5.35 + 6.4 %
t1/2 [h] 3.5 3.7 + 5.7 %
kel   (1/MRT) 0.2 0.19 - 5 %
Table 14: DB 820 i.p. vs. s.c.
parameter uninfected mice
i.p.
uninfected mice
s.c.
s.c./i.p.
Cmax [nM] 16607 36533 2.2 x
tmax [h] 0.25 0.25
AUC 21635 94971 4.4 x
AUMC 90282 449591 5 x
MRT [h] 4.17 4.73 + 13.4 %
t1/2 [h] 2.9 3.3 + 13.8 %
kel   (1/MRT) 0.24 0.21 - 12.5 %
Table 15: Pharmacokinetic parameters: DB 75 s.c. vs. DB 820 s.c.
parameter uninfected mice
DB 75 s.c.
uninfected mice
DB 820 s.c.
820/75
Cmax [nM] 13667 36533 2.7 x
tmax [h] 0.25 0.25
AUC 58390 94971 + 63 %
AUMC 312666 449591 + 44 %
MRT [h] 5.35 4.73 - 11.6 %
t1/2 [h] 3.7 3.3 - 10.8 %
kel   (1/MRT) 0.19 0.21 + 10.1 %
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Table 1: Average amount of DB 75 in supernatant after various
incubation periods
Average amount of DB 75 in ng/ml, measured in the supernatant of trypanosomes solutions
containing various densities of trypanosomes after 1 hour incubation with DB 75:
DB 75 in
ng/ml
DB 75 in ng/ml in
supernatant after
incubation with
1*10e4 tryps/well
DB 75 in ng/ml in
supernatant after
incubation with
2*10e5 tryps/well
DB 75 in ng/ml in
supernatant after
incubation with
1*10e6 tryps/ well
250 87.11 81.15 105.64
500 232.66 219.41 286.75
1000 807.80 556.88 890.43
2500 1280.71 1181.23 1624.16
5000 2799.84 2571.28 3574.72
10000 6084.25 5718.80 7006.90
Average amount of DB 75 in ng/ml, measured in the supernatant of trypanosomes solutions
containing various densities of trypanosomes after 2 hours incubation with DB 75:
DB 75 in
ng/ml
DB 75 in ng/ml in
supernatant after
incubation with
1*10e4 tryps/well
DB 75 in ng/ml in
supernatant after
incubation with
2*10e5 tryps/well
DB 75 in ng/ml in
supernatant after
incubation with
1*10e6 tryps/ well
250 91.01 85.00 101.21
500 229.31 215.13 244.98
1000 727.75 693.26 695.83
2500 1219.77 1145.21 1370.34
5000 2690.38 2429.93 2937.86
10000 5725.07 5327.30 6096.31
Average amount of DB 75 in ng/ml, measured in the supernatant of trypanosomes solutions
containing various densities of trypanosomes after 4 hours incubation with DB 75:
DB 75 in
ng/ml
DB 75 in ng/ml in
supernatant after
incubation with
1*10e4 tryps/well
DB 75 in ng/ml in
supernatant after
incubation with
2*10e5 tryps/well
DB 75 in ng/ml in
supernatant after
incubation with
1*10e6 tryps/ well
250 128.97 116.13 104.23
500 315.88 262.93 257.27
1000 1064.96 708.40 788.54
2500 1601.36 1349.09 1444.48
5000 3089.27 3050.45 3111.59
10000 6469.27 6474.27 6461.84
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 RAW DATA BIOASSAY I
time sample HPLC/ bioassay dil. factor ratio time sample HPLC/ bioassay dil. factor ratio
[h] code MS/MS [h] code MS/MS
0.25 WU01 9190 13904.55 30.0 1.5 0.25 WI01 16420 26966.4 30.0 1.6
0.25 WU02 10620 30969.23 30.0 2.9 0.25 WI02 13240 40449.6 30.0 3.1
0.25 WU03 11380 26545.05 30.0 2.3 0.25 WI03 9610 30969.23 30.0 3.2
0.5 WU04 7720 16011.30 20.0 2.1 0.5 WI04 5090 12640.5 20.0 2.5
0.5 WU05 4560 5688.23 10.0 1.2 0.5 WI05 5120 11587.13 20.0 2.3
0.5 WU06 3600 2067 10.0 0.6 0.5 WI06 6520 10533.75 20.0 1.6
1 WU07 1400 954 10.0 0.7 1 WI07 1580 1311.75 1.0 0.8
1 WU08 1760 1391.25 5.0 0.8 1 WI08 1800 2424.75 5.0 1.3
1 WU09 2850 3686.81 5.0 1.3 1 WI09 1930 1208.4 4.0 0.6
2 WU10 689 429.3 3.0 0.6 2 WI10 1850 7695.6 4.0 4.2
2 WU11 786 906.3 1.0 1.2 2 WI11 803 1073.25 3.0 1.3
2 WU12 1560 2544 5.0 1.6 2 WI12 1960 3458.25 5.0 1.8
4 WU13 482 620.1 1.0 1.3 4 WI13 442 1351.5 1.0 3.1
4 WU14 329 341.85 1.0 4 WI14 455 882.45 1.9
4 WU15 447 333.9 1.0 0.7 4 WI15 403 771.15 1.9
8 WU16 277 318 1.1 8 WI16 340 1256.1 1.0 3.7
8 WU17 273 413.4 1.5 8 WI17 294 969.9 3.3
8 WU18 242 389.55 1.6 8 WI18 826 1892.1 1.0 2.3
24 WU19 297 294.15 1.0 24 WI19 318 604.2 1.9
24 WU20 257 532.65 2.1 24 WI20 387 286.2 1.0 0.7
24 WU21 24 WI21
time sample HPLC/ bioassay dil. factor ratio time sample HPLC/ bioassay dil. factor ratio
[h] code MS/MS [h] code MS/MS
0.5 XU22 0.5 XI22 64.3 198.75 3.1
0.5 XU23 83.1 166.95 1.5 2.0 0.5 XI23 19.6 262.35 13.4
0.5 XU24 135 1081.2 8.0 0.5 XI24
1 XU25 207 437.25 2.1 1 XI25 148 321.98 1.5 2.2
1 XU26 165 198.75 1.2 1 XI26 140 206.7 1.5
1 XU27 618 190.8 0.3 1 XI27 191 182.85 1.0
2 XU28 519 1637.16 1.0 3.2 2 XI28 174 198.75 1.1
2 XU29 234 302.1 1.3 2 XI29 228 381.6 1.7
2 XU30 263 127.2 0.5 2 XI30 207 206.7 1.0
4 XU31 477 818.85 1.7 4 XI31 229 771.15 3.4
4 XU32 441 159 1.0 0.4 4 XI32 217 516.75 2.4
4 XU33 322 198.75 0.6 4 XI33 321 278.25 0.9
6 XU34 221 190.8 0.9 6 XI34 189 890.4 4.7
6 XU35 3970 2067 10.0 0.5 6 XI35 198 270.3 1.4
6 XU36 191 143.1 0.7 6 XI36 243 341.85 1.4
8 XU37 383 739.35 1.9 8 XI37 211 500.85 2.4
8 XU38 322 214.65 0.7 8 XI38 275 842.7 3.1
8 XU39 223 477 2.1 8 XI39 199 691.65 1.5 3.5
24 XU40 202 437.25 2.2 24 XI40 177 174.9 1.0
24 XU41 214 262.35 1.2 24 XI41 89.9 333.9 3.7
24 XU42 150 405.45 1.5 2.7 24 XI42 154 166.95 1.1
sample codes:
W= treatment with DB 75 X= treatment with DB 289 U= uninfected mice
Y= treatment with DB 820 Z= treatment with DB 844 I= infected mice
ratios bigger than a factor of 2 are highlighted
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 RAW DATA BIOASSAY II
time sample HPLC/ bioassay dil. factor ratio time sample HPLC/ bioassay dil. factor ratio
[h] code MS/MS [h] code MS/MS
0.25 YU01 17480 20165.93 30.0 1.2 0.25 YI01 19940 22406.59 30.0 1.1
0.25 YU02 16000 30246.90 30.0 1.9 0.25 YI02 12920 35477.10 30.0 2.7
0.25 YU03 11380 17551.83 30.0 1.5 0.25 YI03 31400 22406.59 100.0 0.7
0.5 YU04 6600 29502.01 30.0 4.5 0.5 YI04 13920 8215.75 30.0 0.6
0.5 YU05 4740 3983.39 20.0 0.8 0.5 YI05 9220 5499.9 20.0 0.6
0.5 YU06 3600 4232.36 10.0 1.2 0.5 YI06 7930 10829.85 30.0 1.4
1 YU07 23.2 336.11 20.0 14.5 1 YI07 6500 3734.43 30.0 0.6
1 YU08 2070 8555.54 5.0 4.1 1 YI08 3200 1649.97 10.0 0.5
1 YU09 2050 1271.09 10.0 0.6 1 YI09 5500 2138.85 10.0 0.4
2 YU10 864 501.1 5.0 0.6 2 YI10 606 1161.09 1.0 1.9
2 YU11 719 549.99 1.0 0.8 2 YI11 643 439.99 3.0 0.7
2 YU12 650 757.76 3.0 1.2 2 YI12 1210 1081.65 3.0 0.9
4 YU13 301 110 1.0 0.4 4 YI13 469 403.33 0.9
4 YU14 351 281.11 0.8 4 YI14 290 1002.2 3.5
4 YU15 244 391.1 1.6 4 YI15 293 311.66 1.0 1.1
8 YU16 277 342.22 1.2 8 YI16 209 507.21 2.4
8 YU17 256 110 0.4 8 YI17 254 556.1 2.2
8 YU18 187 488.88 2.6 8 YI18 229 482.77 2.1
24 YU19 168 452.21 2.7 24 YI19 183 577.49 1.5 3.2
24 YU20 197 220 1.1 24 YI20 216 262.77 1.2
24 YU21 182 1307.75 1.0 7.2 24 YI21 173 409.44 2.4
time sample HPLC/ bioassay dil. factor ratio time sample HPLC/ bioassay dil. factor ratio
[h] code MS/MS [h] code MS/MS
0.5 ZU22 139 275 2.0 0.5 ZI22 86.5 256.66 3.0
0.5 ZU23 152 531.66 3.5 0.5 ZI23 85.5 430.83 1.5 5.0
0.5 ZU24 0.5 ZI24 152 482.77 3.2
1 ZU25 162 97.78 3.0 0.6 1 ZI25 506 366.66 1.0 0.7
1 ZU26 176 525.55 3.0 1 ZI26 248 409.44 1.7
1 ZU27 242 299.44 1.2 1 ZI27 248 262.77 1.1
2 ZU28 225 226.11 1.0 2 ZI28 290 354.44 1.2
2 ZU29 235 323.88 1.4 2 ZI29 261 378.88 1.5
2 ZU30 233 275 1.2 2 ZI30 232 250.55 1.1
4 ZU31 264 293.33 1.1 4 ZI31 286 696.65 2.4
4 ZU32 292 598.88 2.1 4 ZI32 313 232.22 1.0 0.7
4 ZU33 263 226.11 0.9 4 ZI33 409 329.99 0.8
6 ZU34 356 562.21 1.0 1.6 6 ZI34 379 983.87 2.6
6 ZU35 319 470.55 1.5 6 ZI35 335 403.33 1.2
6 ZU36 178 806.65 4.5 6 ZI36 249 623.32 2.5
8 ZU37 458 745.54 1.0 1.6 8 ZI37 536 525.55 1.0
8 ZU38 334 708.88 2.1 8 ZI38 323 537.77 1.0 1.7
8 ZU39 322 207.77 1.0 0.6 8 ZI39 433 1209.98 2.8
24 ZU40 160 244.44 1.5 24 ZI40 172 238.33 1.4
24 ZU41 132 531.66 4.0 24 ZI41 172 110 0.6
24 ZU42 159 146.66 0.9 24 ZI42 169 531.66 3.1
sample codes:
W= treatment with DB 75 X= treatment with DB 289 U= uninfected mice
Y= treatment with DB 820 Z= treatment with DB 844 I= infected mice
ratios bigger than a factor of 2 are highlighted
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RAW DATA
MALARIA
Pharmacokinetic parameters of active compound:
Table 1: DB 75:
parameter infected mice uninfected mice inf./uninf.
Cmax [nM] 5980 6210 - 10.5 %
tmax [h] 0.5 0.5
AUC 30307 33766 - 10.2 %
AUMC 268153 290582 - 7.7 %
MRT 8.85 8.61 + 2.8 %
t1/2 6.1 6.0 + 1.7%
kel   (1/MRT) 0.11 0.12 - 2.6 %
Pharmacokinetic parameters of prodrug:
Table 2: DB 289:
parameter infected mice uninfected mice inf/uninf.
Cmax [nM] 2046.7 2190 - 6.5 %
tmax [h] 2 2
AUC 30516 15170 2 x
AUMC 297792 76764 3.9 x
MRT 9.76 5.06 1.9 x
t1/2 6.8 3.5 1.9 x
kel   (1/MRT) 0.10 0.20 - 48,5%
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Pharmacokinetic parameters:
Table 3: DB 75 after DB 289:
parameter infected mice uninfected mice inf./uninf.
Cmax [nM] 381 260 + 46.7 %
tmax [h] 24 24
AUC 5921 4732 + 25.1 %
AUMC 92434 65842 + 40.4 %
MRT 15.61 13.32 + 12.1 %
t1/2 10.8 9.6 + 12.5 %
kel   (1/MRT) 0.06 0.07 - 14.3 %
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Table 4: Calculations of free plasma levels and required dose to
kill malaria parasites
DB 75 [nM]
in
free DB 75 plasma level [nM] with
protein binding of
time in h uninfected 75% 70%
0.5 154.00 38.50 46.20
1.00 166.00 41.50 49.80
2.00 158.00 39.50 47.40
4.00 201.67 50.42 60.50
6.00 201.33 50.33 60.40
8.00 156.33 39.08 46.90
24.00 260.00 65.00 78.00
DB 75 [nM]
in
free DB 75 plasma level [nM] with
protein binding of
time in h infected 75% 70%
0.5 88.40 22.10 26.52
1.00 82.87 20.72 24.86
2.00 139.33 34.83 41.80
4.00 141.00 35.25 42.30
6.00 149.67 37.42 44.90
8.00 219.33 54.83 65.80
24.00 381.33 95.33 114.40
P. falciparum in vitro IC50 for DB 75 [Schild N. (2003)]:
time in h IC50 IC50 IC50 average in
[ng/ml]
average in
[nM]
1 23 98 29 50.0 132.5
2 19 96 19 44.7 118.4
4 22 67 28 39.0 103.4
8 15 33 14 20.7 54.8
24 4 11 8 7.7 20.3
required dose of DB 75 to kill parasites (MIC= 3-5x IC50):
time in h 3x IC50 in [nM] 5x IC50 in [nM]
1 397.5 662.5
2 355.1 591.8
4 310.05 516.8
8 164.3 273.8
24 60.95 101.6
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